

Membrane transporters in drug development

Nature Reviews Drug Discovery

9, 215-236

DOI: 10.1038/nrd3028

Citation Report

#	ARTICLE	IF	CITATIONS
1	Oxidative Rancidity and Discoloration in Meat. Advances in Food Research, 1954, 5, 1-52.	0.3	139
2	[120] DPNH cytochrome c reductase (animal). Methods in Enzymology, 1955, 2, 688-693.	1.0	89
3	Triggering of Ovulation by Coitus in the Rat. International Review of Cytology, 1966, 20, 139-172.	6.2	53
4	Soviet Literature on the Nervous System and Psychobiology of Cetacea. International Review of Neurobiology, 1979, 21, 47-127.	2.0	37
5	[5] Ascorbate oxidase. Methods in Enzymology, 1979, 62, 30-39.	1.0	15
6	Structural Effect of Bimetallic Catalysts in the Co+H ₂ Reaction. Studies in Surface Science and Catalysis, 1988, 38, 85-96.	1.5	8
7	Chapter 1 Metals in Human Toxicology. Techniques and Instrumentation in Analytical Chemistry, 1989, , 3-16.	0.0	0
8	Chapter 2 Carbonate Rock Classifications. Developments in Petroleum Science, 1992, 30, 59-108.	0.2	8
9	Heterogeneous Photocatalysis: Mechanistic Considerations of Photocatalytic Reductions and Photocatalytic Oxidations on Semiconductor Oxide Surfaces. Studies in Surface Science and Catalysis, 1993, , 2151-2154.	1.5	4
10	Chapter 3 Greenstones Through Time. Neoproterozoic-Cambrian Tectonics, Global Change and Evolution: A Focus on South Western Gondwana, 1994, , 85-120.	0.2	75
11	Poly(imide)s. Studies in Physical and Theoretical Chemistry, 1998, 84, 469-490.	0.0	0
12	23. Pyrazines. Sugar Series, 2000, , 181-183.	0.0	0
13	Syntheses and properties of azafulvalenes. Advances in Heterocyclic Chemistry, 2000, 77, 115-181.	1.7	5
15	Acquisition and archiving of information for bacterial proteomics: From sample preparation to database. Methods in Enzymology, 2002, 358, 207-227.	1.0	20
16	Some Special Problems and the Behavior of Deep Caps. Studies in Applied Mechanics, 2002, 48, 289-325.	0.4	0
17	Chapter 3 Naturally occurring halogenated pyrroles and Indoles. Progress in Heterocyclic Chemistry, 2003, 15, 58-74.	0.5	10
18	Chapter 7 Toxicity of surfactants. Comprehensive Analytical Chemistry, 2003, 40, 827-925.	1.3	16
19	Local electronic structures of hydrogen and phase stability of vanadium hydride, V ₂ H. Advances in Quantum Chemistry, 2003, 42, 263-273.	0.8	4

#	ARTICLE	IF	CITATIONS
20	Chapter 58 Contribution of subcortical motor pathways to the execution of ballistic movements. Supplements To Clinical Neurophysiology, 2004, 57, 554-562.	2.1	23
21	Modeling Polarization in Proteins and Proteinâ€“ligand Complexes: Methods and Preliminary Results. Advances in Protein Chemistry, 2005, 72, 79-104.	4.4	68
22	Families of Protein Phosphatase 1 Modulators Activated by Protein Kinases A and C: Focus on Brain. Progress in Molecular Biology and Translational Science, 2005, 79, 371-404.	1.9	5
23	Chapter 5 Schauder-type estimates and applications. Handbook of Differential Equations: Stationary Partial Differential Equations, 2006, , 401-464.	0.7	1
24	Chapter 2 Social Foraging and the Study of Exploitative Behavior. Advances in the Study of Behavior, 2008, 38, 59-104.	1.6	96
26	Predicting Drug â€“ Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein. Current Drug Metabolism, 2010, 11, 762-777.	1.2	57
27	PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism. Current Drug Metabolism, 2010, 11, 743-761.	1.2	52
28	Pharmacogenomics of Human ABC Transporter ABCC11 (MRP8): Potential Risk of Breast Cancer and Chemotherapy Failure. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 617-624.	1.7	29
29	Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. European Journal of Clinical Pharmacology, 2010, 66, 865-870.	1.9	7
30	Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 575-590.	1.8	101
31	Lipid outward translocation by ABC proteins. FEBS Letters, 2010, 584, 2717-2723.	2.8	49
32	Impact of the Recent Mouse Pâ€“Glycoprotein Structure for Structureâ€“Based Ligand Design. Molecular Informatics, 2010, 29, 276-286.	2.5	21
33	Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3. Analytical Biochemistry, 2010, 405, 50-58.	2.4	53
34	Clinical Relevance of Impaired Nonrenal Drug Clearance in ESRD. Seminars in Dialysis, 2010, 23, 482-485.	1.3	11
35	Therapeutic Proteinâ€“Drug Interactions and Implications for Drug Development. Clinical Pharmacology and Therapeutics, 2010, 87, 497-503.	4.7	142
36	Seeing the future of bioactive lipid drug targets. Nature Chemical Biology, 2010, 6, 476-479.	8.0	14
37	Transporters in drug development: advancing on the Critical Path. Nature Reviews Drug Discovery, 2010, 9, 175-176.	46.4	42
38	Heading a consortium. Nature Reviews Drug Discovery, 2010, 9, 411-411.	46.4	0

#	ARTICLE	IF	CITATIONS
39	Understanding transport through pharmacological barriers “are we there yet?”. Nature Reviews Drug Discovery, 2010, 9, 897-898.	46.4	15
40	Coexistence of passive and carrier-mediated processes in drug transport. Nature Reviews Drug Discovery, 2010, 9, 597-614.	46.4	526
41	Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE, 2010, 5, e13792.	2.5	45
42	Pharmacogenomics and adverse drug reactions. Personalized Medicine, 2010, 7, 633-642.	1.5	16
43	Comparative Use of Isolated Hepatocytes and Hepatic Microsomes for Cytochrome P450 Inhibition Studies: Transporter-Enzyme Interplay. Drug Metabolism and Disposition, 2010, 38, 2139-2146.	3.3	30
44	Organic Anion Transporter 6 (<i>Slc22a20</i>) Specificity and Sertoli Cell-Specific Expression Provide New Insight on Potential Endogenous Roles. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 927-935.	2.5	20
45	4 The Value of Insects in Paleoecology. Developments in Quaternary Sciences, 2010, , 39-51.	0.1	1
46	Type-2 fuzzy control of a fed-batch fermentation reactor. Computer Aided Chemical Engineering, 2010, , 571-576.	0.5	5
47	Cryoelectron Tomography of Eukaryotic Cells. Methods in Enzymology, 2010, 483, 245-265.	1.0	16
48	Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 939-952.	3.3	82
49	Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. American Journal of Physiology - Renal Physiology, 2010, 299, F767-F775.	2.7	22
50	Human Erythrocyte Nucleoside Transporter ENT1 Functions at Ice-cold Temperatures. Drug Metabolism and Pharmacokinetics, 2010, 25, 351-360.	2.2	16
51	The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 601-616.	1.7	3
52	Targeting Intestinal Transporters for Optimizing Oral Drug Absorption. Current Drug Metabolism, 2010, 11, 730-742.	1.2	109
53	ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1161-1174.	3.3	55
57	A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development. Clinical Pharmacokinetics, 2010, 49, 703-727.	3.5	14
58	Structural Requirements of the ASBT by 3D-QSAR Analysis Using Aminopyridine Conjugates of Chenodeoxycholic Acid. Bioconjugate Chemistry, 2010, 21, 2038-2048.	3.6	15
59	Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions. Trends in Pharmacological Sciences, 2010, 31, 351-355.	8.7	5

#	ARTICLE	IF	CITATIONS
60	â€œClickedâ€•Bivalent Ligands Containing Curcumin and Cholesterol As Multifunctional A ² Oligomerization Inhibitors: Design, Synthesis, and Biological Characterization. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6198-6209.	6.4	62
61	ABCB1 and ABCG2 expression in the placenta and fetus: an interspecies comparison. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1385-1398.	3.3	23
62	Organic cation transporter pharmacogenomics and drugâ€“drug interaction. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 707-711.	3.1	10
63	Substrate recognition and transport behavior analyses of amino acid antiporter with coarse-grained models. <i>Molecular BioSystems</i> , 2010, 6, 2430.	2.9	30
64	Drug transport by breast cancer resistance protein. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1363-1384.	3.3	23
65	Allosteric and transport behavior analyses of a fucose transporter with network models. <i>Soft Matter</i> , 2011, 7, 4661.	2.7	12
66	Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drugâ€“drug interaction to support regulatory submissions. <i>Xenobiotica</i> , 2011, 41, 764-783.	1.1	36
67	Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. <i>Pharmacological Reviews</i> , 2011, 63, 157-181.	16.0	546
68	Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 15810-15815.	7.1	120
69	Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 457-477.	3.3	36
70	Bioactivation of herbal constituents: simple alerts in the complex system. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 989-1007.	3.3	32
71	Calcein assay: a high-throughput method to assess P-gp inhibition. <i>Xenobiotica</i> , 2011, 41, 712-719.	1.1	34
72	Effect of Structural Modification of Î±-Aminoxy Peptides on Their Intestinal Absorption and Transport Mechanism. <i>Molecular Pharmaceutics</i> , 2011, 8, 1073-1082.	4.6	8
73	Pharmacokinetic drugâ€“drug interactions with methotrexate in oncology. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 743-750.	3.1	50
74	Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. <i>Future Medicinal Chemistry</i> , 2011, 3, 2063-2077.	2.3	183
75	Pharmacogenetics of drug transporters in the enterohepatic circulation. <i>Pharmacogenomics</i> , 2011, 12, 611-631.	1.3	33
76	The P-glycoprotein multidrug transporter. <i>Essays in Biochemistry</i> , 2011, 50, 161-178.	4.7	403
77	Current understanding of hepatic and intestinal OATP-mediated drugâ€“drug interactions. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 729-742.	3.1	36

#	ARTICLE	IF	CITATIONS
78	The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. <i>Pharmacological Research</i> , 2011, 64, 359-363.	7.1	26
80	Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence. <i>MedChemComm</i> , 2011, 2, 1001.	3.4	15
81	Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. <i>Drug Metabolism and Disposition</i> , 2011, 39, 15-21.	3.3	53
82	Renal Transport of Organic Anions and Cations. , 2011, 1, 1795-1835.		45
83	Discovery and pharmacological characterization of a selective delta opiate receptor antagonist (CP-646,777). <i>MedChemComm</i> , 2011, 2, 413.	3.4	3
84	Homology Modeling of Transporter Proteins (Carriers and Ion Channels). <i>Methods in Molecular Biology</i> , 2011, 857, 281-299.	0.9	20
85	DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. <i>Genome Medicine</i> , 2011, 3, 82.	8.2	124
86	Pulmonary Drug Metabolism, Clearance, and Absorption. , 2011, , 21-50.		91
87	Experimental determination and prediction of bilitranslocase transport activity. <i>Analytica Chimica Acta</i> , 2011, 705, 322-333.	5.4	22
88	Selective Regulation of Cardiac Organic Cation Transporter Novel Type 2 (OCTN2) in Dilated Cardiomyopathy. <i>American Journal of Pathology</i> , 2011, 178, 2547-2559.	3.8	64
89	Non-invasive imaging in experimental medicine for drug development. <i>Current Opinion in Pharmacology</i> , 2011, 11, 501-507.	3.5	32
90	Profiling of a Prescription Drug Library for Potential Renal Drug-Drug Interactions Mediated by the Organic Cation Transporter 2. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4548-4558.	6.4	141
91	Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. <i>Annual Review of Pharmacology and Toxicology</i> , 2011, 51, 45-73.	9.4	548
92	Development of a quantification method for digoxin, a typical P-glycoprotein probe in clinical and non-clinical studies, using high performance liquid chromatography-tandem mass spectrometry: The usefulness of negative ionization mode to avoid competitive adduct-ion formation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 3837-3844.	2.3	24
93	Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery. <i>Biological Chemistry</i> , 2011, 392, 77-94.	2.5	55
94	Animal Model Systems Suitable for Controlled Release Modeling. , 2011, , 71-90.		1
95	Preclinical Disposition (In Vitro) of Novel μ -Opioid Receptor Selective Antagonists. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1589-1596.	3.3	21
97	Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 1119-1135.	2.4	229

#	ARTICLE	IF	CITATIONS
98	Drug delivery to the brain via the bloodâ€‘brain barrier: a review of the literature and some recent patent disclosures. Therapeutic Delivery, 2011, 2, 311-327.	2.2	11
99	An HPLC-UV method for the measurement of permeability of marker drugs in the Caco-2 cell assay. Brazilian Journal of Medical and Biological Research, 2011, 44, 531-537.	1.5	20
100	Oral Bioavailability and Disposition of Phytochemicals. , 0, , .		3
101	Microbial Efflux Pump Inhibition: Tactics and Strategies. Current Pharmaceutical Design, 2011, 17, 1291-1302.	1.9	140
102	Predicting P-Glycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of P-glycoprotein. PLoS ONE, 2011, 6, e25815.	2.5	103
103	Sensitive and Specific Fluorescent Probes for Functional Analysis of the Three Major Types of Mammalian ABC Transporters. PLoS ONE, 2011, 6, e22429.	2.5	75
104	Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study. Clinical Pharmacology and Therapeutics, 2011, 90, 575-581.	4.7	192
105	Pharmacogenomics of Human ABC Transporters: Detection of Clinically Important SNPs by SmartAmp2 Method. Current Pharmaceutical Biotechnology, 2011, 12, 693-704.	1.6	7
106	Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer. Current Pharmaceutical Biotechnology, 2011, 12, 686-692.	1.6	62
107	Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice. Current Drug Metabolism, 2011, 12, 621-634.	1.2	17
108	Clinical Importance of OATP1B1 and OATP1B3 in Drugâ‘Drug Interactions. Drug Metabolism and Pharmacokinetics, 2011, 26, 220-227.	2.2	101
109	Towards a structural understanding of drug and peptide transport within the proton-dependent oligopeptide transporter (POT) family. Biochemical Society Transactions, 2011, 39, 1353-1358.	3.4	47
112	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. British Journal of Clinical Pharmacology, 2011, 71, 718-726.	2.4	80
113	A comprehensive nonâ‘clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. British Journal of Clinical Pharmacology, 2011, 72, 235-246.	2.4	152
114	The ABCG family of membraneâ‘associated transporters: you don't have to be big to be mighty. British Journal of Pharmacology, 2011, 164, 1767-1779.	5.4	109
115	The SLC36 family of protonâ‘coupled amino acid transporters and their potential role in drug transport. British Journal of Pharmacology, 2011, 164, 1802-1816.	5.4	128
116	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia, 2011, 52, 1894-1904.	5.1	77
117	The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nature Reviews Drug Discovery, 2011, 10, 75-75.	46.4	17

#	ARTICLE	IF	CITATIONS
118	Response from the International Transporter Consortium. Nature Reviews Drug Discovery, 2011, 10, 75-75.	46.4	5
119	Why, When, and How Should Pharmacogenetics Be Applied in Clinical Studies?: Current and Future Approaches to Study Designs. Clinical Pharmacology and Therapeutics, 2011, 89, 198-209.	4.7	39
120	Functional Characterization of Liver Enhancers That Regulate Drug-Associated Transporters. Clinical Pharmacology and Therapeutics, 2011, 89, 571-578.	4.7	24
121	Transporter-Mediated Drug-Drug Interactions. Clinical Pharmacology and Therapeutics, 2011, 89, 481-484.	4.7	65
122	Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2011, 89, 837-844.	4.7	196
123	Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2. Clinical Pharmacology and Therapeutics, 2011, 89, 816-820.	4.7	53
124	Potential Risks Resulting from Fruit/Vegetable-Drug Interactions: Effects on Drug-Metabolizing Enzymes and Drug Transporters. Journal of Food Science, 2011, 76, R112-24.	3.1	153
125	Benchmarking Membrane Protein Detergent Stability for Improving Throughput of High-Resolution X-ray Structures. Structure, 2011, 19, 17-25.	3.3	133
126	Rapid detection of ABC transporter interaction: Potential utility in pharmacology. Journal of Pharmacological and Toxicological Methods, 2011, 63, 217-222.	0.7	34
127	Drug uptake transporters in antiretroviral therapy. , 2011, 132, 268-279.		62
128	In vivo imaging of drug delivery systems in the gastrointestinal tract. International Journal of Pharmaceutics, 2011, 417, 216-226.	5.2	50
129	Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discovery Today, 2011, 16, 704-714.	6.4	160
130	Drug discovery in the next decade: innovation needed ASAP. Drug Discovery Today, 2011, 16, 779-792.	6.4	69
131	In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. European Journal of Pharmaceutical Sciences, 2011, 43, 41-49.	4.0	27
132	Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. European Journal of Pharmaceutical Sciences, 2011, 43, 297-307.	4.0	54
133	Simulating kinetic parameters in transporter mediated permeability across Caco-2 cells. A case study of estrone-3-sulfate. European Journal of Pharmaceutical Sciences, 2011, 44, 218-226.	4.0	7
134	Interaction of fluvastatin with the liver-specific Na ⁺ -dependent taurocholate cotransporting polypeptide (NTCP). European Journal of Pharmaceutical Sciences, 2011, 44, 487-496.	4.0	40
135	MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochemical Pharmacology, 2011, 82, 24-34.	4.4	19

#	ARTICLE	IF	CITATIONS
136	OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. <i>Biochemical Pharmacology</i> , 2011, 82, 1219-1226.	4.4	35
137	In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. <i>Biochemical Pharmacology</i> , 2011, 82, 1562-1571.	4.4	17
138	The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions. , 2011, , 285-313.		2
140	Transporter-mediated drug-drug interactions. <i>Pharmacogenomics</i> , 2011, 12, 1017-1037.	1.3	148
142	Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. <i>Chemical Research in Toxicology</i> , 2011, 24, 1345-1410.	3.3	569
143	Challenges in inhaled product development and opportunities for open innovation. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 69-87.	13.7	95
144	Novel strategies for microdose studies using non-radiolabeled compounds. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 532-538.	13.7	47
145	Assessment of P-glycoprotein Activity in the Blood-Brain Barrier (BBB) Using Near Infrared Fluorescence (NIRF) Imaging Techniques. <i>Pharmaceutical Research</i> , 2011, 28, 2505-2515.	3.5	19
146	Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 11-17.	3.3	64
147	Role of transporters in drug interactions. <i>Archives of Pharmacal Research</i> , 2011, 34, 1865-1877.	6.3	158
148	Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 115-119.	1.6	19
150	Validation of 96-well Equilibrium Dialysis with Non-radiolabeled Drug for Definitive Measurement of Protein Binding and Application to Clinical Development of Highly-Bound Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2498-2507.	3.3	52
151	Substrate- and Species-dependent Inhibition of P-glycoprotein-mediated Transport: Implications for Predicting in vivo Drug Interactions. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3055-3061.	3.3	43
152	Structural Features Determining the Intestinal Epithelial Permeability and Efflux of Novel HIV-1 Protease Inhibitors. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3763-3772.	3.3	12
153	A Comprehensive Study Demonstrating that P-glycoprotein Function is Directly Affected by Changes in pH: Implications for Intestinal pH and Effects on Drug Absorption. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4258-4268.	3.3	8
154	Interactions Between Organic Anions on Multiple Transporters in Caco-2 Cells. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3817-3830.	3.3	14
155	Establishment of In Vitro P-Glycoprotein Inhibition Assay and Its Exclusion Criteria to Assess the Risk Of Drug-Drug Interaction at the Drug Discovery Stage. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4013-4023.	3.3	37
156	Randomly methylated β -cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco-2 cell monolayer. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4734-4744.	3.3	34

#	ARTICLE	IF	CITATIONS
157	Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 5018-5030.	3.3	74
158	The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 446-457.	1.9	29
159	Development and validation of a highly sensitive LC-MS/MS method for organic cation transporter (OCT) substrate tetraethylammonium (TEA) in rabbits. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 585-590.	2.3	10
160	Strategies to optimize the brain availability of central nervous system drug candidates. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 371-381.	5.0	48
161	In Silico, In Vitro and In Situ Models to Assess Interplay Between CYP3A and P-gp. <i>Current Drug Metabolism</i> , 2011, 12, 750-773.	1.2	33
162	Interplay of Drug Metabolizing CYP450 Enzymes and ABC Transporters in the Blood-Brain Barrier. <i>Current Drug Metabolism</i> , 2011, 12, 732-741.	1.2	75
163	ABC Proteins Protect the Human Body and Maintain Optimal Health. <i>Bioscience, Biotechnology and Biochemistry</i> , 2011, 75, 401-409.	1.3	71
164	Automated Applications of Sandwich-Cultured Hepatocytes in the Evaluation of Hepatic Drug Transport. <i>Journal of Biomolecular Screening</i> , 2011, 16, 427-435.	2.6	6
165	In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 372-380.	2.5	193
166	Addressing micronutrient malnutrition through food fortification. , 0, , 795-843.		5
168	Manufacture and Chemical Structure of Biopolymers. , 2011, , 71-148.		3
169	Functional Maturation of Drug Transporters in the Developing, Neonatal, and Postnatal Kidney. <i>Molecular Pharmacology</i> , 2011, 80, 147-154.	2.3	59
170	Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1808-1814.	3.3	115
171	Tissue Distribution and Characterization of Drug-Related Material in Rats and Dogs after Repeated Oral Administration of Casopitant. <i>Drug Metabolism and Disposition</i> , 2011, 39, 283-293.	3.3	6
172	Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation. <i>Clinical Cancer Research</i> , 2011, 17, 89-99.	7.0	97
173	Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2314-2320.	3.3	49
175	Molecular Dissection of Dual Pseudosymmetric Solute Translocation Pathways in Human P-Glycoprotein. <i>Molecular Pharmacology</i> , 2011, 79, 443-452.	2.3	48
176	Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics. <i>Xenobiotica</i> , 2011, 41, 687-700.	1.1	8

#	ARTICLE	IF	CITATIONS
177	Sex Differences in Drug Disposition. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-14.	3.0	224
178	Effect of Culture Time on the Basal Expression Levels of Drug Transporters in Sandwich-Cultured Primary Rat Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2387-2394.	3.3	45
179	Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening. <i>Journal of Nuclear Medicine</i> , 2011, 52, 415-423.	5.0	43
180	Quantitative Investigation of the Impact of P-Glycoprotein Inhibition on Drug Transport across Blood-Brain Barrier in Rats. <i>Drug Metabolism and Disposition</i> , 2011, 39, 8-14.	3.3	45
181	The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672. <i>Drug Metabolism and Disposition</i> , 2011, 39, 275-282.	3.3	23
182	Effects of Chronic Renal Failure on Kidney Drug Transporters and Cytochrome P450 in Rats. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1363-1369.	3.3	94
183	Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 181-9.	0.3	11
184	Translational Research Insights into Pharmacokinetic Herb-Drug Interactions. <i>Current Drug Metabolism</i> , 2011, 12, 850-870.	1.2	6
185	Efflux Transport Is an Important Determinant of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1794-1800.	3.3	35
186	Quinidine as an ABCB1 Probe for Testing Drug Interactions at the Bloodâ€”Brain Barrier: An In Vitro In Vivo Correlation Study. <i>Journal of Biomolecular Screening</i> , 2011, 16, 886-894.	2.6	28
187	Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 531-539.	4.1	172
188	Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 137-146.	3.3	28
189	Interactions of Green Tea Catechins with Organic Anion-Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2011, 39, 920-926.	3.3	168
190	Urinary Elimination of Coproporphyrins Is Dependent on <i>ABCC2</i> Polymorphisms and Represents a Potential Biomarker of MRP2 Activity in Humans. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	20
192	<i>SLCO2B1</i> and <i>SLCO1B3</i> May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2565-2573.	1.6	153
193	Inhibitory Effect of Caffeic Acid on Human Organic Anion Transporters hOAT1 and hOAT3: A Novel Candidate for Foodâ€”Drug Interaction. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 486-493.	2.2	26
194	Analysis of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell culture models1. <i>Journal of Animal Science</i> , 2011, 89, 4325-4338.	0.5	29
195	Microcystin-LR Induces Apoptosis via NF- κ B /iNOS Pathway in INS-1 Cells. <i>International Journal of Molecular Sciences</i> , 2011, 12, 4722-4734.	4.1	38

#	ARTICLE	IF	CITATIONS
196	Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2361-2369.	3.3	22
197	Challenges in the Development of Functional Assays of Membrane Proteins. <i>Materials</i> , 2012, 5, 2205-2242.	2.9	40
198	Visualization of Hepatic Uptake Transporter Function in Healthy Subjects by Using Gadoteric Acid-enhanced MR Imaging. <i>Radiology</i> , 2012, 264, 741-750.	7.3	123
199	The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. <i>Xenobiotica</i> , 2012, 42, 28-45.	1.1	51
200	Functional significance of conserved cysteines in the human organic cation transporter 2. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F313-F320.	2.7	15
201	Ablation of Both Organic Cation Transporter (Oct)1 and Oct2 Alters Metformin Pharmacokinetics but Has No Effect on Tissue Drug Exposure and Pharmacodynamics. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1170-1177.	3.3	99
202	Mechanistic Studies on the Absorption and Disposition of Scutellarin in Humans: Selective OATP2B1-Mediated Hepatic Uptake Is a Likely Key Determinant for Its Unique Pharmacokinetic Characteristics. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2009-2020.	3.3	44
203	Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout Rats Generated by Zinc Finger Nucleases. <i>Molecular Pharmacology</i> , 2012, 81, 220-227.	2.3	48
204	Evaluation of Organic Anion-Transporting Polypeptide 1B1 and CYP3A4 Activities in Primary Human Hepatocytes and HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor System. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 145-156.	2.5	20
205	The Role of a Basolateral Transporter in Rosuvastatin Transport and Its Interplay with Apical Breast Cancer Resistance Protein in Polarized Cell Monolayer Systems. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2102-2108.	3.3	33
206	Drug Transporters. <i>Current Protocols in Toxicology</i> / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2012, 52, 23.0.1.	1.1	0
207	Different Effects of the Selective Serotonin Reuptake Inhibitors Fluvoxamine, Paroxetine, and Sertraline on the Pharmacokinetics of Fexofenadine in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 195-199.	1.4	19
208	The Liver Partition Coefficient-Corrected Inhibitory Quotient and the Pharmacokinetic-Pharmacodynamic Relationship of Directly Acting Anti-Hepatitis C Virus Agents in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5381-5386.	3.2	20
209	Expression of Organic Anion Transporter 2 in the Human Kidney and Its Potential Role in the Tubular Secretion of Guanine-Containing Antiviral Drugs. <i>Drug Metabolism and Disposition</i> , 2012, 40, 617-624.	3.3	70
210	Rationale for Further Medical and Health Research on High-Potency Sweeteners. <i>Chemical Senses</i> , 2012, 37, 671-679.	2.0	46
211	Can a cocktail designed for phenotyping pharmacokinetics and metabolism enzymes in human be used efficiently in rat?. <i>Xenobiotica</i> , 2012, 42, 349-354.	1.1	25
212	Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs. <i>Current Cancer Drug Targets</i> , 2012, 12, 962-986.	1.6	55
214	Influence of <i>SLCO1B1</i> Polymorphisms on the Drug-Drug Interaction Between Darunavir/Ritonavir and Pravastatin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1725-1738.	2.0	22

#	ARTICLE	IF	CITATIONS
215	Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities. <i>Drug Metabolism and Disposition</i> , 2012, 40, 83-92.	3.3	373
216	Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (<i>SLCO2B1</i>), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1078-1089.	2.0	91
217	Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model. <i>Xenobiotica</i> , 2012, 42, 327-338.	1.1	16
218	Renal drug-drug interactions: what we have learned and where we are going. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 433-448.	3.3	54
219	Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1825-1833.	3.3	85
220	Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1007-1017.	3.3	228
221	Recent advances in pharmacogenomics of ABC transporters involved in breast cancer therapy. <i>Pharmacogenomics</i> , 2012, 13, 633-636.	1.3	8
222	In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1085-1092.	3.3	58
223	Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. <i>Xenobiotica</i> , 2012, 42, 57-74.	1.1	15
225	Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1744-1756.	3.3	106
226	Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidney. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 393-403.	2.5	183
227	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. <i>Clinical Cancer Research</i> , 2012, 18, 4433-4440.	7.0	80
228	Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein. <i>Journal of Clinical Oncology</i> , 2012, 30, 340-341.	1.6	12
229	Regulation of Tissue-Specific Expression of Renal Organic Anion Transporters by Hepatocyte Nuclear Factor 1 α/β and DNA Methylation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 648-655.	2.5	43
230	Models to Predict Unbound Intracellular Drug Concentrations in the Presence of Transporters. <i>Drug Metabolism and Disposition</i> , 2012, 40, 865-876.	3.3	50
231	Commentary: Nonspecific Protein Binding versus Membrane Partitioning: It Is Not Just Semantics. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1649-1652.	3.3	57
232	Clarithromycin Is Absorbed by an Intestinal Uptake Mechanism That Is Sensitive to Major Inhibition by Rifampicin: Results of a Short-Term Drug Interaction Study in Foals. <i>Drug Metabolism and Disposition</i> , 2012, 40, 522-528.	3.3	34
233	The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1641-1648.	3.3	31

#	ARTICLE	IF	CITATIONS
234	Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, <i>in vitro</i> . Antimicrobial Agents and Chemotherapy, 2012, 56, 5409-5413.	3.2	126
235	A high throughput <i>in vitro</i> mrp2 assay to predict <i>in vivo</i> biliary excretion. Xenobiotica, 2012, 42, 157-163.	1.1	14
236	Interactions of bilastine, a new oral H ₁ antihistamine, with human transporter systems. Drug and Chemical Toxicology, 2012, 35, 8-17.	2.3	37
237	Stereoselective Interaction of Pantoprazole with ABCG2. I. Drug Accumulation in Rat Milk. Drug Metabolism and Disposition, 2012, 40, 1018-1023.	3.3	6
238	Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Human Molecular Genetics, 2012, 21, R58-R65.	2.9	70
239	Synchronized Activity of Organic Cation Transporter 3 (Oct3/Slc22a3) and Multidrug and Toxin Extrusion 1 (MATE1/Slc47a1) Transporter in Transplacental Passage of MPP+ in Rat. Toxicological Sciences, 2012, 128, 471-481.	3.1	38
240	Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2012, 40, 852-855.	3.3	79
241	Characterization of THLE-Cytochrome P450 (P450) Cell Lines: Gene Expression Background and Relationship to P450-Enzyme Activity. Drug Metabolism and Disposition, 2012, 40, 2054-2058.	3.3	18
242	Generation and Characterization of a Novel Multidrug Resistance Protein 2 Humanized Mouse Line. Drug Metabolism and Disposition, 2012, 40, 2212-2218.	3.3	21
243	Absolute Quantification and Differential Expression of Drug Transporters, Cytochrome P450 Enzymes, and UDP-Glucuronosyltransferases in Cultured Primary Human Hepatocytes. Drug Metabolism and Disposition, 2012, 40, 93-103.	3.3	121
244	Stereoselective Interaction of Pantoprazole with ABCG2. II. In Vitro Flux Analysis. Drug Metabolism and Disposition, 2012, 40, 1024-1031.	3.3	7
248	Long-lasting Inhibitory Effects of Cyclosporin A, but Not Tacrolimus, on OATP1B1- and OATP1B3-mediated Uptake. Drug Metabolism and Pharmacokinetics, 2012, 27, 368-378.	2.2	77
249	Comments on Mougey et al. (2009). Pharmacogenetics and Genomics, 2012, 22, 319-322.	1.5	12
250	Drug Disposition in Pathophysiological Conditions. Current Drug Metabolism, 2012, 13, 1327-1344.	1.2	70
251	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. Journal of Cardiovascular Pharmacology, 2012, 60, 335-341.	1.9	29
252	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. Journal of Cardiovascular Pharmacology, 2012, Publish Ahead of Print, .	1.9	32
253	Non-Systemic Drugs: A Critical Review. Current Pharmaceutical Design, 2012, 18, 1434-1445.	1.9	63
257	Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats. Experimental and Therapeutic Medicine, 2012, 4, 524-532.	1.8	10

#	ARTICLE	IF	CITATIONS
259	A Screening Study of Drug-Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 896-904.	4.7	56
262	Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [11C]MC113. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1219-1225.	0.6	17
263	Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. <i>European Journal of Medicinal Chemistry</i> , 2012, 57, 441-448.	5.5	119
264	Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. <i>British Journal of Pharmacology</i> , 2012, 167, 654-665.	5.4	30
265	Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis. <i>Pharmaceutical Research</i> , 2012, 29, 3040-3052.	3.5	50
267	Intrinsically disordered proteins and novel strategies for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 475-488.	5.0	96
268	Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes. <i>Molecular Pharmaceutics</i> , 2012, 9, 3535-3542.	4.6	94
269	Expression and Transport Function of Drug Uptake Transporters in Differentiated HepaRG Cells. <i>Molecular Pharmaceutics</i> , 2012, 9, 3434-3441.	4.6	45
270	Effect of Renal Disease on Pharmacokinetics. , 2012, , 55-64.		2
271	Mechanisms and Genetics of Drug Transport. , 2012, , 217-237.		0
272	Clinical Pharmacogenetics. , 2012, , 195-215.		0
273	Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 199-206.	2.4	14
274	Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist. <i>AAPS Journal</i> , 2012, 14, 68-78.	4.4	63
275	The Solubility-Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs. <i>AAPS Journal</i> , 2012, 14, 244-251.	4.4	217
276	Discrepancies in the P-glycoprotein-Mediated Transport of 18F-MPPF: A Pharmacokinetic Study in Mice and Non-human Primates. <i>Pharmaceutical Research</i> , 2012, 29, 2468-2476.	3.5	27
277	Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2012, 29, 2860-2873.	3.5	122
278	Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells. <i>International Journal of Pharmaceutics</i> , 2012, 436, 426-443.	5.2	12
279	The impact of training set data distributions for modelling of passive intestinal absorption. <i>International Journal of Pharmaceutics</i> , 2012, 436, 711-720.	5.2	10

#	ARTICLE	IF	CITATIONS
280	A Study on Protein (P-glycoprotein) Homology Detection using Hidden Markov Model. <i>Procedia Engineering</i> , 2012, 38, 3541-3546.	1.2	2
281	The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3535-3543.	3.2	27
282	Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 349-360.	3.3	30
283	Human and Rat ABC Transporter Efflux of Bisphenol A and Bisphenol A Glucuronide: Interspecies Comparison and Implications for Pharmacokinetic Assessment. <i>Toxicological Sciences</i> , 2012, 128, 317-325.	3.1	59
284	Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. <i>RSC Advances</i> , 2012, 2, 7948.	3.6	64
285	Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 723-743.	3.3	49
286	Importance of Multi-P450 Inhibition in Drug–Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data. <i>Chemical Research in Toxicology</i> , 2012, 25, 2285-2300.	3.3	39
287	Environmental chemicals as substrates, inhibitors or inducers of drug transporters: implication for toxicokinetics, toxicity and pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 29-46.	3.3	52
289	The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship. <i>Molecular Pharmaceutics</i> , 2012, 9, 1847-1851.	4.6	74
291	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 312-322.	8.7	85
292	Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an <i>in vivo</i> inhibitor of BCRP. <i>British Journal of Pharmacology</i> , 2012, 166, 1793-1803.	5.4	118
293	Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 203-213.	4.7	267
294	Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 874-883.	4.3	53
295	Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?. <i>Diabetes</i> , 2012, 61, 2199-2204.	0.6	172
296	Computational Modeling to Accelerate the Identification of Substrates and Inhibitors for Transporters That Affect Drug Disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 661-665.	4.7	22
297	Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 2-15.	2.5	94
298	Efflux transporters in the blood–brain interfaces – <i>in vitro</i> and <i>in vivo</i> methods and correlations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 419-431.	3.3	16
299	Utility of Drug Depletion-Time Profiles in Isolated Hepatocytes for Accessing Hepatic Uptake Clearance: Identifying Rate-Limiting Steps and Role of Passive Processes. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1596-1602.	3.3	17

#	ARTICLE	IF	CITATIONS
300	Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues. <i>Analytica Chimica Acta</i> , 2012, 717, 67-76.	5.4	40
301	Oxazaphosphorine bioactivation and detoxification: the role of xenobiotic receptors. <i>Acta Pharmaceutica Sinica B</i> , 2012, 2, 107-117.	12.0	32
302	Noncoding microRNAs: small RNAs play a big role in regulation of ADME?. <i>Acta Pharmaceutica Sinica B</i> , 2012, 2, 93-101.	12.0	46
303	Primovist, Eovist: What to expect?. <i>Journal of Hepatology</i> , 2012, 57, 421-429.	3.7	343
304	A LC-MS/MS method to evaluate the hepatic uptake of the liver-specific magnetic resonance imaging contrast agent gadoxetate (Gd-EOB-DTPA) in vitro and in humans. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 891-892, 20-26.	2.3	15
305	Synthesis of [¹¹ C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3703-3709.	3.0	26
306	Contribution of tumoral and host solute carriers to clinical drug response. <i>Drug Resistance Updates</i> , 2012, 15, 5-20.	14.4	25
307	Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 244-255.	4.0	46
308	The right compound in the right assay at the right time: an integrated discovery DMPK strategy. <i>Drug Metabolism Reviews</i> , 2012, 44, 224-252.	3.6	51
309	Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. <i>Biopharmaceutics and Drug Disposition</i> , 2012, 33, 304-315.	1.9	23
310	Impact of the Pharmaceutical Sciences on Health Care: A Reflection over the Past 50 Years. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 4075-4099.	3.3	32
311	Annotating Human P-Glycoprotein Bioassay Data. <i>Molecular Informatics</i> , 2012, 31, 599-609.	2.5	30
312	Long-acting μ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. <i>BMC Pharmacology</i> , 2012, 12, 5.	0.4	78
313	Potential P-Glycoprotein-Mediated Drug-Drug Interactions of Antimalarial Agents in Caco-2 cells. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 64-69.	1.4	14
314	Membrane Transporters in Drug Development. <i>Advances in Pharmacology</i> , 2012, 63, 1-42.	2.0	51
315	Renal Transporters in Drug Disposition, Drug-Drug Interactions, and Nephrotoxicity. <i>Current Protocols in Toxicology</i> / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2012, 53, Unit 23.3.1-15.	1.1	9
316	A Perspective on Efflux Transport Proteins in the Liver. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 599-612.	4.7	95
317	Medicinal Chemistry Challenges in CNS Drug Discovery. <i>RSC Drug Discovery Series</i> , 2012, , 465-509.	0.3	7

#	ARTICLE	IF	CITATIONS
318	The UCSF-FDA TransPortal: A Public Drug Transporter Database. Clinical Pharmacology and Therapeutics, 2012, 92, 545-546.	4.7	155
319	Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions. Journal of Pharmacy and Pharmacology, 2012, 64, 1523-1548.	2.4	30
321	The determination and interpretation of the therapeutic index in drug development. Nature Reviews Drug Discovery, 2012, 11, 751-761.	46.4	418
322	The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review. Clinical Pharmacology and Therapeutics, 2012, 91, 542-549.	4.7	140
324	Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug-Drug Interactions. Journal of Medicinal Chemistry, 2012, 55, 4740-4763.	6.4	299
325	8.8 Molecular Aspects of the Translocation Process by ABC Proteins. , 2012, , 145-173.		9
326	The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. Xenobiotica, 2012, 42, 1197-1205.	1.1	27
327	Pharmaceutical Excipients Influence the Function of Human Uptake Transporting Proteins. Molecular Pharmaceutics, 2012, 9, 2577-2581.	4.6	62
328	Psychotropic Drug-Drug Interactions Involving P-Glycoprotein. CNS Drugs, 2012, 26, 959-973.	5.9	49
329	Regulatory Pathways for ATP-binding Cassette Transport Proteins in Kidney Proximal Tubules. AAPS Journal, 2012, 14, 883-894.	4.4	56
330	Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. Journal of Drug Targeting, 2012, 20, 736-763.	4.4	99
331	N-Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug-Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2-K). Clinical Pharmacology and Therapeutics, 2012, 92, 635-641.	4.7	90
332	CHAPTER 17. Crossing the Blood-brain Barrier - Methods for Evaluating CNS Exposure. RSC Drug Discovery Series, 2012, , 445-464.	0.3	1
333	Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury. International Journal of Antimicrobial Agents, 2012, 39, 343-345.	2.5	15
334	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 5388-5395.	3.0	70
335	Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and) TJ ETQq1 1 0.784314 rgBT /Overlock 10 T Pharmaceutics and Biopharmaceutics, 2012, 82, 340-351.	4.3	188
336	Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 156-162.	4.8	15
337	In Vitro and In Vivo Assessment of Renal Drug Transporters in the Disposition of Mesna and Dimesna. Journal of Clinical Pharmacology, 2012, 52, 530-542.	2.0	28

#	ARTICLE	IF	CITATIONS
338	Exploring membrane protein structural features by oxidative labeling and mass spectrometry. Expert Review of Proteomics, 2012, 9, 497-504.	3.0	21
339	Assessment of P-glycoprotein Substrate and Inhibition Potential of Test Compounds in MDR1-transfected MDCK Cells. Current Protocols in Pharmacology, 2012, 58, Unit7.13.	4.0	4
341	The Pharmacokinetics and Hepatic Disposition of Repaglinide in Pigs: Mechanistic Modeling of Metabolism and Transport. Molecular Pharmaceutics, 2012, 9, 823-841.	4.6	24
343	Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica, 2012, 42, 94-106.	1.1	81
344	Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier. Xenobiotica, 2012, 42, 880-890.	1.1	38
345	Steroid hormones specifically modify the activity of organic anion transporting polypeptides. European Journal of Pharmaceutical Sciences, 2012, 47, 774-780.	4.0	57
346	Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1565-1577.	3.3	24
347	Modeling of Absorption. Methods in Molecular Biology, 2012, 929, 313-336.	0.9	3
348	Mesoporous Silica Nanoparticles for Increasing the Oral Bioavailability and Permeation of Poorly Water Soluble Drugs. Molecular Pharmaceutics, 2012, 9, 505-513.	4.6	173
352	Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology and Therapeutics, 2012, 91, 227-233.	4.7	108
353	LC/MS/MS and radioisotope method combined for recognizing the affinity between catalpol and OCT2 transporter. Frontiers of Chemical Science and Engineering, 2012, 6, 436-442.	4.4	0
354	Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharmaceutica Sinica B, 2012, 2, 549-561.	12.0	217
355	Transporter-Mediated Drug-Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies. Clinical Pharmacology and Therapeutics, 2012, 91, 1053-1064.	4.7	144
356	Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion-Transporting Polypeptides. Clinical Pharmacology and Therapeutics, 2012, 92, 622-630.	4.7	64
357	A decade in drug discovery. Nature Reviews Drug Discovery, 2012, 11, 3-3.	46.4	6
359	Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions. Future Medicinal Chemistry, 2012, 4, 681-693.	2.3	10
360	The Critical Path Initiative: Leveraging Collaborations to Enhance Regulatory Science. Clinical Pharmacology and Therapeutics, 2012, 91, 380-383.	4.7	20
363	Methods for Assessing Blood-Brain Barrier Penetration in Drug Discovery. , 2012, , 169-175.		3

#	ARTICLE	IF	CITATIONS
366	Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Review of Clinical Pharmacology, 2012, 5, 69-89.	3.1	89
367	Pharmacogenomic Mechanisms of Drug Toxicity. , 2012, , 285-306.		0
368	Research Highlights: Highlights from the latest articles in methotrexate- and tamoxifen-related pharmacogenomics. Pharmacogenomics, 2012, 13, 993-995.	1.3	3
369	Drug metabolite heterogeneity in cultured single cells profiled by pico-trapping direct mass spectrometry. Nanomedicine, 2012, 7, 1365-1374.	3.3	29
370	Single-vesicle estimation of ATP-binding cassette transporters in microfluidic channels. Lab on A Chip, 2012, 12, 702-704.	6.0	8
371	Male-Dominant Activation of Rat Renal Organic Anion Transporter 1 (Oat1) and 3 (Oat3) Expression by Transcription Factor BCL6. PLoS ONE, 2012, 7, e35556.	2.5	17
372	Organic Anion and Cation SLC22 "Drug" Transporter (Oat1, Oat3, and Oct1) Regulation during Development and Maturation of the Kidney Proximal Tubule. PLoS ONE, 2012, 7, e40796.	2.5	34
373	Active Sulforhodamine 101 Uptake into Hippocampal Astrocytes. PLoS ONE, 2012, 7, e49398.	2.5	52
374	In Vitro Methods to Study the Interplay of Drug Metabolism and Efflux in the Intestine. Current Drug Metabolism, 2012, 14, 102-111.	1.2	1
375	Interactions between Phytochemical Components of Sutherlandia Frutescens and the Antiretroviral, Atazanavir In Vitro: Implications for Absorption and Metabolism. Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15, 221.	2.1	15
378	Molecular Modeling and Simulation of Membrane Transport Proteins. , 0, , .		0
379	Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability. , 0, , .		42
380	The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics. Current Drug Metabolism, 2012, 13, 624-639.	1.2	34
381	Use of Zinc Finger Nuclease Technology to Knock Out Efflux Transporters in C2BBel Cells. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2012, 52, Unit 23.2..	1.1	10
382	Structure"Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein. Journal of Medicinal Chemistry, 2012, 55, 3261-3273.	6.4	99
383	Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab on A Chip, 2012, 12, 2165.	6.0	1,304
384	Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. Expert Opinion on Drug Delivery, 2012, 9, 1001-1013.	5.0	55
385	The HepaRG cell line: a unique<i>in vitro</i>tool for understanding drug metabolism and toxicology in human. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 909-920.	3.3	187

#	ARTICLE	IF	CITATIONS
386	Differential Selectivity of Efflux Transporter Inhibitors in Caco-2 and MDCKâ€“MDR1 Monolayers: A Strategy to Assess the Interaction of a New Chemical Entity with P-gp, BCRP, and MRP2. Journal of Pharmaceutical Sciences, 2012, 101, 1888-1897.	3.3	60
387	Assessment of Biliary Clearance in Early Drug Discovery using Sandwich-cultured Hepatocyte Model. Journal of Pharmaceutical Sciences, 2012, 101, 1898-1908.	3.3	25
388	Long-Lasting Inhibition of the Intestinal Absorption of Fexofenadine by Cyclosporin a in Rats. Journal of Pharmaceutical Sciences, 2012, 101, 2606-2615.	3.3	5
389	Preclinical<i>in vivo</i>ADME studies in drug development: a critical review. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 161-172.	3.3	40
390	Predicting human hepatic clearance from <i>in vitro</i> drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drugâ€“drug interactions. Biopharmaceutics and Drug Disposition, 2012, 33, 179-194.	1.9	72
391	A Decade of the Human Genome Sequenceâ€“How Does the Medicinal Chemist Benefit?. ChemMedChem, 2012, 7, 194-203.	3.2	19
392	A Substrate Pharmacophore for the Human Organic Cation/Carnitine Transporter Identifies Compounds Associated with Rhabdomyolysis. Molecular Pharmaceutics, 2012, 9, 905-913.	4.6	16
393	Drug Transporters in Drug Efficacy and Toxicity. Annual Review of Pharmacology and Toxicology, 2012, 52, 249-273.	9.4	308
394	Assessment of membrane protein expression and stability using a split green fluorescent protein reporter. Analytical Biochemistry, 2012, 423, 7-14.	2.4	9
395	The transport of antiepileptic drugs by P-glycoprotein. Advanced Drug Delivery Reviews, 2012, 64, 930-942.	13.7	182
396	Drug discovery in the next decade: innovation needed ASAP. Drug Discovery Today, 2012, 17, S31-S44.	6.4	13
397	Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic Î±-aminoxy peptidomimetic. International Journal of Pharmaceutics, 2012, 424, 33-39.	5.2	24
398	Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(Î²-amino esters). Biomaterials, 2012, 33, 6495-6506.	11.4	94
399	Molecular and functional identification of organic anion transporter isoforms in cultured bovine mammary epithelial cells (BMEâ€“UV). Journal of Veterinary Pharmacology and Therapeutics, 2012, 35, 209-215.	1.3	4
400	Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique. Epilepsia, 2012, 53, 529-538.	5.1	45
401	Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. Journal of Controlled Release, 2012, 161, 50-61.	9.9	75
402	Determining P-glycoproteinâ€“drug interactions: Evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. Journal of Pharmacological and Toxicological Methods, 2012, 65, 64-74.	0.7	30
403	Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells. Human Mutation, 2012, 33, 750-762.	2.5	16

#	ARTICLE	IF	CITATIONS
404	Functional Consequences of Genetic Variations in the Human Organic Anion Transporting Polypeptide 1B3 (OATP1B3) in the Korean Population. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1302-1313.	3.3	16
405	Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?. <i>Biopharmaceutics and Drug Disposition</i> , 2012, 33, 55-71.	1.9	78
406	Estimating Intestinal Absorption of Inorganic and Organic Selenium Compounds by in Vitro Flux and Biotransformation Studies in Caco-2 Cells and ICP-MS Detection. <i>Biological Trace Element Research</i> , 2012, 145, 248-256.	3.5	38
407	In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2012, 29, 411-426.	3.5	108
408	The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. <i>Fluids and Barriers of the CNS</i> , 2013, 10, 12.	5.0	98
409	Computational analysis and predictive modeling of polymorph descriptors. <i>Chemistry Central Journal</i> , 2013, 7, 23.	2.6	4
410	Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. <i>Genome Medicine</i> , 2013, 5, 1.	8.2	198
411	The impact of drug transporters on adverse drug reaction. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2013, 38, 77-85.	1.6	11
412	The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 327-342.	1.8	44
413	Epigenetic Regulation of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines. <i>Pharmaceutical Research</i> , 2013, 30, 2880-2890.	3.5	46
414	Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide. <i>Pharmaceutical Research</i> , 2013, 30, 1188-1199.	3.5	96
415	Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential. <i>Pharmaceutical Research</i> , 2013, 30, 761-780.	3.5	128
416	An Overview of Transporter Information in Package Inserts of Recently Approved New Molecular Entities. <i>Pharmaceutical Research</i> , 2013, 30, 899-910.	3.5	22
417	Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1785-1793.	1.9	25
418	In Vivo Inhibition of Trans-Plasma Membrane Electron Transport by Antiviral Drugs in Grapevine. <i>Journal of Membrane Biology</i> , 2013, 246, 513-518.	2.1	4
420	Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 230-242.	4.7	35
421	In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 95-112.	4.7	224
422	Coordinating the impact of structural genomics on the human α -helical transmembrane proteome. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 135-138.	8.2	64

#	ARTICLE	IF	CITATIONS
423	Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells. <i>Toxicology in Vitro</i> , 2013, 27, 1979-1986.	2.4	73
424	Impact of Osmotically Active Excipients on Bioavailability and Bioequivalence of BCS Class III Drugs. <i>AAPS Journal</i> , 2013, 15, 1043-1050.	4.4	40
425	In vitro, in vivo and in silico models of drug distribution into the brain. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 301-314.	1.8	24
426	Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 80-94.	4.7	177
427	Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells. <i>Journal of Drug Targeting</i> , 2013, 21, 776-786.	4.4	20
428	Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. <i>Biochemical Pharmacology</i> , 2013, 86, 691-702.	4.4	87
429	Predicting substrates of the human breast cancer resistance protein using a support vector machine method. <i>BMC Bioinformatics</i> , 2013, 14, 130.	2.6	48
430	An integrated pharmacokinetics ontology and corpus for text mining. <i>BMC Bioinformatics</i> , 2013, 14, 35.	2.6	44
431	Transporter Studies in Drug Development: Experience to Date and Follow-Up on Decision Trees From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 113-125.	4.7	121
432	A P-gp vesicular transport inhibition assay – Optimization and validation for drug–drug interaction testing. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 773-781.	4.0	29
433	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. <i>Archives of Toxicology</i> , 2013, 87, 1315-1530.	4.2	1,089
434	Mass Spectrometry-Based Targeted Proteomics as a Tool to Elucidate the Expression and Function of Intestinal Drug Transporters. <i>AAPS Journal</i> , 2013, 15, 1128-1140.	4.4	52
435	Identification of Novel Substrates and Structure–Activity Relationship of Cellular Uptake Mediated by Human Organic Cation Transporters 1 and 2. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7232-7242.	6.4	78
436	<i>In vivo</i> induction of P-glycoprotein expression at the mouse blood–brain barrier: an intracerebral microdialysis study. <i>Journal of Neurochemistry</i> , 2013, 127, 342-352.	3.9	40
437	An analysis of a –community-driven–™ reconstruction of the human metabolic network. <i>Metabolomics</i> , 2013, 9, 757-764.	3.0	30
438	Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines. <i>International Journal of Pharmaceutics</i> , 2013, 441, 40-49.	5.2	15
439	Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 331-342.	2.2	179
440	Disposition Pathway-Dependent Approach for Predicting Organic Anion-Transporting Polypeptide-Mediated Drug–Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2013, 52, 433-441.	3.5	10

#	ARTICLE	IF	CITATIONS
441	An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3037-3057.	3.3	95
442	LC-MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 85, 253-261.	2.8	135
443	Long-Term Cisplatin Exposure Promotes Methylation of the OCT1 Gene in Human Esophageal Cancer Cells. <i>Digestive Diseases and Sciences</i> , 2013, 58, 694-698.	2.3	27
444	Transporter biology in drug approval: Regulatory aspects. <i>Molecular Aspects of Medicine</i> , 2013, 34, 711-718.	6.4	41
445	The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 767-772.	4.0	7
446	Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology. <i>International Journal of Pharmaceutics</i> , 2013, 452, 8-13.	5.2	42
447	A Moment of Reflection: Sixty Years After the Nobel Prize for Hermann Staudinger. <i>Advances in Polymer Science</i> , 2013, , 1-19.	0.8	4
448	Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in Rat Sandwich-Cultured Hepatocytes Compared with Liver Tissue. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1949-1956.	3.3	32
449	A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1975-1993.	3.3	89
450	Evidence of Drug-Drug Interactions through Uptake and Efflux Transport Systems in Rat Hepatocytes: Implications for Cellular Concentrations of Competing Drugs. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1548-1556.	3.3	17
451	OCTN Cation Transporters in Health and Disease. <i>Journal of Biomolecular Screening</i> , 2013, 18, 851-867.	2.6	86
452	Interaction of Silymarin Flavonolignans with Organic Anion-Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2013, 41, 958-965.	3.3	44
453	In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters. <i>Drug Metabolism and Disposition</i> , 2013, 41, 668-681.	3.3	50
454	Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. <i>Biochemical Pharmacology</i> , 2013, 86, 666-678.	4.4	168
455	[11C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: A PET study using Bcrp TGEM knockout rats. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 520-525.	4.0	10
456	Major Active Components in Grapefruit, Orange, and Apple Juices Responsible for OATP2B1-Mediated Drug Interactions. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3418-3426.	3.3	57
457	Substrate-Dependent Ligand Inhibition of the Human Organic Cation Transporter OCT2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 300-310.	2.5	94
458	The Utility of Modeling and Simulation in Drug Development and Regulatory Review. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2912-2923.	3.3	180

#	ARTICLE	IF	CITATIONS
459	The anthraquinone drug rhein potently interferes with organic anion transporter-mediated renal elimination. <i>Biochemical Pharmacology</i> , 2013, 86, 991-996.	4.4	30
460	Purely in Silico BCS Classification: Science Based Quality Standards for the World's Drugs. <i>Molecular Pharmaceutics</i> , 2013, 10, 4378-4390.	4.6	66
461	Combined in Vitro–in Vivo Approach To Assess the Hepatobiliary Disposition of a Novel Oral Thrombin Inhibitor. <i>Molecular Pharmaceutics</i> , 2013, 10, 4252-4262.	4.6	14
462	Impact of Food and the Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of GDC-0941 in Healthy Volunteers: Bench to Bedside Investigation of pH-Dependent Solubility. <i>Molecular Pharmaceutics</i> , 2013, 10, 4074-4081.	4.6	14
463	Clinical pharmacokinetics of second generation antisense oligonucleotides. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 169-182.	3.3	111
464	Gene Expression Profiling of Transporters in the Solute Carrier and ATP-Binding Cassette Superfamilies in Human Eye Substructures. <i>Molecular Pharmaceutics</i> , 2013, 10, 650-663.	4.6	50
465	Alternative Fusion Protein Strategies to Express Recalcitrant QconCAT Proteins for Quantitative Proteomics of Human Drug Metabolizing Enzymes and Transporters. <i>Journal of Proteome Research</i> , 2013, 12, 5934-5942.	3.7	52
466	Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects. <i>Pharmacological Reviews</i> , 2013, 65, 944-966.	16.0	475
467	Drug-Induced Liver Injury: The Role of Drug Metabolism and Transport. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 463-474.	2.0	126
468	Variability in P-Glycoprotein Inhibitory Potency (IC_{50}) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1347-1366.	3.3	136
469	Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1367-1374.	3.3	41
470	In vitro characterization of ABC transporters involved in the absorption and distribution of liensinine and its analogs. <i>Journal of Ethnopharmacology</i> , 2013, 150, 485-491.	4.1	25
471	Clinical relevance of drug efflux pumps in the gut. <i>Current Opinion in Pharmacology</i> , 2013, 13, 847-852.	3.5	44
472	New Insights into the Carrier-Mediated Transport of Estrone-3-sulfate in the Caco-2 Cell Model. <i>Molecular Pharmaceutics</i> , 2013, 10, 3285-3295.	4.6	13
473	Transport of organic cationic drugs: Effect of ion-pair formation with bile salts on the biliary excretion and pharmacokinetics. , 2013, 138, 142-154.		17
474	Assessment of Drug Transporter Function Using Fluorescent Cell Imaging. <i>Current Protocols in Toxicology</i> / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2013, 57, Unit 23.6..	1.1	19
475	The utility of cold-preserved human hepatocytes in studies on cytochrome P450 induction and hepatic drug transport. <i>Xenobiotica</i> , 2013, 43, 785-791.	1.1	1
476	Organic anion, organic cation and zwitterion transporters of the SLC22 and SLC47 superfamily (OATs,) Tj ETQq1 1 0.784314rgBT /Over		

#	ARTICLE	IF	CITATIONS
477	Assessment of gadoxetate DCEâ€MRI as a biomarker of hepatobiliary transporter inhibition. NMR in Biomedicine, 2013, 26, 1258-1270.	2.8	44
478	Prediction of Clinical Drugâ€Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). Journal of Pharmaceutical Sciences, 2013, 102, 4426-4432.	3.3	57
479	Drug transporters in drug discovery and development. , 2013, , 633-674.		3
480	Renal Uptake of Substrates for Organic Anion Transporters Oat1 and Oat3 and Organic Cation Transporters Oct1 and Oct2 is Altered in Rats with Adenine-Induced Chronic Renal Failure. Journal of Pharmaceutical Sciences, 2013, 102, 1086-1094.	3.3	44
481	Cut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. Integrative Biology (United Kingdom), 2013, 5, 1130.	1.3	560
482	Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2013, 16, 399-451.	6.5	109
483	Detection of Statin Cytotoxicity Is Increased in Cells Expressing the OATP1B1 Transporter. Toxicological Sciences, 2013, 134, 73-82.	3.1	18
484	In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor. Drug Metabolism and Disposition, 2013, 41, 353-361.	3.3	201
485	Confounding Parameters in Preclinical Assessment of Bloodâ€Brain Barrier Permeation: An Overview With Emphasis on Species Differences and Effect of Disease States. Molecular Pharmaceutics, 2013, 10, 1581-1595.	4.6	82
486	The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discovery Today, 2013, 18, 218-239.	6.4	130
487	Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics?. Canadian Journal of Cardiology, 2013, 29, 58-66.	1.7	13
488	Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling. Journal of Medicinal Chemistry, 2013, 56, 781-795.	6.4	131
489	Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions. Pharmaceutical Research, 2013, 30, 996-1007.	3.5	76
490	Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms. Annual Review of Pharmacology and Toxicology, 2013, 53, 581-612.	9.4	111
491	Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharmaceutics and Drug Disposition, 2013, 34, 45-78.	1.9	345
492	Pharmacokinetics and metabolism of [¹⁴ C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica, 2013, 43, 432-442.	1.1	33
493	Complementary Techniques: Positron Emission Tomography. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 269-282.	0.6	0
494	Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 237-252.	3.3	239

#	ARTICLE	IF	CITATIONS
495	The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 267-285.	3.3	33
496	Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Regionâ€‘Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 879-894.	6.4	125
497	Tissue distribution and phenobarbital induction of target SLCâ€‘and <scp>ABC</scp>â€‘transporters in cattle. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2013, 36, 358-369.	1.3	8
498	A Physiologically Based Pharmacokinetic Model of the Minipig: Data Compilation and Model Implementation. <i>Pharmaceutical Research</i> , 2013, 30, 1-15.	3.5	75
499	Renal Transporters in Drug Development. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 503-529.	9.4	267
500	Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic <i>in vitroâ€‘in vivo</i> extrapolation of oral drug absorption. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 2-28.	1.9	96
501	Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50	1.9	122
502	Major Active Components in Grapefruit, Orange, and Apple Juices Responsible for OATP2B1-Mediated Drug Interactions. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 280-288.	3.3	55
503	The synthesis and biodistribution of [11C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7584-7590.	3.0	36
504	Role of membrane transporters in drug interactions. <i>Clinical Therapeutics</i> , 2013, 35, e122.	2.5	1
505	Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. <i>Nuclear Medicine and Biology</i> , 2013, 40, 755-763.	0.6	15
506	Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 420-428.	4.0	40
507	Kinetic Analysis of Human and Canine P-Glycoprotein-Mediated Drug Transport in MDR1-MDCK Cell Model: Approaches to Reduce False-Negative Substrate Classification. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3436-3446.	3.3	20
508	Human Organic Cation Transporters 1 (<i>SLC22A1</i>), 2 (<i>SLC22A2</i>), and 3 (<i>SLC22A3</i>) as Disposition Pathways for Fluoroquinolone Antimicrobials. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2705-2711.	3.2	27
509	Structure-Based Identification of OATP1B1/3 Inhibitors. <i>Molecular Pharmacology</i> , 2013, 83, 1257-1267.	2.3	110
510	Potential Role of Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1725-1731.	3.3	68
511	Drug disposition: From cradle to cane. <i>International Journal of Pharmaceutics</i> , 2013, 452, 1-2.	5.2	1
512	Functional expression and regulation of drug transporters in monolayer- and sandwich-cultured mouse hepatocytes. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 39-50.	4.0	15

#	ARTICLE	IF	CITATIONS
513	Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 767-774.	4.0	26
514	Detergent-mediated protein aggregation. <i>Chemistry and Physics of Lipids</i> , 2013, 169, 72-84.	3.2	13
515	Domoic acid toxicokinetics in Dungeness crabs: New insights into mechanisms that regulate bioaccumulation. <i>Aquatic Toxicology</i> , 2013, 140-141, 77-88.	4.0	16
516	Drugs interacting with organic anion transporter-1 affect uptake of Tc-99m-mercaptoacetyl-triglycine (MAG3) in the human kidney: Therapeutic drug interaction in Tc-99m-MAG3 diagnosis of renal function and possible application of Tc-99m-MAG3 for drug development. <i>Nuclear Medicine and Biology</i> , 2013, 40, 643-650.	0.6	22
517	The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin. <i>Cardiovascular Toxicology</i> , 2013, 13, 33-47.	2.7	21
518	Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 103-115.	46.4	66
519	Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 319-330.	5.0	53
520	Preclinical Development of Oncology Drugs. , 2013, , 543-565.		1
521	Apple juice greatly reduces systemic exposure to atenolol. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 172-179.	2.4	60
522	Intestinal drug transporters: An overview. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1340-1356.	13.7	265
523	Free energy of WALP23 dimer association in DMPC, DPPC, and DOPC bilayers. <i>Chemistry and Physics of Lipids</i> , 2013, 169, 95-105.	3.2	111
524	A strategy to reduce biliary clearance in early drug discovery. <i>Journal of Pharmacological and Toxicological Methods</i> , 2013, 68, 346-348.	0.7	1
530	Pharmacokinetics of two common antiretroviral regimens in older <sc>HIV</sc>-infected patients: a pilot study. <i>HIV Medicine</i> , 2013, 14, 401-409.	2.2	20
531	Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 459-472.	3.3	63
532	Evaluation of transporter-mediated hepatic uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference and plasma protein effect. <i>Xenobiotica</i> , 2013, 43, 253-262.	1.1	10
533	Renal Disposition of Drugs and Translation to Dosing Strategies. , 2013, , 3185-3214.		0
534	Primary hepatocyte cultures as prominent<i>in vitro</i> tools to study hepatic drug transporters. <i>Drug Metabolism Reviews</i> , 2013, 45, 196-217.	3.6	26
535	ADME characterization in rats revealed immediate secretion of AZD7903 into the stomach after IV dosing. <i>Xenobiotica</i> , 2013, 43, 823-835.	1.1	3

#	ARTICLE	IF	CITATIONS
536	A membrane vesicle-based assay to enable prediction of human biliary excretion. <i>Xenobiotica</i> , 2013, 43, 915-919.	1.1	8
537	Induction of Xenobiotic Receptors, Transporters, and Drug Metabolizing Enzymes by Oxycodone. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1060-1069.	3.3	7
538	Homogeneous size reduction of metallic glass in a common acidic aqueous medium. <i>Materials Letters</i> , 2013, 100, 299-302.	2.6	2
539	Drug Discovery and Regulatory Considerations for Improving In Silico and In Vitro Predictions that Use Caco-2 as a Surrogate for Human Intestinal Permeability Measurements. <i>AAPS Journal</i> , 2013, 15, 483-497.	4.4	113
540	Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects. <i>Pharmacology</i> , 2013, 91, 12-19.	2.2	22
542	Optimizing the<i>in vitro</i> and clinical assessment of drug interaction risk by understanding co-medications in patient populations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 737-751.	3.3	12
543	Crystal structure of a eukaryotic phosphate transporter. <i>Nature</i> , 2013, 496, 533-536.	27.8	202
544	Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 143-157.	3.1	51
545	The P-Glycoprotein Transport System and Cardiovascular Drugs. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2495-2502.	2.8	297
546	Absorption: In Vitro Tests – Cell Based. , 2013, , 745-777.		0
547	Pharmacogenomics in Drug Metabolizing Enzymes and Transporters. , 2013, , 1095-1123.		0
548	Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1699-1715.	13.7	331
549	Prediction of Drug Disposition on the Basis of its Chemical Structure. <i>Clinical Pharmacokinetics</i> , 2013, 52, 415-431.	3.5	25
550	Improved Oral Bioavailability of BCS Class 2 Compounds by Self Nano-Emulsifying Drug Delivery Systems (SNEDDS): The Underlying Mechanisms for Amiodarone and Talinolol. <i>Pharmaceutical Research</i> , 2013, 30, 3029-3044.	3.5	82
551	Renal Organic Anion Transporters (SLC22 Family): Expression, Regulation, Roles in Toxicity, and Impact on Injury and Disease. <i>AAPS Journal</i> , 2013, 15, 53-69.	4.4	117
552	Evaluating the In Vitro Inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in Predicting Drug-Induced Hyperbilirubinemia. <i>Molecular Pharmaceutics</i> , 2013, 10, 3067-3075.	4.6	62
553	Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin. <i>Clinical Pharmacokinetics</i> , 2013, 52, 805-813.	3.5	16
554	Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. <i>Pharmacogenomics Journal</i> , 2013, 13, 251-256.	2.0	35

#	ARTICLE	IF	CITATIONS
555	Lamivudine permeability study: A comparison between PAMPA, ex vivo and in situ Single-Pass Intestinal Perfusion (SPIP) in rat jejunum. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 781-789.	4.0	39
556	Constrained H-Phe-Phe-NH ₂ Analogues with High Affinity to the Substance P τ Binding Site and with Improved Metabolic Stability and Cell Permeability. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4953-4965.	6.4	16
557	Organic Stereochemistry. Part 5. <i>Helvetica Chimica Acta</i> , 2013, 96, 747-798.	1.6	19
558	Animal models of toxicology testing: the role of pigs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 127-139.	3.3	93
559	Drug-Drug Interaction Studies: Regulatory Guidance and An Industry Perspective. <i>AAPS Journal</i> , 2013, 15, 629-645.	4.4	193
560	Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 275-282.	4.7	82
561	Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3018-3036.	3.3	28
562	Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor α . <i>Xenobiotica</i> , 2013, 43, 963-972.	1.1	8
563	Ischemia/Reperfusion-Inducible Protein Modulates the Function of Organic Cation Transporter 1 and Multidrug and Toxin Extrusion 1. <i>Molecular Pharmaceutics</i> , 2013, 10, 2578-2587.	4.6	14
564	Review of IC_{50} Inhibition Data in Recently Approved New Drug Applications: Utility of the Proposed IC_{50} and IC_{25} Criteria in the IC_{50} Decision Tree. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 228-233.	2.0	52
565	Pharmacophore-Based Drug Design and Biological Evaluation of Novel ABCB1 Inhibitors. <i>Chemical Biology and Drug Design</i> , 2013, 81, 349-358.	3.2	5
566	The SLCO (former SLC21) superfamily of transporters. <i>Molecular Aspects of Medicine</i> , 2013, 34, 396-412.	6.4	312
567	P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. <i>Lancet Neurology</i> , The, 2013, 12, 777-785.	10.2	155
568	Transporters in Drug Development and Clinical Pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 3-9.	4.7	127
569	Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 52-63.	4.7	307
570	Different strategies to overcome multidrug resistance in cancer. <i>Biotechnology Advances</i> , 2013, 31, 1397-1407.	11.7	215
571	An Integrated <i>In Vitro</i> Model for Simultaneous Assessment of Drug Uptake, Metabolism, and Efflux. <i>Molecular Pharmaceutics</i> , 2013, 10, 3152-3163.	4.6	14
574	Development of an Improved Three-Dimensional <i>In Vitro</i> Intestinal Mucosa Model for Drug Absorption Evaluation. <i>Tissue Engineering - Part C: Methods</i> , 2013, 19, 708-719.	2.1	90

#	ARTICLE	IF	CITATIONS
575	Mechanistic Role of Acyl Glucuronides. , 2013, , 35-70.		11
576	Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug. Xenobiotica, 2013, 43, 355-367.	1.1	11
577	Molecular Insight into Affinities of Drugs and Their Metabolites to Lipid Bilayers. Journal of Physical Chemistry B, 2013, 117, 2403-2410.	2.6	50
578	Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. European Journal of Pharmacology, 2013, 701, 168-175.	3.5	41
579	Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metabolism and Disposition, 2013, 41, 827-835.	3.3	109
580	Intestinal Absorption Mechanism of Mirabegron, a Potent and Selective β_2 -Adrenoceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems. Molecular Pharmaceutics, 2013, 10, 1783-1794.	4.6	18
581	ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans. Clinical Pharmacology and Therapeutics, 2013, 94, 64-79.	4.7	172
582	Metallic nano/microglasses: new approaches in nanostructured materials science. Physics-Uspekhi, 2013, 56, 261-268.	2.2	18
583	Tissue Analysis for Drug Development. , 2013, , .		0
584	Expression analysis of MDR1, BCRP and MRP3 transporter proteins in different in vitro and ex vivo cornea models for drug absorption studies. International Journal of Pharmaceutics, 2013, 441, 765-775.	5.2	25
585	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from <i>in vitro</i> data to clinical study design. Xenobiotica, 2013, 43, 498-508.	1.1	42
586	Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Investigational New Drugs, 2013, 31, 1125-1135.	2.6	24
587	In Vivo Absorption and Disposition of Cefadroxil After Escalating Oral Doses in Wild-Type and PepT1 Knockout Mice. Pharmaceutical Research, 2013, 30, 2931-2939.	3.5	20
588	Resolving the Distributionâ€“Metabolism Interplay of Eight OATP Substrates in the Standard Clearance Assay with Suspended Human Cryopreserved Hepatocytes. Molecular Pharmaceutics, 2013, 10, 4443-4451.	4.6	17
589	Combinatorial Pharmacophore Modeling of Organic Cation Transporter 2 (OCT2) Inhibitors: Insights into Multiple Inhibitory Mechanisms. Molecular Pharmaceutics, 2013, 10, 4611-4619.	4.6	21
590	Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 495-503.	2.5	40
591	Thermosensitive Liposomes for the Delivery of Gemcitabine and Oxaliplatin to Tumors. Molecular Pharmaceutics, 2013, 10, 4499-4508.	4.6	47
592	Demystifying Brain Penetration in Central Nervous System Drug Discovery. Journal of Medicinal Chemistry, 2013, 56, 2-12.	6.4	243

#	ARTICLE	IF	CITATIONS
593	Effect of Ritonavir on ^{99m} Tc-Mebrofenin Disposition in Humans: A Semi-MPBPK Modeling and <i>In Vitro</i> Approach to Predict Transporter-Mediated DDIs. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-10.	2.5	39
594	Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response. Drug Metabolism and Pharmacokinetics, 2013, 28, 4-18.	2.2	108
595	A virtual high-throughput screening approach to the discovery of novel inhibitors of the bacterial leucine transporter, LeuT. Molecular Membrane Biology, 2013, 30, 184-194.	2.0	3
596	Chronic nicotine exposure and acute kidney injury: new concepts and experimental evidence. Nephrology Dialysis Transplantation, 2013, 28, 1329-1331.	0.7	8
597	Transporter pharmacogenetics: do we need function? Do we need motion?. Pharmacogenomics, 2013, 14, 1537-1540.	1.3	1
598	Cholinergic Modulation by Opioid Receptor Ligands: Potential Application to Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2013, 13, 456-466.	2.4	7
599	Ex Vivo and In Vivo Investigations of the Effects of Extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on Digoxin Transport and Pharmacokinetics: Assessing the Significance on Rat Intestinal P-glycoprotein Efflux. Drug Metabolism and Pharmacokinetics, 2013, 28, 314-320.	2.2	10
600	Biology of ocular transporters: efflux and influx transporters in the eye. , 2013, , 37-84.		6
601	HIV pre-exposure prophylaxis trials: the road to success. Clinical Investigation, 2013, 3, 295-308.	0.0	16
603	Modeling Human Liver Biology Using Stem Cell-Derived Hepatocytes. International Journal of Molecular Sciences, 2013, 14, 22011-22021.	4.1	6
604	Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. Xenobiotica, 2013, 43, 229-235.	1.1	36
605	Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circulation: Cardiovascular Genetics, 2013, 6, 400-408.	5.1	168
606	Pharmacogenomics in early-phase clinical development. Pharmacogenomics, 2013, 14, 1085-1097.	1.3	50
607	Metformin Sinusoidal Efflux from the Liver Is Consistent with Negligible Biliary Excretion and Absence of Enterohepatic Cycling. Drug Metabolism and Disposition, 2013, 41, 1967-1971.	3.3	24
608	Exploration of the Protection of Riboflavin Laurate on Oral Mucositis Induced by Chemotherapy or Radiotherapy at the Cellular Level: What Is the Leading Contributor?. International Journal of Molecular Sciences, 2013, 14, 4722-4733.	4.1	6
609	Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. American Journal of Physiology - Cell Physiology, 2013, 305, C1223-C1229.	4.6	14
610	Integrated Approach of In Vivo and In Vitro Evaluation of the Involvement of Hepatic Uptake Organic Anion Transporters in the Drug Disposition in Rats Using Rifampicin as an Inhibitor. Drug Metabolism and Disposition, 2013, 41, 1442-1449.	3.3	19
611	Organic Cation Transporter 1 (OCT1/mOct1) Is Localized in the Apical Membrane of Caco-2 Cell Monolayers and Enterocytes. Molecular Pharmacology, 2013, 84, 182-189.	2.3	93

#	ARTICLE	IF	CITATIONS
612	Hepatocyte Nuclear Factors 4<i>Ï±</i> and 1<i>Ï±</i> Regulate Kidney Developmental Expression of Drug-Metabolizing Enzymes and Drug Transporters. <i>Molecular Pharmacology</i> , 2013, 84, 808-823.	2.3	101
613	DNA Methylation and Histone Modification Profiles of Mouse Organic Anion Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2013, 41, 72-78.	3.3	21
614	Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2013, 41, 206-213.	3.3	39
615	Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data. <i>Drug Metabolism and Disposition</i> , 2013, 41, 744-753.	3.3	24
616	Development of Novel, 384-Well High-Throughput Assay Panels for Human Drug Transporters: Drug Interaction and Safety Assessment in Support of Discovery Research. <i>Journal of Biomolecular Screening</i> , 2013, 18, 1072-1083.	2.6	15
617	Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma. <i>Journal of International Medical Research</i> , 2013, 41, 964-974.	1.0	5
618	Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 673-685.	2.5	73
619	Organic anion-transporting polypeptides (OATPs/SLCOs). , 2013, , 353-454.		0
620	In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1575-1583.	3.3	40
621	Fruit/Vegetable-Drug Interactions: Effects on Drug Metabolizing Enzymes and Drug Transporters. , 0, , .		9
622	Evaluation and Prediction of Potential Drug-Drug Interactions of Linagliptin Using In Vitro Cell Culture Methods. <i>Drug Metabolism and Disposition</i> , 2013, 41, 149-158.	3.3	26
623	Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin. <i>Drug Metabolism and Disposition</i> , 2013, 41, 966-974.	3.3	55
624	Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1994-2003.	3.3	35
625	Minor Compensatory Changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Do Not Detract from Their Utility in the Study of Transporter-Mediated Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1174-1178.	3.3	17
626	The Role of Human Equilibrative Nucleoside Transporter 1 on the Cellular Transport of the DNA Methyltransferase Inhibitors 5-Azacytidine and CP-4200 in Human Leukemia Cells. <i>Molecular Pharmacology</i> , 2013, 84, 438-450.	2.3	45
627	Effect of Gestational Age on mRNA and Protein Expression of Polyspecific Organic Cation Transporters during Pregnancy. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2225-2232.	3.3	53
628	Liver Fibrosis: Histopathologic and Biochemical Influences on Diagnostic Efficacy of Hepatobiliary Contrast-enhanced MR Imaging in Staging. <i>Radiology</i> , 2013, 269, 460-468.	7.3	80
629	Gefitinib Enhances the Antitumor Activity of CPT-11 in vitro and in vivo by Inhibiting ABCG2 but Not ABCB1: A New Clue to Circumvent Gastrointestinal Toxicity Risk. <i>Chemotherapy</i> , 2013, 59, 260-272.	1.6	4

#	ARTICLE	IF	CITATIONS
630	Functional liver reserve parameters predictive for posthepatectomy complications. Journal of Surgical Research, 2013, 185, 127-135.	1.6	22
632	Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17 β -Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein. Drug Metabolism and Disposition, 2013, 41, 1859-1866.	3.3	84
633	Transporter study methodologies. , 2013, , 675-718.		2
634	OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenetics and Genomics, 2013, 23, 355-364.	1.5	47
635	Organic Cation Transporter 3 (OCT3/SLC22A3) and Multidrug and Toxin Extrusion 1 (MATE1/SLC47A1) Transporter in the Placenta and Fetal Tissues: Expression Profile and Fetus Protective Role at Different Stages of Gestation. Biology of Reproduction, 2013, 88, 55.	2.7	58
636	Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. American Journal of Physiology - Renal Physiology, 2013, 304, F56-F67.	2.7	55
637	In Vivo Characterization of Interactions on Transporters. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 67-97.	0.6	3
638	The Use of Microdialysis Techniques in Mice to Study P-gp Function at the Blood-Brain Barrier. Journal of Biomolecular Screening, 2013, 18, 430-440.	2.6	15
639	Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. Pharmacogenomics, 2013, 14, 1745-1764.	1.3	17
640	Metabolic Interactions of Purine Derivatives with Human ABC Transporter ABCG2: Genetic Testing to Assess Gout Risk. Pharmaceuticals, 2013, 6, 1347-1360.	3.8	54
641	Expression of Efflux Transporters in Human Ocular Tissues. Drug Metabolism and Disposition, 2013, 41, 1934-1948.	3.3	42
642	Long-Term Stability of Primary Rat Hepatocytes in Micropatterned Cocultures. Journal of Biochemical and Molecular Toxicology, 2013, 27, 204-212.	3.0	54
643	Long-Lasting Inhibitory Effects of Saquinavir and Ritonavir on OATP1B1-Mediated Uptake. Journal of Pharmaceutical Sciences, 2013, 102, 3427-3435.	3.3	33
644	Drug interactions with statins. Acta Pharmaceutica, 2013, 63, 277-293.	2.0	35
645	New QSAR Models for Human Cytochromes P450, 1A2, 2D6 and 3A4 Implicated in the Metabolism of Drugs. Relevance of Dataset on Model Development.. Molecular Informatics, 2013, 32, 573-577.	2.5	3
646	Relationship Between the Urinary Excretion Mechanisms of Drugs and Their Physicochemical Properties. Journal of Pharmaceutical Sciences, 2013, 102, 3294-3301.	3.3	19
647	Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 164-170.	2.5	41
648	Membrane transporters and the diseases corresponding to functional defects. , 2013, , 1-146.		2

#	ARTICLE	IF	CITATIONS
649	Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3228-3238.	3.3	17
650	Quantitative assessment of the contribution of sodiumâ€dependent taurocholate coâ€transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 452-461.	1.9	72
651	Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 787-793.	3.3	99
652	Fentanyl Pharmacokinetics is not Dependent on Hepatic Uptake by Organic Anionâ€Transporting Polypeptide 1B1 in Human Beings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 43-48.	2.5	9
653	Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats. <i>Drug Metabolism and Disposition</i> , 2013, 41, 906-915.	3.3	49
654	International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 23-26.	4.7	147
655	Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [¹¹ C]Dehydropravastatin in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 193-202.	2.5	51
656	Overview of Experimental Models of the Bloodâ€Brain Barrier in CNS Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2013, 62, 7.15.1-7.15.30.	4.0	17
657	Involvement of Organic Anion-Transporting Polypeptides in the Hepatic Uptake of Dioscin in Rats and Humans. <i>Drug Metabolism and Disposition</i> , 2013, 41, 994-1003.	3.3	33
658	Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5612-5618.	3.2	26
659	Interaction of Ethambutol with Human Organic Cation Transporters of the SLC22 Family Indicates Potential for Drug-Drug Interactions during Antituberculosis Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5053-5059.	3.2	27
660	Principles of Pharmacogenomics. , 2013, , 1-44.		4
661	Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam. <i>Xenobiotica</i> , 2013, 43, 598-606.	1.1	5
662	Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. <i>Cell Death and Disease</i> , 2013, 4, e905-e905.	6.3	25
663	Short Communication: Expression of Transporters and Metabolizing Enzymes in the Female Lower Genital Tract: Implications for Microbicide Research. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1496-1503.	1.1	41
664	Potential involvement of the proton-coupled amino acid transporter PAT1 (SLC36A1) in the delivery of pharmaceutical agents. <i>Journal of Drug Delivery Science and Technology</i> , 2013, 23, 293-306.	3.0	5
665	Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 287-306.	3.3	26
666	P-Glycoprotein Increases Portal Bioavailability of Loperamide in Mouse by Reducing First-Pass Intestinal Metabolism. <i>Drug Metabolism and Disposition</i> , 2013, 41, 642-650.	3.3	18

#	ARTICLE	IF	CITATIONS
667	Multispecific Drug Transporter <i>Slc22a8</i> (<i>Oat3</i>) Regulates Multiple Metabolic and Signaling Pathways. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1825-1834.	3.3	62
668	Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-9.	2.5	42
670	Competitive Inhibition of Human Organic Anion Transporters 1 (SLC22A6), 3 (SLC22A8) and 4 (SLC22A11) by Major Components of the Medicinal Herb <i>Salvia miltiorrhiza</i> (Danshen). <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 220-228.	2.2	26
671	In Vitro Methods to Study the Interplay of Drug Metabolism and Efflux in the Intestine. <i>Current Drug Metabolism</i> , 2013, 14, 102-111.	1.2	13
673	Inhibition of Phosphate Transporters Ameliorates the Inflammatory and Necrotic Side Effects of the Nitrogen-Containing Bisphosphonate Zoledronate in Mice. <i>Tohoku Journal of Experimental Medicine</i> , 2013, 231, 145-158.	1.2	19
674	Proteoliposomes as Tool for Assaying Membrane Transporter Functions and Interactions with Xenobiotics. <i>Pharmaceutics</i> , 2013, 5, 472-497.	4.5	59
675	Intestinal Ischemia-Reperfusion Suppresses Biliary Excretion of Hepatic Organic Anion Transporting Polypeptides Substrate. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 722.	2.1	2
676	The Roles of Membrane Transporters on the Oral Drug Absorption. <i>Journal of Molecular Pharmaceutics & Organic Process Research</i> , 2013, 1, .	2.0	10
677	A Method to Measure Hydrolytic Activity of Adenosinetriphosphatases (ATPases). <i>PLoS ONE</i> , 2013, 8, e58615.	2.5	29
678	Gene Expression Variability in Human Hepatic Drug Metabolizing Enzymes and Transporters. <i>PLoS ONE</i> , 2013, 8, e60368.	2.5	43
679	Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1). <i>PLoS ONE</i> , 2013, 8, e75520.	2.5	6
680	Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro. <i>PLoS ONE</i> , 2013, 8, e83467.	2.5	27
681	Bioengineered 3D Human Kidney Tissue, a Platform for the Determination of Nephrotoxicity. <i>PLoS ONE</i> , 2013, 8, e59219.	2.5	105
682	The blood-brain barrier: an engineering perspective. <i>Frontiers in Neuroengineering</i> , 2013, 6, 7.	4.8	458
683	Cell volume regulation in epithelial physiology and cancer. <i>Frontiers in Physiology</i> , 2013, 4, 233.	2.8	81
684	Metabolism and pharmacokinetic optimization strategies in drug discovery. , 2013, , 135-155.		3
685	Integrative analysis of transporter-mediated drug-drug interactions. <i>Drug Delivery System</i> , 2014, 29, 426-438.	0.0	0
687	Effects of Danshen Ethanol Extract on the Pharmacokinetics of Fexofenadine in Healthy Volunteers. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-5.	1.2	8

#	ARTICLE	IF	CITATIONS
688	Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. <i>Frontiers in Chemistry</i> , 2014, 2, 61.	3.6	193
689	Inhibition of Human Efflux Transporter ABCC2 (MRP2) by Self-emulsifying Drug Delivery System: Influences of Concentration and Combination of Excipients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2014, 17, 447.	2.1	16
690	Tacrine Sinusoidal Uptake and Biliary Excretion in Sandwich-Cultured Primary Rat Hepatocytes. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2014, 17, 427.	2.1	5
691	Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study. <i>Clinical Pharmacology: Advances and Applications</i> , 2014, 6, 149.	1.2	3
692	AMINO ACID TRANSPORTERS IN DRUG DISCOVERY. <i>Current Research in Drug Discovery</i> , 2014, 1, 1-16.	0.4	0
694	Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1780-1784.	3.3	15
695	The Mechanism of Enterohepatic Circulation in the Formation of Gallstone Disease. <i>Journal of Membrane Biology</i> , 2014, 247, 1067-1082.	2.1	56
696	â€œEffect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183â€. <i>Investigational New Drugs</i> , 2014, 32, 1083-1095.	2.6	11
697	Membrane transporters and transporter substrates as biomarkers for drug pharmacokinetics, pharmacodynamics, and toxicity/adverse events. , 2014, , 947-963.		2
698	Cationic micellar nanoparticles for DNA and doxorubicin co-delivery. <i>Materials Science and Engineering C</i> , 2014, 44, 430-439.	7.3	26
699	Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. <i>Xenobiotica</i> , 2014, 44, 96-108.	1.1	40
700	Ivermectin exposure leads to up-regulation of detoxification genes in vitro and in vivo in mice. <i>European Journal of Pharmacology</i> , 2014, 740, 428-435.	3.5	12
701	Pharmacokinetic Comparison To Determine the Mechanisms Underlying the Differential Efficacies of Cationic Diamidines against First- and Second-Stage Human African Trypanosomiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4064-4074.	3.2	20
702	Effect of transporter inhibition on the distribution of cefadroxil in rat brain. <i>Fluids and Barriers of the CNS</i> , 2014, 11, 25.	5.0	21
703	Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1411-1422.	3.3	38
704	Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate. <i>American Journal of Physiology - Cell Physiology</i> , 2014, 307, C1071-C1080.	4.6	54
705	Effects of Proton Pump Inhibitors on Metformin Pharmacokinetics and Pharmacodynamics. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1174-1179.	3.3	37
706	Quantitative Prediction of Transporter- and Enzyme-Mediated Clinical Drug-Drug Interactions of Organic Anion-Transporting Polypeptide 1B1 Substrates Using a Mechanistic Net-Effect Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 214-223.	2.5	61

#	ARTICLE	IF	CITATIONS
707	Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 283-291.	6.1	9
708	Edoxaban population pharmacokinetics and exposureâ€“response analysis in patients with non-valvular atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1339-1351.	1.9	60
709	In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. <i>Xenobiotica</i> , 2014, 44, 276-282.	1.1	32
710	Principles and Experimental Considerations for In Vitro Transporter Interaction Assays. <i>Methods in Molecular Biology</i> , 2014, 1113, 229-252.	0.9	8
711	Rationalizing Underprediction of Drug Clearance from Enzyme and Transporter Kinetic Data: From In Vitro Tools to Mechanistic Modeling. <i>Methods in Molecular Biology</i> , 2014, 1113, 255-288.	0.9	19
712	Docking Applied to the Prediction of the Affinity of Compounds to P-Glycoprotein. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	25
713	Persistent pharmacokinetic challenges to pediatric drug development. <i>Frontiers in Genetics</i> , 2014, 5, 281.	2.3	19
714	Evaluation of drug interaction potential of <i>Labisia pumila</i> (Kacip Fatimah) and its constituents. <i>Frontiers in Pharmacology</i> , 2014, 5, 178.	3.5	21
715	How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. <i>Frontiers in Pharmacology</i> , 2014, 5, 231.	3.5	136
716	Differentiation of Human Induced Pluripotent Stem Cells into Functional Enterocyte-like Cells Using a Simple Method. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 44-51.	2.2	52
717	Barriers to Drug Delivery for Brain Trauma. , 2014, , 125-140.		1
718	Pore-Exposed Tyrosine Residues of P-Glycoprotein Are Important Hydrogen-Bonding Partners for Drugs. <i>Molecular Pharmacology</i> , 2014, 85, 420-428.	2.3	30
719	Understanding transporter specificity and the discrete appearance of channel-like gating domains in transporters. <i>Frontiers in Pharmacology</i> , 2014, 5, 207.	3.5	61
720	Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole. <i>Xenobiotica</i> , 2014, 44, 926-932.	1.1	7
721	In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases. <i>Pharmacotherapy</i> , 2014, 34, 114-122.	2.6	26
722	<i>In vitro</i> experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506). <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 135-144.	1.9	4
723	Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1301-1313.	3.3	31
724	Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein. <i>SAR and QSAR in Environmental Research</i> , 2014, 25, 939-966.	2.2	28

#	ARTICLE	IF	CITATIONS
725	Novel <i>in vitro</i> systems for prediction of veterinary drug residues in ovine milk and dairy products. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2014, 31, 1026-1037.	2.3	15
727	Inhibitory Effect of Valsartan on the Intestinal Absorption and Renal Excretion of Bestatin in Rats. Journal of Pharmaceutical Sciences, 2014, 103, 719-729.	3.3	17
728	Gene expression analysis of membrane transporters and drug-metabolizing enzymes in the lung of healthy and COPD subjects. Pharmacology Research and Perspectives, 2014, 2, e00054.	2.4	23
729	Species differences in sinusoidal and canalicular efflux transport of mycophenolic acid glucuronide in sandwich-cultured hepatocytes. Pharmacology Research and Perspectives, 2014, 2, e00035.	2.4	8
730	Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 561-580.	3.3	48
731	Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. Journal of Clinical Pharmacology, 2014, 54, 46-52.	2.0	45
732	Regulation of Hepatic Drug Transporter Activity and Expression by Organochlorine Pesticides. Journal of Biochemical and Molecular Toxicology, 2014, 28, 119-128.	3.0	21
733	HNF4 α Induced Chemosensitivity to Oxaliplatin and 5-FU Mediated by OCT1 and CNT3 in Renal Cell Carcinoma. Journal of Pharmaceutical Sciences, 2014, 103, 3326-3334.	3.3	7
734	Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Induction of Efavirenz Clearance. Pharmacotherapy, 2014, 34, 265-271.	2.6	24
735	The Transport and Efflux of Glycosylated Luteinising Hormone-Releasing Hormone Analogues in Caco-2 Cell Model: Contributions of Glucose Transporters and Efflux Systems. Journal of Pharmaceutical Sciences, 2014, 103, 3217-3224.	3.3	10
736	Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management. Molecular Diversity, 2014, 18, 895-909.	3.9	13
737	Structural basis for polyspecificity in the POT family of proton-coupled oligopeptide transporters. EMBO Reports, 2014, 15, 886-893.	4.5	118
738	Radioligand development for molecular imaging of the central nervous system with positron emission tomography. Drug Discovery Today, 2014, 19, 1936-1944.	6.4	67
739	Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information. Xenobiotica, 2014, 44, 1135-1144.	1.1	9
740	Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. Journal of Clinical Pharmacology, 2014, 54, 574-583.	2.0	42
741	Characterizing the Structure, Function, and Evolution of Human Solute Carrier (SLC) Transporters Using Computational Approaches. Springer Series in Biophysics, 2014, , 23-57.	0.4	2
744	Variable Frequency Operation for Future Offshore Wind Farm Design: A Comparison with Conventional Wind Turbines. Energy Procedia, 2014, 53, 280-289.	1.8	10
746	Characterization of dielectric behavior in ZnO electroceramic: Superior grain boundary, inferior grain boundary and grain. Materials Letters, 2014, 132, 240-242.	2.6	10

#	ARTICLE	IF	CITATIONS
748	Effects of Renal Impairment on the Pharmacokinetics of Morinidazole: Uptake Transporter-Mediated Renal Clearance of the Conjugated Metabolites. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4153-4161.	3.2	26
749	Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1638-1646.	2.6	21
750	OATP1B3 Is Expressed in Pancreatic β -Islet Cells and Enhances the Insulinotropic Effect of the Sulfonylurea Derivative Glibenclamide. <i>Diabetes</i> , 2014, 63, 775-784.	0.6	29
751	Quantitative whole-body autoradiography, LC-MS/MS and MALDI for drug-distribution studies in biological samples: the ultimate matrix trilogy. <i>Bioanalysis</i> , 2014, 6, 377-391.	1.5	17
752	Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. <i>Therapeutic Advances in Infectious Disease</i> , 2014, 2, 17-42.	1.8	21
753	P-Glycoprotein. <i>American Journal of Therapeutics</i> , 2014, 21, 2-9.	0.9	5
754	Proton Pump Inhibitors Inhibit Methotrexate Transport by Renal Basolateral Organic Anion Transporter hOAT3. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2041-2048.	3.3	49
755	Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs <i>in vitro</i> . <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 1371-1377.	2.0	34
756	Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 249-259.	0.3	27
757	Role of prostacyclin in pulmonary hypertension. <i>Global Cardiology Science & Practice</i> , 2014, 2014, 53.	0.4	55
758	Na ⁺ /H ⁺ Exchanger Regulatory Factor 3 Is Critical for Multidrug Resistance Protein 4-Mediated Drug Efflux in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 726-736.	6.1	26
759	Characterization of the Intestinal and Hepatic Uptake/Efflux Transport of the Magnetic Resonance Imaging Contrast Agent Gadolinium-Ethoxylbenzyl-Diethylenetriamine-Pentaacetic Acid. <i>Investigative Radiology</i> , 2014, 49, 78-86.	6.2	43
760	Arrayed lipid bilayer chambers allow single-molecule analysis of membrane transporter activity. <i>Nature Communications</i> , 2014, 5, 4519.	12.8	101
761	Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 214-223.	4.0	5
762	Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier. <i>Drug Metabolism Reviews</i> , 2014, 46, 19-32.	3.6	36
763	Re-evaluation of the role of P-glycoprotein in <i>in vitro</i> drug permeability studies with the bovine brain microvessel endothelial cells. <i>Xenobiotica</i> , 2014, 44, 283-294.	1.1	4
764	Inhibitory effect of medicinal plant-derived carboxylic acids on the human transporters hOAT1, hOAT3, hOATP1B1, and hOATP2B1. <i>Chinese Journal of Natural Medicines</i> , 2014, 12, 131-138.	1.3	2
765	Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression. <i>Toxicology and Applied Pharmacology</i> , 2014, 275, 36-43.	2.8	8

#	ARTICLE	IF	CITATIONS
766	The pharmacology of novel oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 217-233.	2.1	54
767	Polyamines and membrane transporters. <i>Amino Acids</i> , 2014, 46, 655-660.	2.7	97
768	Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. <i>Drug Discovery Today</i> , 2014, 19, 171-182.	6.4	140
769	A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine. <i>Clinical Pharmacokinetics</i> , 2014, 53, 73-87.	3.5	136
770	Segmental-Dependent Drug Absorption and Delivery: The Intestinal Tract. <i>Advances in Delivery Science and Technology</i> , 2014, , 343-357.	0.4	0
771	Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 499-507.	1.6	7
772	In vitro methods in drug transporter interaction assessment. <i>Drug Discovery Today: Technologies</i> , 2014, 12, e105-e112.	4.0	13
773	Inherited Disorders of Bilirubin Transport and Conjugation: New Insights Into Molecular Mechanisms and Consequences. <i>Gastroenterology</i> , 2014, 146, 1625-1638.	1.3	186
774	Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism. <i>Drug Metabolism Reviews</i> , 2014, 46, 261-282.	3.6	81
775	Chromone: A Valid Scaffold in Medicinal Chemistry. <i>Chemical Reviews</i> , 2014, 114, 4960-4992.	47.7	576
776	Genetic Biomarkers in Epilepsy. <i>Neurotherapeutics</i> , 2014, 11, 324-333.	4.4	26
777	Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir. <i>Clinical Drug Investigation</i> , 2014, 34, 173-182.	2.2	52
778	In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 99-151.	4.0	226
779	Establishment of Optimized MDCK Cell Lines for Reliable Efflux Transport Studies. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1298-1304.	3.3	44
780	Ion channels and transporters in the development of drug resistance in cancer cells. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130109.	4.0	93
781	The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 869-874.	2.3	14
782	A clinician's guide to statin drug-drug interactions. <i>Journal of Clinical Lipidology</i> , 2014, 8, S30-S46.	1.5	124
783	Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development. <i>Drug Metabolism and Disposition</i> , 2014, 42, 650-664.	3.3	53

#	ARTICLE	IF	CITATIONS
784	Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. <i>Biomaterials</i> , 2014, 35, 2272-2282.	11.4	84
791	A Plasma Concentration of $\hat{\pm}$ -Ketoglutarate Influences the Kinetic Interaction of Ligands with Organic Anion Transporter 1. <i>Molecular Pharmacology</i> , 2014, 86, 86-95.	2.3	25
792	Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex. <i>Drug Metabolism and Disposition</i> , 2014, 42, 78-88.	3.3	169
793	Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein. <i>Drug Metabolism and Disposition</i> , 2014, 42, 182-192.	3.3	77
794	Impact of Endogenous Esterase Activity on In Vitro P-Glycoprotein Profiling of Dabigatran Etexilate in Caco-2 Monolayers. <i>Drug Metabolism and Disposition</i> , 2014, 42, 250-256.	3.3	40
795	Functional ATP-Binding Cassette Drug Efflux Transporters in Isolated Human and Rat Hepatocytes Significantly Affect Assessment of Drug Disposition. <i>Drug Metabolism and Disposition</i> , 2014, 42, 448-458.	3.3	42
796	Cytochrome P450 Inhibitory Properties of Common Efflux Transporter Inhibitors. <i>Drug Metabolism and Disposition</i> , 2014, 42, 441-447.	3.3	35
797	Prediction of In Vivo Rat Biliary Drug Clearance from an In Vitro Hepatocyte Efflux Model. <i>Drug Metabolism and Disposition</i> , 2014, 42, 459-468.	3.3	13
798	The Impact of Solute Carrier (SLC) Drug Uptake Transporter Loss in Human and Rat Cryopreserved Hepatocytes on Clearance Predictions. <i>Drug Metabolism and Disposition</i> , 2014, 42, 469-480.	3.3	32
799	The Role of Transporters in Toxicity and Disease. <i>Drug Metabolism and Disposition</i> , 2014, 42, 541-545.	3.3	32
800	Uptake Carriers and Oncology Drug Safety. <i>Drug Metabolism and Disposition</i> , 2014, 42, 611-622.	3.3	35
801	6 <i>Î²</i> -Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug-Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2014, 42, 685-694.	3.3	47
802	Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. <i>Drug Metabolism and Disposition</i> , 2014, 42, 932-942.	3.3	44
803	Edoxaban Transport via P-Glycoprotein Is a Key Factor for the Drug's Disposition. <i>Drug Metabolism and Disposition</i> , 2014, 42, 520-528.	3.3	82
804	Aspirin and Probenecid Inhibit Organic Anion Transporter 3-Mediated Renal Uptake of Cilostazol and Probenecid Induces Metabolism of Cilostazol in the Rat. <i>Drug Metabolism and Disposition</i> , 2014, 42, 996-1007.	3.3	22
805	<i>In vitro</i> and <i>in vivo</i> approaches to characterize transporter-mediated disposition in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 873-890.	5.0	31
806	Single compartment drug delivery. <i>Journal of Controlled Release</i> , 2014, 190, 157-171.	9.9	46
807	An atlas of genetic influences on human blood metabolites. <i>Nature Genetics</i> , 2014, 46, 543-550.	21.4	1,084

#	ARTICLE	IF	CITATIONS
808	Rhabdomyolysis in an elderly multitreated patient: Multiple drug interactions after statin withdrawal. <i>Journal of the Neurological Sciences</i> , 2014, 336, 284-287.	0.6	13
809	In Vitro–In Vivo Extrapolation Method to Predict Human Renal Clearance of Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 994-1001.	3.3	34
810	Bioreactor technologies to support liver function in vitro. <i>Advanced Drug Delivery Reviews</i> , 2014, 69-70, 132-157.	13.7	116
811	Screening for P-Glycoprotein (Pgp) Substrates and Inhibitors. <i>Methods in Pharmacology and Toxicology</i> , 2014, , 337-352.	0.2	1
812	Defining and characterizing drug/compound function. <i>Biochemical Pharmacology</i> , 2014, 87, 40-63.	4.4	49
813	<i>In Silico</i> Analysis of the Conservation of Human Toxicity and Endocrine Disruption Targets in Aquatic Species. <i>Environmental Science & Technology</i> , 2014, 48, 1964-1972.	10.0	51
814	Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. <i>Pflügers Archiv European Journal of Physiology</i> , 2014, 466, 77-89.	2.8	119
815	Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 173-199.	4.0	221
816	Sex Differences in Sensitivity to the Depressive-like Effects of the Kappa Opioid Receptor Agonist U-50488 in Rats. <i>Biological Psychiatry</i> , 2014, 76, 213-222.	1.3	82
817	Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. <i>Journal of Controlled Release</i> , 2014, 175, 17-24.	9.9	50
818	Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis. <i>Fä-toterapÄ-Ä</i> , 2014, 92, 133-147.	2.2	243
819	Bioavailability of Flavonoids. , 2014, , 489-511.		22
820	Vaginal Expression of Efflux Transporters and the Potential Impact on the Disposition of Microbicides in Vitro and in Rabbits. <i>Molecular Pharmaceutics</i> , 2014, 11, 4405-4414.	4.6	14
821	Macitentan Does Not Interfere with Hepatic Bile Salt Transport. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 130-143.	2.5	33
822	Transport characteristics and transporter-based drug–drug interactions of TM-25659, a novel TAZ modulator. <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 183-194.	1.9	10
823	Transport in technicolor: Mapping ATP-binding cassette transporters in sea urchin embryos. <i>Molecular Reproduction and Development</i> , 2014, 81, 778-793.	2.0	25
824	Expression and Localization of P-Glycoprotein, Multidrug Resistance Protein 4, and Breast Cancer Resistance Protein in the Female Lower Genital Tract of Human and Pigtailed Macaque. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1106-1116.	1.1	20
825	Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 395-408.	3.3	40

#	ARTICLE	IF	CITATIONS
826	Titanium Dioxide in the Service of the Biomedical Revolution. Chemical Reviews, 2014, 114, 10177-10216.	47.7	254
827	Transcriptional regulation of human organic anion transporter 1 by B-cell CLL/lymphoma 6. American Journal of Physiology - Renal Physiology, 2014, 307, F1283-F1291.	2.7	7
828	Potent Nonimmunosuppressive Cyclophilin Inhibitors With Improved Pharmaceutical Properties and Decreased Transporter Inhibition. Journal of Medicinal Chemistry, 2014, 57, 8503-8516.	6.4	28
829	The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nature Chemical Biology, 2014, 10, 768-773.	8.0	157
831	The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug Discovery and Development: Why, When, and How?. Drug Metabolism and Disposition, 2014, 42, 1466-1477.	3.3	38
832	Mechanistic interpretation of conventional Michaelis-Menten parameters in a transporter system. European Journal of Pharmaceutical Sciences, 2014, 64, 44-52.	4.0	15
833	The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs. Molecular Pharmaceutics, 2014, 11, 1301-1313.	4.6	9
834	In Vitro Characterization of Intestinal and Hepatic Transporters: MRP2. Methods in Pharmacology and Toxicology, 2014, , 369-404.	0.2	0
835	From Chemical Tools to Clinical Medicines: Nonimmunosuppressive Cyclophilin Inhibitors Derived from the Cyclosporin and Sanglifehrin Scaffolds. Journal of Medicinal Chemistry, 2014, 57, 7145-7159.	6.4	50
836	Cell-Culture Models of the Blood-Brain Barrier. Stroke, 2014, 45, 2514-2526.	2.0	129
837	Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine. Molecular Pharmaceutics, 2014, 11, 3547-3555.	4.6	211
838	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9983-9988.	7.1	203
839	Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on humanized-animal models. Drug Metabolism Reviews, 2014, 46, 475-493.	3.6	28
840	Predicting when Biliary Excretion of Parent Drug is a Major Route of Elimination in Humans. AAPS Journal, 2014, 16, 1085-1096.	4.4	31
841	Multilayer Spheroids To Quantify Drug Uptake and Diffusion in 3D. Molecular Pharmaceutics, 2014, 11, 2071-2081.	4.6	74
842	SLC19A1, SLC46A1 and SLC01B1 Polymorphisms as Predictors of Methotrexate-Related Toxicity in Portuguese Rheumatoid Arthritis Patients. Toxicological Sciences, 2014, 142, 196-209.	3.1	52
843	Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation. Antimicrobial Agents and Chemotherapy, 2014, 58, 1294-1301.	3.2	24
844	Organic Anion-Transporting Polypeptides. Current Topics in Membranes, 2014, 73, 205-232.	0.9	136

#	ARTICLE	IF	CITATIONS
845	Cell-Specific Expression of Uptake Transportersâ€”A Potential Approach for Cardiovascular Drug Delivery Devices. <i>Molecular Pharmaceutics</i> , 2014, 11, 665-672.	4.6	4
846	Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of <i>Salvia miltiorrhiza</i> . <i>Phytomedicine</i> , 2014, 21, 1264-1272.	5.3	82
847	Role of Hepatic Efflux Transporters in Regulating Systemic and Hepatocyte Exposure to Xenobiotics. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 509-535.	9.4	57
848	Prediction of Pharmacokinetics and Drugâ€”Drug Interactions When Hepatic Transporters are Involved. <i>Clinical Pharmacokinetics</i> , 2014, 53, 659-678.	3.5	92
849	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. <i>Future Oncology</i> , 2014, 10, 107-122.	2.4	75
850	Selective Inhibition of Human Solute Carrier Transporters by Multikinase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1851-1857.	3.3	55
851	Structural characterization and subcellular localization of <i>Drosophila</i> organic solute carrier partner 1. <i>BMC Biochemistry</i> , 2014, 15, 11.	4.4	7
852	Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 251.	3.7	20
853	Drug Disposition and Drug-Drug Interaction Data in 2013 FDA New Drug Applications: A Systematic Review. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1991-2001.	3.3	44
854	<i>In Silico</i> Identification and <i>In Vitro</i> Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors. <i>Chemical Research in Toxicology</i> , 2014, 27, 873-881.	3.3	28
855	Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. <i>Chemistry and Biology</i> , 2014, 21, 1115-1142.	6.0	523
856	Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1087-1095.	1.9	28
857	No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1031-1039.	2.3	23
858	Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 159-171.	1.8	22
859	Compartmental Models for Apical Efflux by P-glycoprotein: Part 2â€”A Theoretical Study on Transporter Kinetic Parameters. <i>Pharmaceutical Research</i> , 2014, 31, 335-346.	3.5	17
860	Compartmental Models for Apical Efflux by P-glycoproteinâ€”Part 1: Evaluation of Model Complexity. <i>Pharmaceutical Research</i> , 2014, 31, 347-359.	3.5	21
861	Cell-Free Microfluidic Determination of P-glycoprotein Interactions with Substrates and Inhibitors. <i>Pharmaceutical Research</i> , 2014, 31, 3415-3425.	3.5	16
862	Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination. <i>AAPS Journal</i> , 2014, 16, 172-180.	4.4	49

#	ARTICLE	IF	CITATIONS
863	Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics. <i>AAPS Journal</i> , 2014, 16, 634-648.	4.4	90
864	Absence of P-Glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 336-345.	2.5	17
865	In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers. <i>European Journal of Pharmacology</i> , 2014, 732, 86-95.	3.5	15
866	Evaluation of drug-drug interaction potential between DA-9801 and metformin. <i>Journal of Pharmaceutical Investigation</i> , 2014, 44, 401-409.	5.3	3
867	A critical assessment of in vitro tissue models for ADME and drug delivery. <i>Journal of Controlled Release</i> , 2014, 190, 94-114.	9.9	32
868	The xenoestrogens ethinylestradiol and bisphenol A regulate BCRP at the blood-brain barrier of rats. <i>Xenobiotica</i> , 2014, 44, 1046-1054.	1.1	14
869	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. <i>Hepatology</i> , 2014, 60, 1015-1022.	7.3	188
870	Interaction of Digitalis-Like Compounds with Liver Uptake Transporters NTCP, OATP1B1, and OATP1B3. <i>Molecular Pharmaceutics</i> , 2014, 11, 1844-1855.	4.6	32
871	Highly Parallel Transport Recordings on a Membrane-on-Nanopore Chip at Single Molecule Resolution. <i>Nano Letters</i> , 2014, 14, 1674-1680.	9.1	37
872	Cumulative Organic Anion Transporter-Mediated Drug-Drug Interaction Potential of Multiple Components in <i>Salvia Miltiorrhiza</i> (Danshen) Preparations. <i>Pharmaceutical Research</i> , 2014, 31, 3503-3514.	3.5	12
873	Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity. <i>Toxicology</i> , 2014, 322, 34-42.	4.2	35
874	Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2014, 36, 280-290.e1.	2.5	26
875	Nimesulide binding site in the BOAT1 (SLC6A19) amino acid transporter. Mechanism of inhibition revealed by proteoliposome transport assay and molecular modelling. <i>Biochemical Pharmacology</i> , 2014, 89, 422-430.	4.4	27
876	The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 61, 11-17.	4.0	40
877	The Kidney and Uremic Toxin Removal: Glomerulus or Tubule?. <i>Seminars in Nephrology</i> , 2014, 34, 191-208.	1.6	129
878	Quantitative Targeted Proteomics for Membrane Transporter Proteins: Method and Application. <i>AAPS Journal</i> , 2014, 16, 714-726.	4.4	18
879	Therapeutic applications of hydrogels in oral drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 901-915.	5.0	259
880	A high throughput flow cytometric assay platform targeting transporter inhibition. <i>Drug Discovery Today: Technologies</i> , 2014, 12, e95-e103.	4.0	20

#	ARTICLE	IF	CITATIONS
881	Three dimensional human small intestine models for ADME-Tox studies. Drug Discovery Today, 2014, 19, 1587-1594.	6.4	36
882	Restricting CNS penetration of drugs to minimise adverse events: role of drug transporters. Drug Discovery Today: Technologies, 2014, 12, e79-e85.	4.0	19
883	Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 235-246.	2.8	9
884	Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 883-891.	3.0	37
885	Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Materials Today, 2014, 17, 298-306.	14.2	128
886	Transporter assays and assay ontologies: useful tools for drug discovery. Drug Discovery Today: Technologies, 2014, 12, e47-e54.	4.0	4
887	Challenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier. Pharmaceutical Research, 2014, 31, 1-19.	3.5	24
888	Downregulation of CYP3A and P-Glycoprotein in the Secondary Inflammatory Response of Mice With Dextran Sulfate Sodium-Induced Colitis and Its Contribution to Cyclosporine A Blood Concentrations. Journal of Pharmacological Sciences, 2014, 124, 180-191.	2.5	30
890	Cellular Transport Mechanisms of Cytotoxic Metallodrugs: An Overview beyond Cisplatin. Molecules, 2014, 19, 15584-15610.	3.8	155
891	Modern Prodrug Design for Targeted Oral Drug Delivery. Molecules, 2014, 19, 16489-16505.	3.8	48
893	Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI. Hepatic Oncology, 2014, 1, 95-105.	4.2	0
897	Using Positron Emission Tomography to Study Transporter-Mediated Drug-Drug Interactions in Tissues. Clinical Pharmacology and Therapeutics, 2014, 96, 206-213.	4.7	31
898	Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-9.	2.5	14
899	Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP. International Journal of Pharmaceutics, 2015, 496, 440-447.	5.2	14
901	Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. Journal of Clinical Pharmacology, 2015, 55, 534-542.	2.0	38
902	Dealing with the complex drug-drug interactions: Towards mechanistic models. Biopharmaceutics and Drug Disposition, 2015, 36, 71-92.	1.9	58
904	P-Glycoprotein (ABCB1) Limits the Brain Distribution of YQA-14, a Novel Dopamine D ₂ Receptor Antagonist. Chemical and Pharmaceutical Bulletin, 2015, 63, 512-518.	1.3	3
906	Impaired Hepatic Uptake by Organic Anion-Transporting Polypeptides Is Associated with Hyperbilirubinemia and Hypercholanemia in Atp11c Mutant Mice. Molecular Pharmacology, 2015, 88, 1085-1092.	2.3	17

#	ARTICLE	IF	CITATIONS
909	Combinatorial Pharmacophore Modeling of Multidrug and Toxin Extrusion Transporter 1 Inhibitors: a Theoretical Perspective for Understanding Multiple Inhibitory Mechanisms. <i>Scientific Reports</i> , 2015, 5, 13684.	3.3	15
910	Generation of enterocyte-like cells from human induced pluripotent stem cells for drug absorption and metabolism studies in human small intestine. <i>Scientific Reports</i> , 2015, 5, 16479.	3.3	55
916	Influence of puerarin, paeoniflorin, and menthol on structure and barrier function of tight junctions in MDCK and MDCK-MDR1 Cells. <i>Journal of Traditional Chinese Medical Sciences</i> , 2015, 2, 111-119.	0.2	6
917	The transporter-mediated cellular uptake of pharmaceutical drugs is based on their metabolite-likeness and not on their bulk biophysical properties: Towards a systems pharmacology. <i>Perspectives in Science</i> , 2015, 6, 66-83.	0.6	18
918	Pre-Plated Cell Lines for ADMETox Applications in the Pharmaceutical Industry. <i>Current Protocols in Toxicology</i> / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2015, 65, 23.8.1-23.8.23.	1.1	1
919	A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier. <i>British Journal of Pharmacology</i> , 2015, 172, 4714-4725.	5.4	23
920	Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro. <i>Transplant International</i> , 2015, 28, 1152-1161.	1.6	7
921	Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 15-33.	1.9	12
922	Pharmacophore-based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell line. <i>British Journal of Pharmacology</i> , 2015, 172, 4888-4904.	5.4	28
923	Molecular architecture of the stria vascularis membrane transport system, which is essential for physiological functions of the mammalian cochlea. <i>European Journal of Neuroscience</i> , 2015, 42, 1984-2002.	2.6	33
924	Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 266-287.	4.7	147
925	Radionuclide cholescintigraphy in genetically confirmed Rotor syndrome. <i>Pediatrics International</i> , 2015, 57, 981-985.	0.5	1
926	Piezoelectric tuning fork biosensors for the quantitative measurement of biomolecular interactions. <i>Nanotechnology</i> , 2015, 26, 495502.	2.6	4
927	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 382-387.	1.5	122
928	Tumor suppressor gene OSCP 1 / NOR 1 regulates apoptosis, proliferation, differentiation, and ROS generation during eye development of <i>Drosophila melanogaster</i> . <i>FEBS Journal</i> , 2015, 282, 4727-4746.	4.7	8
929	The apparent permeabilities of Caco-2 cells to marketed drugs: magnitude, and independence from both biophysical properties and endogenite similarities. <i>PeerJ</i> , 2015, 3, e1405.	2.0	39
930	Possibilities of Cancer Chemotherapy Based on Transporter-Conscious Drug Design. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2015, 06, .	0.3	1
931	Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells. <i>Pharmaceutics</i> , 2015, 7, 554-564.	4.5	14

#	ARTICLE	IF	CITATIONS
932	Evaluation by microarray of the potential safety of <i>Sarracenia purpurea</i> L. (Sarraceniaceae) a traditional medicine used by the Cree of Eeyou Istchee. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 562.	2.1	1
934	Microchamber Device for Detection of Transporter Activity of Adherent Cells. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 32.	4.1	4
935	Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 13760-13780.	4.1	36
936	Studies on Pharmacokinetic Drug Interaction Potential of Vinpocetine. <i>Medicines (Basel, Switzerland)</i> , 2015, 2, 93-105.	1.4	9
937	Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide. <i>Drug Design, Development and Therapy</i> , 2015, 9, 643.	4.3	15
938	Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates. <i>PLoS ONE</i> , 2015, 10, e0136451.	2.5	92
939	Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220. <i>PLoS ONE</i> , 2015, 10, e0144667.	2.5	11
940	Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites. <i>Frontiers in Pharmacology</i> , 2015, 6, 105.	3.5	27
941	Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines. <i>Frontiers in Pharmacology</i> , 2015, 6, 216.	3.5	14
942	Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-10.	1.2	76
944	Protective Mechanisms of Hypothermia in Liver Surgery and Transplantation. <i>Molecular Medicine</i> , 2015, 21, 833-846.	4.4	28
945	Tables of Anti-infective Agent Pharmacology. , 2015, , 631-707.		1
946	Functional and Molecular Effects of Mercury Compounds on the Human OCTN1 Cation Transporter: C50 and C136 Are the Targets for Potent Inhibition. <i>Toxicological Sciences</i> , 2015, 144, 105-113.	3.1	21
947	Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions ^{<sup>/>} . <i>Drug Metabolism and Disposition</i> , 2015, 43, 235-247.	3.3	125
948	Characterization of Chrysin Glucuronidation in UGT1A1-Overexpressing HeLa Cells: Elucidating the Transporters Responsible for Efflux of Glucuronide. <i>Drug Metabolism and Disposition</i> , 2015, 43, 433-443.	3.3	43
949	Mass Balance, Metabolite Profile, and <i><i>In Vitro-In Vivo</i></i> Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 25-37.	3.2	12
951	Rat precision-cut intestinal slices to study P-gp activity and the potency of its inhibitors <i>ex vivo</i> . <i>Toxicology in Vitro</i> , 2015, 29, 1070-1078.	2.4	16
952	Clinical Relevance of Multidrug-Resistance-Proteins (MRPs) for Anticancer Drug Resistance and Prognosis. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 27-52.	0.1	10

#	ARTICLE	IF	CITATIONS
953	Advanced Fibrosis: Correlation between Pharmacokinetic Parameters at Dynamic Gadoxetate-enhanced MR Imaging and Hepatocyte Organic Anion Transporter Expression in Rat Liver. <i>Radiology</i> , 2015, 274, 379-386.	7.3	36
954	Drug Metabolism and Drug Interactions: Potential Application to Antituberculosis Drugs. <i>Journal of Infectious Diseases</i> , 2015, 211, S107-S114.	4.0	16
955	Sequence-structure relationship study in all- α transmembrane proteins using an unsupervised learning approach. <i>Amino Acids</i> , 2015, 47, 2303-2322.	2.7	8
956	The Role of ABC Multidrug Transporters in Resistance to Targeted Anticancer Kinase Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 209-244.	0.1	1
957	Distinct Conformational Spectrum of Homologous Multidrug ABC Transporters. <i>Structure</i> , 2015, 23, 450-460.	3.3	94
958	Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-Glucuronide. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1108-1118.	3.3	65
959	Nature and uses of fluorescent dyes for drug transporter studies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1233-1251.	3.3	32
960	Identification of trichlormethiazide as a Mdr1a/b gene expression enhancer via a dual secretion-based promoter assay. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00109.	2.4	3
961	Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1872-1881.	3.3	45
962	Computational modeling to predict the functions and impact of drug transporters. <i>In Silico Pharmacology</i> , 2015, 3, 8.	3.3	21
963	Development and Validation of Semiautomated 96-Well Transport Assay Using LLC-PK1 Cells Transfected with Human P-Glycoprotein for High-Throughput Screening. <i>Assay and Drug Development Technologies</i> , 2015, 13, 79-87.	1.2	4
964	Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 1520-1527.	6.1	30
965	Fitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can Fly. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 710-723.	8.7	24
966	The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3220-3228.	3.3	58
967	Isomeric methoxy analogs of nimesulide for development of brain cyclooxygenase-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6807-6814.	3.0	13
968	Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology. <i>Toxicology in Vitro</i> , 2015, 29, 1868-1877.	2.4	51
969	ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs. <i>Journal of Biological Chemistry</i> , 2015, 290, 30429-30440.	3.4	47
970	Metabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling. <i>Journal of Cheminformatics</i> , 2015, 7, 31.	6.1	47

#	ARTICLE	IF	CITATIONS
971	Membrane transport of nobilin conjugation products and use of the extract of <i>Chamomillae romanae</i> flos influence absorption of nobilin in the Caco-2 model. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 70, 92-106.	4.0	3
972	SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. <i>Nature</i> , 2015, 519, 477-481.	27.8	561
973	Predicting Drug-Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 177-185.	4.7	26
974	Mass Spectrometry Imaging in Drug Development. <i>Analytical Chemistry</i> , 2015, 87, 1437-1455.	6.5	153
975	Comparison of minipig, dog, monkey and human drug metabolism and disposition. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 74, 80-92.	0.7	93
976	The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective. <i>Physiological Reviews</i> , 2015, 95, 83-123.	28.8	346
977	Role of drug transporters: an overview based on knockout animal model studies. <i>Journal of Pharmaceutical Investigation</i> , 2015, 45, 101-114.	5.3	4
979	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 723-731.	5.5	19
980	Quantitative Analysis of the ABCG2 c.421C>T Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3039-3048.	3.3	18
981	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. <i>Advances in Cancer Research</i> , 2015, 125, 217-243.	5.0	43
982	Caffeic Acid and Organic Anion Transporters hOAT1 and hOAT3. , 2015, , 905-912.		0
983	Evaluation of drug-drug interaction between the novel cPLA ₂ inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients. <i>Xenobiotica</i> , 2015, 45, 615-624.	1.1	5
984	A Q^2 rule of 0.5 for the metabolite-likeness of approved pharmaceutical drugs. <i>Metabolomics</i> , 2015, 11, 323-339.	3.0	84
985	Generation of Enterocyte-Like Cells with Pharmacokinetic Functions from Human Induced Pluripotent Stem Cells Using Small-Molecule Compounds. <i>Drug Metabolism and Disposition</i> , 2015, 43, 603-610.	3.3	50
986	P-glycoprotein interactions of novel psychoactive substances – Stimulation of ATP consumption and transport across Caco-2 monolayers. <i>Biochemical Pharmacology</i> , 2015, 94, 220-226.	4.4	27
987	Effects of tanshinones from <i>Salvia miltiorrhiza</i> on CYP2C19 activity in human liver microsomes: Enzyme kinetic and molecular docking studies. <i>Chemico-Biological Interactions</i> , 2015, 230, 1-8.	4.0	20
988	What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible?. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 15-21.	8.7	46
989	Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1 ^{Δ15} and OATP1B3. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 70, 29-36.	4.0	19

#	ARTICLE	IF	CITATIONS
990	Microengineered Liver Tissues for Drug Testing. <i>Journal of the Association for Laboratory Automation</i> , 2015, 20, 216-250.	2.8	92
991	The Effect of Streptozotocin and Alloxan on the mRNA Expression of Rat Hepatic Transporters In Vivo. <i>AAPS PharmSciTech</i> , 2015, 16, 767-770.	3.3	5
992	Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3049-3059.	3.3	27
993	Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition. <i>Advances in Cancer Research</i> , 2015, 125, 1-41.	5.0	83
994	N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 85-94.	1.9	79
995	Drug-Drug Interactions Related to Altered Absorption and Plasma Protein Binding: Theoretical and Regulatory Considerations, and an Industry Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 916-929.	3.3	21
996	A primary fish gill cell culture model to assess pharmaceutical uptake and efflux: Evidence for passive and facilitated transport. <i>Aquatic Toxicology</i> , 2015, 159, 127-137.	4.0	49
997	Molecular Properties Determining Unbound Intracellular and Extracellular Brain Exposure of CNS Drug Candidates. <i>Molecular Pharmaceutics</i> , 2015, 12, 520-532.	4.6	54
998	Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1121-1133.	5.0	116
999	Design, synthesis and biological profile of new inhibitors of multidrug resistance associated proteins carrying a polycyclic scaffold. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 471-480.	5.5	24
1000	Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 1522-1532.	3.3	16
1001	Drug Access to the Central Nervous System in Alzheimer's Disease: Preclinical and Clinical Insights. <i>Pharmaceutical Research</i> , 2015, 32, 819-839.	3.5	34
1002	Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes. <i>Toxicological Sciences</i> , 2015, 145, 157-168.	3.1	62
1003	Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 15-23.	1.9	4
1004	pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. <i>Pharmaceutical Research</i> , 2015, 32, 2516-26.	3.5	21
1005	Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir. <i>Clinical Pharmacokinetics</i> , 2015, 54, 537-549.	3.5	10
1006	Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on 18F-2-Fluoro-2-Deoxy-d-glucose (18F-FDG) Brain Kinetics. <i>AAPS Journal</i> , 2015, 17, 652-659.	4.4	6
1007	Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design. <i>Drug Metabolism and Disposition</i> , 2015, 43, 490-509.	3.3	116

#	ARTICLE	IF	CITATIONS
1008	Quantitative Structure-Pharmacokinetic Relationships for the Prediction of Renal Clearance in Humans. <i>Drug Metabolism and Disposition</i> , 2015, 43, 73-81.	3.3	29
1009	Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2015, 71, 732-741.	2.5	149
1010	Attolitre-sized lipid bilayer chamber array for rapid detection of single transporters. <i>Scientific Reports</i> , 2015, 5, 11025.	3.3	30
1011	A Call for Systematic Research on Solute Carriers. <i>Cell</i> , 2015, 162, 478-487.	28.9	457
1012	Decellularized skeletal muscle as an inÂvitro model for studying drug-extracellular matrix interactions. <i>Biomaterials</i> , 2015, 64, 108-114.	11.4	27
1013	Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 345-351.	2.8	16
1014	Role of organic cation transporters in drugâ€“drug interaction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1619-1633.	3.3	79
1015	Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2. <i>Journal of Ethnopharmacology</i> , 2015, 172, 430-435.	4.1	14
1016	Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1190-1207.	3.3	70
1017	Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir. <i>Reproductive Toxicology</i> , 2015, 57, 176-182.	2.9	29
1018	Drug Transporters and Na⁺/H⁺ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins. <i>Pharmacological Reviews</i> , 2015, 67, 656-680.	16.0	17
1019	Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). <i>Pharmaceutical Research</i> , 2015, 32, 3785-3802.	3.5	231
1020	Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6058-6080.	6.4	18
1021	The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 352-357.	2.2	31
1022	Decreased Expression of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Leads to Reduced Glucuronidation of Flavonoids in UGT1A1-Overexpressing HeLa Cells: The Role of Futile Recycling. <i>Journal of Agricultural and Food Chemistry</i> , 2015, 63, 6001-6008.	5.2	21
1023	Structure-Based Identification of Inhibitors for the SLC13 Family of Na ⁺ /Dicarboxylate Cotransporters. <i>Biochemistry</i> , 2015, 54, 4900-4908.	2.5	26
1024	Comparative Proteomic Analysis of Human Liver Tissue and Isolated Hepatocytes with a Focus on Proteins Determining Drug Exposure. <i>Journal of Proteome Research</i> , 2015, 14, 3305-3314.	3.7	92
1025	Drugs That Modulate Resistance to Antitumor Agents. , 2015, , 655-700.		3

#	ARTICLE	IF	CITATIONS
1026	Possible Drug-drug Interaction between Pregabalin and Clozapine in Patients with Schizophrenia: Clinical Perspectives. <i>Pharmacopsychiatry</i> , 2015, 48, 15-18.	3.3	11
1027	Intriguing possibilities and beneficial aspects of transporter-conscious drug design. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4119-4131.	3.0	25
1028	Toxicokinetic Triage for Environmental Chemicals. <i>Toxicological Sciences</i> , 2015, 147, 55-67.	3.1	117
1029	SLC transporters as therapeutic targets: emerging opportunities. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 543-560.	46.4	584
1030	Membrane Assays to Characterize Interaction of Drugs with ABCB1. <i>Journal of Membrane Biology</i> , 2015, 248, 967-977.	2.1	9
1031	Stable Knock-down of Efflux Transporters Leads to Reduced Glucuronidation in UGT1A1-Overexpressing HeLa Cells: The Evidence for Glucuronidation-Transport Interplay. <i>Molecular Pharmaceutics</i> , 2015, 12, 1268-1278.	4.6	34
1032	Exploring the structure-activity relationships of ABCC2 modulators using a screening approach. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3513-3525.	3.0	15
1033	Clinical Association Between Pharmacogenomics and Adverse Drug Reactions. <i>Drugs</i> , 2015, 75, 589-631.	10.9	57
1034	Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 353, 380-391.	2.5	31
1035	Polarized location of SLC and ABC drug transporters in monolayer-cultured human hepatocytes. <i>Toxicology in Vitro</i> , 2015, 29, 938-946.	2.4	25
1036	Investigation of membrane fouling at the microscale using isopore filters. <i>Microfluidics and Nanofluidics</i> , 2015, 19, 307-315.	2.2	14
1037	Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases. <i>Pharmaceutical Research</i> , 2015, 32, 2060-2071.	3.5	27
1038	The physiological role of drug transporters. <i>Protein and Cell</i> , 2015, 6, 334-350.	11.0	81
1039	A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. <i>Clinical Pharmacokinetics</i> , 2015, 54, 943-962.	3.5	40
1040	Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes. <i>AAPS Journal</i> , 2015, 17, 788-801.	4.4	21
1041	Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan. <i>Clinical Pharmacokinetics</i> , 2015, 54, 457-471.	3.5	41
1042	Automated radiosynthesis of [18F]ciprofloxacin. <i>Applied Radiation and Isotopes</i> , 2015, 99, 133-137.	1.5	5
1043	Screening of a microbial consortium for highly simultaneous degradation of lignocellulose and chlorophenols. <i>Bioresource Technology</i> , 2015, 190, 381-387.	9.6	19

#	ARTICLE	IF	CITATIONS
1044	MnFe ₂ O ₄ @CNT-N as novel electrochemical nanosensor for determination of caffeine, acetaminophen and ascorbic acid. <i>Sensors and Actuators B: Chemical</i> , 2015, 218, 128-136.	7.8	83
1045	Thermal Comfort of Residential Building in Malaysia at Different Micro-climates. <i>Procedia, Social and Behavioral Sciences</i> , 2015, 170, 613-623.	0.5	62
1046	Carboxylesterase-mediated insecticide resistance: Quantitative increase induces broader metabolic resistance than qualitative change. <i>Pesticide Biochemistry and Physiology</i> , 2015, 121, 88-96.	3.6	64
1049	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. <i>Lung Cancer</i> , 2015, 89, 76-79.	2.0	58
1050	Using the Theory of Planned Behaviour to examine health professional students' behavioural intentions in relation to medication safety and collaborative practice. <i>Nurse Education Today</i> , 2015, 35, 935-940.	3.3	33
1051	Novel selective area growth (SAG) method for regularly arranged AlGa _N nanocolumns using nanotemplates. <i>Journal of Crystal Growth</i> , 2015, 425, 316-321.	1.5	25
1052	Prediction error and repeatability of near infrared reflectance spectroscopy applied to faeces samples in order to predict voluntary intake and digestibility of forages by ruminants. <i>Animal Feed Science and Technology</i> , 2015, 205, 49-59.	2.2	13
1053	Effects of selenizing angelica polysaccharide and selenizing garlic polysaccharide on immune function of murine peritoneal macrophage. <i>International Immunopharmacology</i> , 2015, 27, 104-109.	3.8	32
1054	Field resistance monitoring of <i>Apolygus lucorum</i> (Hemiptera: Miridae) in Shandong, China to seven commonly used insecticides. <i>Crop Protection</i> , 2015, 76, 127-133.	2.1	19
1056	Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 1950-1955.	0.4	32
1057	A comparison of APACHE II and CPIS scores for the prediction of 30-day mortality in patients with ventilator-associated pneumonia. <i>International Journal of Infectious Diseases</i> , 2015, 30, 144-147.	3.3	28
1058	Pyrrolizidine alkaloids in herbal teas for infants, pregnant or lactating women. <i>Food Chemistry</i> , 2015, 187, 491-498.	8.2	40
1059	Evolving statistical rulesets for network intrusion detection. <i>Applied Soft Computing Journal</i> , 2015, 33, 348-359.	7.2	50
1060	Diverse anatomy of the tongue and taste organs in five species of caecilian (Amphibia: Gymnophiona). <i>Zoologischer Anzeiger</i> , 2015, 257, 103-109.	0.9	5
1061	Application of photoplethysmogram for detecting physiological effects of tractor noise. <i>Engineering in Agriculture, Environment and Food</i> , 2015, 8, 313-317.	0.5	8
1062	Sex, violence, & rock n' roll: Longitudinal effects of music on aggression, sex, and prosocial behavior during adolescence. <i>Journal of Adolescence</i> , 2015, 41, 96-104.	2.4	35
1063	Existe-t-il une corrélation entre la taille tumorale au scanner et les caractéristiques anatomopathologiques du cancer du rein?. <i>African Journal of Urology</i> , 2015, 21, 19-24.	0.4	0
1064	Creative Strategy: A Pilot Evaluation of a Hypothetical Learning Model through Public Speaking Performance. <i>Procedia, Social and Behavioral Sciences</i> , 2015, 171, 919-928.	0.5	2

#	ARTICLE	IF	CITATIONS
1065	Quantitative foundation stability evaluation of urban karst area: Case study of Tangshan, China. <i>Soils and Foundations</i> , 2015, 55, 493-503.	3.1	11
1066	Kinetic study of isothermal crystallization process of Gd ₂ Ti ₂ O ₇ precursor's powder prepared through the Pechini synthetic approach. <i>Journal of Physics and Chemistry of Solids</i> , 2015, 85, 160-172.	4.0	6
1067	suPAR: A New Biomarker for Cardiovascular Disease?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1293-1302.	1.7	84
1068	Chronic Urticaria and Parasitic Infections. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB131.	2.9	0
1069	17AAG improves histological and functional outcomes in a rat CCI model through autophagy activation and apoptosis attenuation. <i>Neuroscience Letters</i> , 2015, 599, 1-6.	2.1	10
1070	Multi-physics modeling for laser micro-transfer printing delamination. <i>Journal of Manufacturing Processes</i> , 2015, 20, 414-424.	5.9	13
1071	State estimation of nonlinear dynamic systems using weighted variance-based adaptive particle swarm optimization. <i>Applied Soft Computing Journal</i> , 2015, 34, 1-17.	7.2	22
1072	New Horizons on Education Inspired by Information and Communication Technologies. <i>Procedia, Social and Behavioral Sciences</i> , 2015, 174, 602-608.	0.5	12
1073	Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2280-2284.	2.2	12
1074	Interaction between <i>Meloidogyne incognita</i> and <i>Rhizoctonia solani</i> on green beans. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 570-574.	3.8	27
1075	Roscovitine inhibits extrusion of second polar body and induces apoptosis in rat eggs cultured in vitro. <i>Pharmacological Reports</i> , 2015, 67, 866-874.	3.3	16
1076	The effect of size and volume fraction of the reinforcement on mechanical property and deformation mechanism of the bulk metallic glassy composite. <i>Journal of Alloys and Compounds</i> , 2015, 644, 25-29.	5.5	4
1077	Relationship between symptom clusters and quality of life in patients at stages 2 to 4 chronic kidney disease in Korea. <i>Applied Nursing Research</i> , 2015, 28, e13-e19.	2.2	23
1078	Predicting CFTR activity with front-runner cystic fibrosis drugs. <i>EBioMedicine</i> , 2015, 2, 100-101.	6.1	1
1080	Organization of wound healing services: The impact on lowering the diabetes foot amputation rate in a ten-year review and the importance of early debridement. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 77-84.	2.8	38
1081	Recomendaciones para el soporte telefónico a la reanimación por testigos desde los centros de coordinación de urgencias y emergencias. <i>Medicina Intensiva</i> , 2015, 39, 298-302.	0.7	19
1083	Traits de personnalité et comportements prosociaux chez les adolescents: le rôle médiateur de l'empathie. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2015, 63, 310-316.	0.2	2
1084	The political economy of technology adoption: The case of Saharan salt mining. <i>The Extractive Industries and Society</i> , 2015, 2, 328-338.	1.2	4

#	ARTICLE	IF	CITATIONS
1085	Effect of vegetation on flow structure and dispersion in strongly curved channels. <i>Journal of Hydrodynamics</i> , 2015, 27, 286-291.	3.2	19
1086	A Gene Expression Profiling of Early Rice Stamen Development that Reveals Inhibition of Photosynthetic Genes by OsMADS58. <i>Molecular Plant</i> , 2015, 8, 1069-1089.	8.3	29
1088	Partial nitrification in an air-lift reactor with long-term feeding of increasing ammonium concentrations. <i>Bioresource Technology</i> , 2015, 185, 134-142.	9.6	38
1089	Serum periostin in smokers and never smokers with asthma. <i>Respiratory Medicine</i> , 2015, 109, 708-715.	2.9	29
1090	Simultaneous determination of polycyclic musks in blood and urine by solid supported liquid-liquid extraction and gas chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 992, 96-102.	2.3	15
1091	Perspectives on the Value of Advanced Medical Imaging: A National Survey of Primary Care Physicians. <i>Journal of the American College of Radiology</i> , 2015, 12, 458-462.	1.8	9
1092	Sarcopenia Should Reflect the Contribution of Age-Associated Changes in Skeletal Muscle to Risk of Morbidity and Mortality in Elderly People. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 546-547.	2.5	19
1093	Arthroscopic Excision of Acetabular Osteoid Osteoma: Computer Tomography-Guided Approach. <i>Arthroscopy Techniques</i> , 2015, 4, e101-e105.	1.3	14
1095	A multipartite Hajnal-Szemerédi theorem. <i>Journal of Combinatorial Theory Series B</i> , 2015, 114, 187-236.	1.0	20
1096	Per-Oral Endoscopic Myotomy: A Series of 500 Patients. <i>Journal of the American College of Surgeons</i> , 2015, 221, 256-264.	0.5	435
1097	Dimensionality reduction of RKHS model parameters. <i>ISA Transactions</i> , 2015, 57, 205-210.	5.7	16
1098	Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans. <i>Drug Metabolism and Disposition</i> , 2015, 43, 851-863.	3.3	55
1099	Quantifying the impact of transporters on cellular drug permeability. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 255-262.	8.7	32
1100	Renal Tubular Secretion of Tanshinol: Molecular Mechanisms, Impact on Its Systemic Exposure, and Propensity for Dose-Related Nephrotoxicity and for Renal Herb-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2015, 43, 669-678.	3.3	34
1101	In silico methods for predicting drug-drug interactions with cytochrome P-450s, transporters and beyond. <i>Advanced Drug Delivery Reviews</i> , 2015, 86, 46-60.	13.7	33
1102	Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2015, 43, 367-374.	3.3	152
1103	Ethnic Variability in the Expression of Hepatic Drug Transporters: Absolute Quantification by an Optimized Targeted Quantitative Proteomic Approach. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1045-1055.	3.3	48
1104	A Comprehensive Review of Drug-Drug Interactions with Metformin. <i>Clinical Pharmacokinetics</i> , 2015, 54, 811-824.	3.5	65

#	ARTICLE	IF	CITATIONS
1105	Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles. <i>Journal of Gastroenterology</i> , 2015, 50, 508-519.	5.1	40
1106	Unstirred Water Layers and the Kinetics of Organic Cation Transport. <i>Pharmaceutical Research</i> , 2015, 32, 2937-2949.	3.5	18
1107	Proximal Roux-En-Y Gastric Bypass Alters Drug Absorption Pattern But Not Systemic Exposure of CYP3A4 and P-glycoprotein Substrates. <i>Pharmacotherapy</i> , 2015, 35, 361-369.	2.6	39
1108	Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 795-809.	3.3	60
1109	Meta-Analysis of Expression of Hepatic Organic Anion-Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue. <i>Drug Metabolism and Disposition</i> , 2015, 43, 424-432.	3.3	75
1110	Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups. <i>Environmental Toxicology and Pharmacology</i> , 2015, 40, 692-697.	4.0	10
1111	Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro. <i>International Journal of Pharmaceutics</i> , 2015, 495, 588-598.	5.2	21
1112	Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O- β -D-Glucuronide. <i>Molecular Pharmaceutics</i> , 2015, 12, 3943-3952.	4.6	33
1113	Role of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia. <i>Toxicology and Applied Pharmacology</i> , 2015, 289, 124-132.	2.8	40
1114	Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2039-2049.	4.5	214
1115	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions <i>in Vivo</i> . <i>Molecular Pharmaceutics</i> , 2015, 12, 4259-4269.	4.6	32
1116	Functional expression of the 11 human Organic Anion Transporting Polypeptides in insect cells reveals that sodium fluorescein is a general OATP substrate. <i>Biochemical Pharmacology</i> , 2015, 98, 649-658.	4.4	42
1117	Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. <i>Pharmacogenomics Journal</i> , 2015, 15, 473-487.	2.0	34
1118	Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. <i>Scientific Reports</i> , 2015, 5, 11747.	3.3	40
1119	Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2015, 71, 1725-1735.	2.5	30
1120	Nonlinear concentration gradients regulated by the width of channels for observation of half maximal inhibitory concentration (IC ₅₀) of transporter proteins. <i>Analyst</i> , 2015, 140, 5557-5562.	3.5	5
1121	Computational classification models for predicting the interaction of compounds with hepatic organic ion importers. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 347-351.	2.2	9
1122	Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1313-1331.	2.0	35

#	ARTICLE	IF	CITATIONS
1123	Discontinued dermatological drugs in 2014. Expert Opinion on Investigational Drugs, 2015, 24, 1483-1491.	4.1	2
1124	Novel delivery approaches for cancer therapeutics. Journal of Controlled Release, 2015, 219, 248-268.	9.9	127
1125	Organic Anion Transporter 1 Is Inhibited by Multiple Mechanisms and Shows a Transport Mode Independent of Exchange. Drug Metabolism and Disposition, 2015, 43, 1847-1854.	3.3	17
1126	Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Controls Efflux Transport of Hesperetin Sulfates in Sulfotransferase 1A3-Overexpressing Human Embryonic Kidney 293 Cells. Drug Metabolism and Disposition, 2015, 43, 1430-1440.	3.3	17
1127	Metabolic fate of endogenous molecular damage: Urinary glutathione conjugates of DNA-derived base propenals as markers of inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4845-53.	7.1	11
1128	Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person. Current HIV/AIDS Reports, 2015, 12, 336-343.	3.1	10
1130	Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. Journal of Controlled Release, 2015, 219, 681-696.	9.9	26
1131	PET-CT imaging with [18F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier. Nuclear Medicine and Biology, 2015, 42, 833-841.	0.6	20
1132	Carrier-Mediated Cocaine Transport at the Blood-Brain Barrier as a Putative Mechanism in Addiction Liability. International Journal of Neuropsychopharmacology, 2015, 18, pyu001-pyu001.	2.1	39
1133	P-Glycoprotein Transport of Neurotoxic Pesticides. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 99-107.	2.5	22
1134	Prediction and validation of enzyme and transporter off-targets for metformin. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 463-475.	1.8	37
1135	Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro. Biochemical Pharmacology, 2015, 98, 465-472.	4.4	27
1136	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Annals of Oncology, 2015, 26, 1470-1475.	1.2	46
1137	Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety. Handbook of Experimental Pharmacology, 2015, 232, 235-260.	1.8	46
1138	Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of ¹¹ C-Erlotinib. Journal of Nuclear Medicine, 2015, 56, 1930-1936.	5.0	52
1139	Application of physiologically-based pharmacokinetic modeling to explore the role of kidney transporters in renal reabsorption of perfluorooctanoic acid in the rat. Toxicology and Applied Pharmacology, 2015, 289, 428-441.	2.8	53
1140	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Molecular Pharmaceutics, 2015, 12, 4301-4310.	4.6	79
1141	Protein kinase C-dependent regulation of human hepatic drug transporter expression. Biochemical Pharmacology, 2015, 98, 703-717.	4.4	14

#	ARTICLE	IF	CITATIONS
1142	Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor <sc>X</sc>a inhibitor. British Journal of Clinical Pharmacology, 2015, 79, 838-846.	2.4	130
1143	Quantitative targeted absolute proteomics for 28 human transporters in plasma membrane of Caco-2 cell monolayer cultured for 2, 3, and 4 weeks. Drug Metabolism and Pharmacokinetics, 2015, 30, 205-208.	2.2	38
1144	Drug transporter expression during in vitro differentiation of first-trimester and term human villous trophoblasts. Placenta, 2015, 36, 93-96.	1.5	25
1145	Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α_2A -adrenoreceptor agonist. Xenobiotica, 2015, 45, 88-94.	1.1	9
1146	Expression of Drug Transporters and Drug Metabolizing Enzymes in the Bladder Urothelium in Man and Affinity of the Bladder Spasmolytic Trospium Chloride to Transporters Likely Involved in Its Pharmacokinetics. Molecular Pharmaceutics, 2015, 12, 171-178.	4.6	29
1147	A2A Adenosine Receptor Regulates the Human Blood-Brain Barrier Permeability. Molecular Neurobiology, 2015, 52, 664-678.	4.0	80
1148	Zinc Finger Nuclease-Mediated Gene Knockout Results in Loss of Transport Activity for P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells. Drug Metabolism and Disposition, 2015, 43, 199-207.	3.3	32
1149	Expression of indocyanine green-related transporters in hepatocellular carcinoma. Journal of Surgical Research, 2015, 193, 567-576.	1.6	41
1150	CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. Journal of Medicinal Chemistry, 2015, 58, 2584-2608.	6.4	406
1151	What do drug transporters really do?. Nature Reviews Drug Discovery, 2015, 14, 29-44.	46.4	411
1152	Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. Archives of Pharmacal Research, 2015, 38, 849-856.	6.3	41
1153	Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicology in Vitro, 2015, 29, 251-258.	2.4	22
1154	Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology. Phytochemistry Reviews, 2015, 14, 233-272.	6.5	38
1155	Research highlights: digital assays on chip. Lab on A Chip, 2015, 15, 17-22.	6.0	9
1156	In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities. International Journal of Pharmaceutics, 2015, 478, 665-681.	5.2	63
1157	P-glycoprotein inhibition by the agricultural pesticide propiconazole and its hydroxylated metabolites: Implications for pesticide-drug interactions. Toxicology Letters, 2015, 232, 37-45.	0.8	26
1158	Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on <sc>OATP</sc>1<sc>B</sc>3. British Journal of Pharmacology, 2015, 172, 1059-1073.	5.4	53
1159	Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture. Xenobiotica, 2015, 45, 177-187.	1.1	31

#	ARTICLE	IF	CITATIONS
1160	Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport: an Update. AAPS Journal, 2015, 17, 65-82.	4.4	463
1161	Effect of Molecular Structure, Substrate and Docking Scores on the Prediction of the Inhibition Constants of P-glycoprotein Inhibitors. Journal of Drug Metabolism & Toxicology, 2016, 07, .	0.1	0
1162	Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors. Current Drug Metabolism, 2016, 17, 308-316.	1.2	35
1163	Membrane Transporters and Pharmacological Implications. Journal of Pharmacovigilance, 2016, 4, .	0.2	0
1164	Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World Journal of Gastroenterology, 2016, 22, 6876.	3.3	289
1165	Genistein and Glyceollin Effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells. International Journal of Environmental Research and Public Health, 2016, 13, 17.	2.6	16
1166	Assessment of Amino Acid/Drug Transporters for Renal Transport of [18F]Fluciclovine (anti-[18F]FACBC) in Vitro. International Journal of Molecular Sciences, 2016, 17, 1730.	4.1	3
1167	The Blood-Brain Barrier Permeability of Lignans and Malabaricones from the Seeds of Myristica fragrans in the MDCK-pHaMDR Cell Monolayer Model. Molecules, 2016, 21, 134.	3.8	22
1168	Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay. Pharmaceutics, 2016, 8, 12.	4.5	103
1169	Uremic Solutes in Chronic Kidney Disease and Their Role in Progression. PLoS ONE, 2016, 11, e0168117.	2.5	20
1170	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Frontiers in Pharmacology, 2016, 7, 111.	3.5	32
1171	Inhibition of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Regulates the Hepatobiliary Excretion and Plasma Exposure of Thienorphine and Its Glucuronide Conjugate. Frontiers in Pharmacology, 2016, 7, 242.	3.5	17
1172	MetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous Metabolites. Frontiers in Pharmacology, 2016, 7, 266.	3.5	26
1173	Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. Frontiers in Pharmacology, 2016, 7, 518.	3.5	93
1174	Modulating Role of TTR in A β 2 Toxicity, from Health to Disease. , 0, , .		1
1175	Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. Clinical Pharmacology and Therapeutics, 2016, 100, 259-267.	4.7	59
1176	Imaging transporters: Transforming diagnostic and therapeutic development. Clinical Pharmacology and Therapeutics, 2016, 100, 479-488.	4.7	14
1177	Posttranslational Regulation of Organic Anion Transporters by Ubiquitination: Known and Novel. Medicinal Research Reviews, 2016, 36, 964-979.	10.5	16

#	ARTICLE	IF	CITATIONS
1178	Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM. <i>Proteomics</i> , 2016, 16, 2106-2117.	2.2	109
1179	Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS. <i>Pharmaceutical Research</i> , 2016, 33, 2280-2288.	3.5	56
1180	A New Level A Type IVVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1179-1190.	3.5	9
1181	Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects. <i>Molecular Pharmaceutics</i> , 2016, 13, 2631-2640.	4.6	69
1182	Natural Polyphenols in Cancer Chemoresistance. <i>Nutrition and Cancer</i> , 2016, 68, 879-891.	2.0	48
1183	Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. <i>AAPS Journal</i> , 2016, 18, 1067-1081.	4.4	38
1184	Pharmacogenomics and the treatment of acute myeloid leukemia. <i>Pharmacogenomics</i> , 2016, 17, 1245-1272.	1.3	25
1185	In silico pharmacology: Drug membrane partitioning and crossing. <i>Pharmacological Research</i> , 2016, 111, 471-486.	7.1	50
1187	Tropium chloride is absorbed from two intestinal absorption windows with different permeability in healthy subjects. <i>International Journal of Pharmaceutics</i> , 2016, 515, 367-373.	5.2	14
1188	Counter-flow suggests transport of dantrolene and 5-OH dantrolene by the organic anion transporters 2 (OAT2) and 3 (OAT3). <i>Pflügers Archiv European Journal of Physiology</i> , 2016, 468, 1909-1918.	2.8	3
1190	Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. <i>Scientific Reports</i> , 2016, 6, 24586.	3.3	20
1191	The Rabbit. , 2016, , 443-510.		2
1192	In vitro blood-brain barrier permeability predictions for GABAA receptor modulating piperine analogs. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 103, 118-126.	4.3	35
1193	How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 320-336.	13.7	78
1194	Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. <i>Molecular Pharmaceutics</i> , 2016, 13, 839-851.	4.6	31
1195	Arrayed water-in-oil droplet bilayers for membrane transport analysis. <i>Lab on A Chip</i> , 2016, 16, 3043-3048.	6.0	19
1196	Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3497-3508.	3.2	11
1197	In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 17-32.	3.0	19

#	ARTICLE	IF	CITATIONS
1198	Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidiny linkers: Understanding and improving key determinants of pharmacological properties. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3746-3753.	2.2	28
1199	Prolonged Oral Administration of a Pan-Retinoic Acid Receptor Antagonist Inhibits Spermatogenesis in Mice With a Rapid Recovery and Changes in the Expression of Influx and Efflux Transporters. Endocrinology, 2016, 157, 1601-1612.	2.8	36
1200	Critical evaluation and methodological positioning of the transdermal microdialysis technique. A review. Journal of Controlled Release, 2016, 233, 147-161.	9.9	41
1201	Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. European Journal of Pharmaceutical Sciences, 2016, 94, 59-71.	4.0	44
1202	Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacological Research, 2016, 110, 89-95.	7.1	29
1203	Fast Conduction of Organic Cations in Metal Sulfate Frameworks. Chemistry of Materials, 2016, 28, 3968-3975.	6.7	19
1204	Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Pharmacogenomics, 2016, 17, 615-631.	1.3	4
1205	The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?. Drug Metabolism and Disposition, 2016, 44, 1498-1509.	3.3	82
1206	Cell permeability beyond the rule of 5. Advanced Drug Delivery Reviews, 2016, 101, 42-61.	13.7	196
1207	Accurate Prediction of Ligand Affinities for a Proton-Dependent Oligopeptide Transporter. Cell Chemical Biology, 2016, 23, 299-309.	5.2	34
1208	Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters. Nucleic Acid Therapeutics, 2016, 26, 111-117.	3.6	21
1209	Intracellular transport of nanocarriers across the intestinal epithelium. Drug Discovery Today, 2016, 21, 856-863.	6.4	60
1210	Pharmacogenetics of Metformin. , 2016, , 463-481.		0
1211	Novel compound, organic cation transporter 3 detection agent and organic cation transporter 3 activity inhibitor, WO2015002150 A1: a patent evaluation. Expert Opinion on Therapeutic Patents, 2016, 26, 857-860.	5.0	5
1212	Quantitative Targeted Absolute Proteomics for 28 Transporters in Brush-Border and Basolateral Membrane Fractions of Rat Kidney. Journal of Pharmaceutical Sciences, 2016, 105, 1011-1016.	3.3	19
1213	The solubility-permeability interplay and oral drug formulation design: Two heads are better than one. Advanced Drug Delivery Reviews, 2016, 101, 99-107.	13.7	138
1214	Physiological and pathophysiological factors affecting the expression and activity of the drug transporter MRP2 in intestine. Impact on its function as membrane barrier. Pharmacological Research, 2016, 109, 32-44.	7.1	21
1215	An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials, 2016, 97, 34-50.	11.4	117

#	ARTICLE	IF	CITATIONS
1216	BDDCS, the Rule of 5 and drugability. <i>Advanced Drug Delivery Reviews</i> , 2016, 101, 89-98.	13.7	475
1217	Effect of Cholesterol on Cellular Uptake of Cancer Drugs Pirarubicin and Ellipticine. <i>Journal of Physical Chemistry B</i> , 2016, 120, 3148-3156.	2.6	38
1218	Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies. <i>Journal of Clinical Pharmacology</i> , 2016, 56, S193-204.	2.0	6
1219	Development of a high-throughput mass spectrometry based analytical method to support an <i>in vitro</i> OATP1B1 inhibition screening assay. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 1787-1796.	1.5	4
1220	Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6558-6567.	3.2	26
1221	Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. <i>Journal of Clinical Pharmacology</i> , 2016, 56, S23-39.	2.0	86
1222	Characteristic Analysis of Intestinal Transport in Enterocyte-Like Cells Differentiated from Human Induced Pluripotent Stem Cells. <i>Drug Metabolism and Disposition</i> , 2016, 44, 0-0.	3.3	28
1223	Assessment of ABCG2-mediated transport of pesticides across the rabbit placenta barrier using a novel MDCKII <i>in vitro</i> model. <i>Toxicology and Applied Pharmacology</i> , 2016, 305, 66-74.	2.8	13
1224	Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing. <i>Biochemical Pharmacology</i> , 2016, 116, 162-175.	4.4	15
1225	Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. <i>Chemical Research in Toxicology</i> , 2016, 29, 1778-1788.	3.3	10
1226	Discovering New Antiepileptic Drugs Addressing the Transporter Hypothesis of Refractory Epilepsy: Structure-Based Approximations. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 281-297.	0.2	0
1227	Generative Topographic Mapping Approach to Modeling and Chemical Space Visualization of Human Intestinal Transporters. <i>BioNanoScience</i> , 2016, 6, 464-472.	3.5	6
1228	Drug Transporters: Advances and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 398-403.	4.7	6
1229	Effect of cigarette smoke extract on P-glycoprotein function in primary cultured and newly developed alveolar epithelial cells. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 417-424.	2.2	12
1230	Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 401-410.	2.5	36
1231	Moxifloxacin Is a Potent <i>In Vitro</i> Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7105-7114.	3.2	24
1232	Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1925-1933.	3.3	55
1233	A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children. <i>AAPS Journal</i> , 2016, 18, 1453-1463.	4.4	31

#	ARTICLE	IF	CITATIONS
1234	Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models. Journal of Clinical Pharmacology, 2016, 56, S99-S109.	2.0	33
1235	Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1. Journal of Clinical Pharmacology, 2016, 56, S59-72.	2.0	85
1236	The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives. Journal of Clinical Pharmacology, 2016, 56, S122-31.	2.0	45
1237	Drug Transporters. , 2016, , 91-119.		0
1238	Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions. Journal of Clinical Pharmacology, 2016, 56, S143-56.	2.0	48
1239	Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy. Journal of Clinical Pharmacology, 2016, 56, S173-92.	2.0	18
1240	Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology, 2016, 363-364, 58-71.	4.2	22
1241	Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans. Journal of Clinical Pharmacology, 2016, 56, S82-98.	2.0	20
1242	Spica prunellae and its marker compound rosmarinic acid induced the expression of efflux transporters through activation of Nrf2-mediated signaling pathway in HepG2 cells. Journal of Ethnopharmacology, 2016, 193, 1-11.	4.1	31
1244	Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology. Cellular Physiology and Biochemistry, 2016, 38, 1815-1830.	1.6	4
1245	Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect. Drug Metabolism and Pharmacokinetics, 2016, 31, 333-339.	2.2	8
1246	Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1. Molecular Pharmacology, 2016, 90, 254-264.	2.3	19
1247	Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine. Antimicrobial Agents and Chemotherapy, 2016, 60, 5563-5572.	3.2	19
1248	Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?. Journal of Clinical Pharmacology, 2016, 56, S40-58.	2.0	9
1249	Role of Transporters in Drug Development. Journal of Clinical Pharmacology, 2016, 56, S7-S10.	2.0	8
1250	Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats. Biopharmaceutics and Drug Disposition, 2016, 37, 421-432.	1.9	10
1251	Role of Hepatic Drug Transporters in Drug Development. Journal of Clinical Pharmacology, 2016, 56, S11-22.	2.0	23
1252	The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1463-1477.	3.3	19

#	ARTICLE	IF	CITATIONS
1253	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. British Journal of Clinical Pharmacology, 2016, 82, 1591-1600.	2.4	75
1254	Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1445-1461.	3.3	36
1255	Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Scientific Reports, 2016, 6, 29930.	3.3	29
1256	A phosphotyrosine switch regulates organic cation transporters. Nature Communications, 2016, 7, 10880.	12.8	100
1257	Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics. Drug Metabolism and Disposition, 2016, 44, 1920-1924.	3.3	114
1258	Whole-Body Distribution and Radiation Dosimetry of ¹¹ C-Elacridar and ¹¹ C-Tarividar in Humans. Journal of Nuclear Medicine, 2016, 57, 1265-1268.	5.0	11
1259	Modeling Organic Anion-Transporting Polypeptide 1B1 Inhibition to Elucidate Interaction Risks in Early Drug Design. Journal of Pharmaceutical Sciences, 2016, 105, 3214-3220.	3.3	2
1260	Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System. Pharmaceutical Research, 2016, 33, 3021-3030.	3.5	31
1261	Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrobial Agents and Chemotherapy, 2016, 60, 5986-5994.	3.2	13
1262	Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 1203-1213.	4.9	31
1263	Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends in Pharmacological Sciences, 2016, 37, 904-932.	8.7	72
1266	MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer Journal, 2016, 6, e470-e470.	6.2	18
1267	2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2. European Journal of Medicinal Chemistry, 2016, 122, 408-418.	5.5	22
1268	Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1. Clinical Pharmacology and Therapeutics, 2016, 100, 524-536.	4.7	79
1270	Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacological Research, 2016, 111, 237-246.	7.1	77
1271	Structural and conformational determinants of macrocycle cell permeability. Nature Chemical Biology, 2016, 12, 1065-1074.	8.0	152
1272	Renal drug transporters and their significance in drug-drug interactions. Acta Pharmaceutica Sinica B, 2016, 6, 363-373.	12.0	134
1273	Induction of P-glycoprotein expression and activity by Aconitum alkaloids: Implication for clinical drug-drug interactions. Scientific Reports, 2016, 6, 25343.	3.3	35

#	ARTICLE	IF	CITATIONS
1274	The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10084-10099.	6.4	78
1275	Global marine pollutants inhibit P-glycoprotein: Environmental levels, inhibitory effects, and cocrystal structure. <i>Science Advances</i> , 2016, 2, e1600001.	10.3	96
1276	Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 505-515.	2.5	19
1278	Membrane Transport Processes Analyzed by a Highly Parallel Nanopore Chip System at Single Protein Resolution. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	2
1279	Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S230-S234.	2.1	17
1280	In vitro blood-brain barrier models for drug research: state-of-the-art and new perspectives on reconstituting these models on artificial basement membrane platforms. <i>Drug Discovery Today</i> , 2016, 21, 1367-1386.	6.4	48
1281	Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2222-2230.	3.3	13
1282	Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [¹¹ C]-N-desmethyl-loperamide PET study in nonhuman primates. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 91, 98-104.	4.0	12
1283	Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail. <i>International Journal of Pharmaceutics</i> , 2016, 514, 364-373.	5.2	4
1284	Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1285-1300.	2.8	83
1285	Dioscin protects against ANIT-induced cholestasis via regulating Oatps, Mrp2 and Bsep expression in rats. <i>Toxicology and Applied Pharmacology</i> , 2016, 305, 127-135.	2.8	34
1286	Benzyl [¹¹ C]Hippurate as an Agent for Measuring the Activities of Organic Anion Transporter 3 in the Brain and Multidrug Resistance-Associated Protein 4 in the Heart of Mice. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5847-5856.	6.4	7
1287	HS-23, a standardized extract of the dried flower buds of <i>Lonicera japonica</i> , has no major impact on drug transporters and on the pharmacokinetics of ceftriaxone and levofloxacin in rats. <i>Journal of Pharmaceutical Investigation</i> , 2016, 46, 13-19.	5.3	1
1288	Transporters. , 2016, , 113-140.		1
1289	Transporter Methods. , 2016, , 339-350.		1
1290	Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 484-496.	3.3	24
1291	Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning. <i>Journal of Cheminformatics</i> , 2016, 8, 7.	6.1	26
1292	Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1005-1013.	3.3	35

#	ARTICLE	IF	CITATIONS
1293	Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. <i>Drug Metabolism and Disposition</i> , 2016, 44, 999-1004.	3.3	22
1294	Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1229-1245.	3.3	87
1295	Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine. <i>Molecular Pharmaceutics</i> , 2016, 13, 2443-2456.	4.6	17
1296	The discovery and evaluation of diaryl ether heterocyclic sulfonamides as URAT1 inhibitors for the treatment of gout. <i>MedChemComm</i> , 2016, 7, 1587-1595.	3.4	10
1297	The design, synthesis and evaluation of low molecular weight acidic sulfonamides as URAT1 inhibitors for the treatment of gout. <i>MedChemComm</i> , 2016, 7, 1572-1579.	3.4	11
1298	A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approach. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 91, 50-63.	4.0	8
1299	Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems. <i>Small</i> , 2016, 12, 2253-2282.	10.0	245
1300	Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. <i>Drug Metabolism and Disposition</i> , 2016, 44, 238-249.	3.3	28
1301	In vitro screening of nanomedicines through the blood brain barrier: A critical review. <i>Biomaterials</i> , 2016, 103, 229-255.	11.4	48
1302	Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier. <i>British Journal of Pharmacology</i> , 2016, 173, 497-510.	5.4	50
1303	Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant. <i>Pharmacogenomics Journal</i> , 2016, 16, 193-201.	2.0	6
1304	Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. <i>Drug Metabolism and Disposition</i> , 2016, 44, 398-408.	3.3	79
1305	In vitro potential modulation of baicalin and baicalein on P-glycoprotein activity and expression in Caco-2 cells and rat gut sacs. <i>Pharmaceutical Biology</i> , 2016, 54, 1548-1556.	2.9	20
1306	The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 817-827.	3.3	58
1307	Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals. <i>Molecular Pharmaceutics</i> , 2016, 13, 1089-1099.	4.6	18
1308	Functional profiles of orphan membrane transporters in the life cycle of the malaria parasite. <i>Nature Communications</i> , 2016, 7, 10519.	12.8	72
1309	Permeability of plumbagin across human intestinal cell in vitro. <i>Archives of Pharmacal Research</i> , 2016, 39, 380-389.	6.3	6
1310	Evaluation of the Intestinal Absorption Mechanism of Casearin X in Caco-2 Cells with Modified Carboxylesterase Activity. <i>Journal of Natural Products</i> , 2016, 79, 1084-1090.	3.0	10

#	ARTICLE	IF	CITATIONS
1311	The ABCG2 Efflux Transporter in the Mammary Gland Mediates Veterinary Drug Secretion across the Blood-Milk Barrier into Milk of Dairy Cows. Drug Metabolism and Disposition, 2016, 44, 700-708.	3.3	35
1312	Novel Nano-Device to Measure Voltage-Driven Membrane Transporter Activity. IEEE Nanotechnology Magazine, 2016, 15, 70-73.	2.0	5
1313	Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine. Biopharmaceutics and Drug Disposition, 2016, 37, 28-38.	1.9	24
1314	SLC transporters: structure, function, and drug discovery. MedChemComm, 2016, 7, 1069-1081.	3.4	152
1315	Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line. Molecular Pharmaceutics, 2016, 13, 933-944.	4.6	41
1316	Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. Journal of Pharmaceutical Sciences, 2016, 105, 1017-1021.	3.3	49
1317	Interaction of GABA-mimetics with the taurine transporter (TauT, Slc6a6) in hyperosmotic treated Caco-2, LLC-PK1 and rat renal SKPT cells. European Journal of Pharmaceutical Sciences, 2016, 82, 138-146.	4.0	17
1318	Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development. Chemical Research in Toxicology, 2016, 29, 545-563.	3.3	18
1319	Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 551-555.	2.2	11
1320	Amorphous solid dispersions: Rational selection of a manufacturing process. Advanced Drug Delivery Reviews, 2016, 100, 85-101.	13.7	279
1321	MicroRNA Pharmacoeigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy. Drug Metabolism and Disposition, 2016, 44, 308-319.	3.3	56
1322	The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. Clinical Pharmacokinetics, 2016, 55, 495-506.	3.5	27
1323	Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. Molecular Pharmacology, 2016, 89, 492-504.	2.3	23
1324	In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. Journal of Proteomics, 2016, 136, 234-247.	2.4	134
1325	Biocompatible hydrogelators based on bile acid ethyl amides. Steroids, 2016, 108, 7-16.	1.8	8
1326	Pharmacokinetic herbâ€drug interactions with traditional Chinese medicine: progress, causes of conflicting results and suggestions for future research. Drug Metabolism Reviews, 2016, 48, 1-26.	3.6	55
1327	Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism. British Journal of Radiology, 2016, 89, 20150666.	2.2	19
1328	Drug Delivery Systems for Ocular Use. , 2016, , 479-515.		0

#	ARTICLE	IF	CITATIONS
1329	A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity. AAPS Journal, 2016, 18, 465-475.	4.4	95
1330	Pharmacological and Toxicological Significance of the Organic Cation Transporters OCT and MATE: Drug Disposition, Interaction and Toxicity. , 2016, , 73-92.		2
1331	Interaction of ABC Transporters with Drugs. , 2016, , 135-151.		0
1332	Dietary Isoflavones as Modulators of Drug Metabolizing Enzymes and Transporters: Effect on Prescription Medicines. Critical Reviews in Food Science and Nutrition, 2016, 56, S95-S109.	10.3	10
1333	Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP. Pharmaceutical Research, 2016, 33, 590-602.	3.5	33
1334	Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. American Journal of Cardiovascular Drugs, 2016, 16, 119-127.	2.2	87
1335	Precision-cut intestinal slices: alternative model for drug transport, metabolism, and toxicology research. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 175-190.	3.3	56
1336	Novel No-Wash Luminogenic Probes for the Detection of Transporter Uptake Activity. Bioconjugate Chemistry, 2016, 27, 87-101.	3.6	5
1337	Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays. Molecular Pharmaceutics, 2016, 13, 438-448.	4.6	44
1338	Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. Drug Metabolism and Disposition, 2016, 44, 356-364.	3.3	54
1339	Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. Tuberculosis, 2016, 96, 150-157.	1.9	38
1340	Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. Clinical Pharmacokinetics, 2016, 55, 605-613.	3.5	44
1341	Transporter modulation by Chinese herbal medicines and its mediated pharmacokinetic herb-drug interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1026, 236-253.	2.3	37
1342	BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. AAPS Journal, 2016, 18, 251-260.	4.4	60
1343	Homology modelling and molecular docking studies of human placental cadherin protein for its role in teratogenic effects of anti-epileptic drugs. Computational Biology and Chemistry, 2016, 60, 1-8.	2.3	16
1344	Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making. Chemical Research in Toxicology, 2016, 29, 452-472.	3.3	24
1345	The importance of drug transporters in human pluripotent stem cells and in early tissue differentiation. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 77-92.	3.3	7
1346	A new paradigm for navigating compound property related drug attrition. Drug Discovery Today, 2016, 21, 72-81.	6.4	41

#	ARTICLE	IF	CITATIONS
1347	Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clinical Pharmacokinetics, 2016, 55, 507-524.	3.5	52
1348	The potential of immobilized artificial membrane chromatography to predict human oral absorption. European Journal of Pharmaceutical Sciences, 2016, 81, 82-93.	4.0	40
1349	Transporter assays as useful <i>in vitro</i> tools in drug discovery and development. Expert Opinion on Drug Discovery, 2016, 11, 91-103.	5.0	29
1350	A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. Drug Discovery Today, 2016, 21, 250-263.	6.4	61
1351	Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica, 2016, 46, 457-466.	1.1	66
1352	Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 93-108.	1.6	46
1353	Effects of Cytochrome P450 3A4 Inhibitorsâ€”Ketoconazole and Erythromycinâ€”on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. Clinical Pharmacokinetics, 2016, 55, 237-247.	3.5	10
1354	Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from <i>in vitro</i> studies and a clinical investigation with midazolam. Xenobiotica, 2016, 46, 445-456.	1.1	38
1355	Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. Clinical Pharmacokinetics, 2016, 55, 143-167.	3.5	21
1356	To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics. Clinical Pharmacokinetics, 2016, 55, 1-15.	3.5	27
1357	Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2016, 55, 47-77.	3.5	11
1358	Un simulador cl�sico de vasculitis sist�mica. Reumatolog�a Cl�nica, 2016, 12, 103-106.	0.5	3
1359	Assessment of pragmatic language in verbal and nonverbal autistic children. Revista De Logopedia, Foniatria Y Audiologia, 2016, 36, 15-22.	0.5	1
1360	Identification of Transporters Involved in Beraprost Sodium Transport In Vitro. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 117-128.	1.6	7
1361	Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 417-429.	1.6	16
1362	<i>In vitro</i> evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseoglitazone, an SGLT2 inhibitor. Xenobiotica, 2017, 47, 314-323.	1.1	3
1363	Biochemical studies on the structureâ€”function relationship of major drug transporters in the ATP-binding cassette family and solute carrier family. Advanced Drug Delivery Reviews, 2017, 116, 3-20.	13.7	21
1364	Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. Xenobiotica, 2017, 47, 267-275.	1.1	23

#	ARTICLE	IF	CITATIONS
1365	Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. <i>Xenobiotica</i> , 2017, 47, 77-85.	1.1	27
1366	Loops and layers of post-translational modifications of drug transporters. <i>Advanced Drug Delivery Reviews</i> , 2017, 116, 37-44.	13.7	25
1367	Human transporters, <scp>PEPT</scp> 1/2, facilitate melatonin transportation into mitochondria of cancer cells: An implication of the therapeutic potential. <i>Journal of Pineal Research</i> , 2017, 62, e12390.	7.4	107
1368	R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From InÂVitro to Pharmacokinetic-Pharmacodynamic Studies. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 1419-1425.	3.3	10
1369	The transepithelial transport mechanism of polybrominated diphenyl ethers in human intestine determined using a Caco-2 cell monolayer. <i>Environmental Research</i> , 2017, 154, 93-100.	7.5	18
1370	Preclinical Development of Oncology Drugs. , 2017, , 685-707.		3
1371	Regulation of multidrug resistance by microRNAs in anti-cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 38-51.	12.0	159
1372	Design, synthesis, in vitro characterization and preliminary imaging studies on fluorinated bile acid derivatives as PET tracers to study hepatic transporters. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 963-976.	3.0	18
1373	Interaction of pharmaceutical excipients with organic cation transporters. <i>International Journal of Pharmaceutics</i> , 2017, 520, 14-20.	5.2	8
1374	Coumarin derivatives as potential antitumor agents: Growth inhibition, apoptosis induction and multidrug resistance reverting activity. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 577-585.	5.5	56
1375	Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 137, 70-77.	2.8	1
1376	P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine. <i>Pharmacological Research</i> , 2017, 119, 61-71.	7.1	27
1377	Enzymatic activation of double-targeted 5â€²-O-l-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis. <i>Drug Delivery and Translational Research</i> , 2017, 7, 304-311.	5.8	9
1378	Anticancer Drug-Induced Acute Kidney Injury. <i>Kidney International Reports</i> , 2017, 2, 504-514.	0.8	81
1379	Quantification of the steady-state plasma concentrations of clozapine and N-desmethylozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 677-685.	1.6	17
1380	Selective Fusion of Heterogeneous Classifiers for Predicting Substrates of Membrane Transporters. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 594-607.	5.4	25
1381	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.4	58
1382	Intracellular drug bioavailability: a new predictor of system dependent drug disposition. <i>Scientific Reports</i> , 2017, 7, 43047.	3.3	59

#	ARTICLE	IF	CITATIONS
1383	Renal Drug Transporters and Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2017, 56, 825-892.	3.5	161
1384	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3124-3153.	6.4	58
1385	Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations. <i>Drug Metabolism and Disposition</i> , 2017, 45, 523-531.	3.3	16
1386	In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2017, 45, 612-623.	3.3	11
1387	Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. <i>Drug Metabolism Reviews</i> , 2017, 49, 197-211.	3.6	414
1388	Evaluation of <i>para</i> -Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18
1389	The importance of drug transporter characterization to precision medicine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 361-365.	3.3	9
1390	Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters – An <i>in Silico</i> Modeling Approach. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 608-615.	5.4	40
1391	A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. <i>Molecular Pharmaceutics</i> , 2017, 14, 686-698.	4.6	21
1392	Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes. <i>AAPS Journal</i> , 2017, 19, 787-796.	4.4	39
1393	Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2). <i>European Journal of Pharmaceutical Sciences</i> , 2017, 103, 70-76.	4.0	27
1394	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs for Substance Abuse. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 201-205.	1.6	10
1395	Importance of Drug Pharmacokinetics at the Site of Action. <i>Clinical and Translational Science</i> , 2017, 10, 133-142.	3.1	86
1396	The Contributions of Human Mini-Intestines to the Study of Intestinal Physiology and Pathophysiology. <i>Annual Review of Physiology</i> , 2017, 79, 291-312.	13.1	46
1397	The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. <i>Drug Resistance Updates</i> , 2017, 30, 15-27.	14.4	29
1398	The Organic Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane of the Human Jejunum and Caco-2 Monolayers. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2657-2663.	3.3	51
1399	Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2017, 45, 721-733.	3.3	38
1400	Brain Uptake of Bioactive Flavones in <i>Scutellariae Radix</i> and Its Relationship to Anxiolytic Effect in Mice. <i>Molecular Pharmaceutics</i> , 2017, 14, 2908-2916.	4.6	25

#	ARTICLE	IF	CITATIONS
1401	Use of biopartitioning micellar chromatography and RP-HPLC for the determination of blood–brain barrier penetration of β -adrenergic/imidazoline receptor ligands, and QSPR analysis. SAR and QSAR in Environmental Research, 2017, 28, 235-252.	2.2	3
1402	Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. Journal of Pharmaceutical Sciences, 2017, 106, 2357-2367.	3.3	59
1403	Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics, 2017, 27, 221-231.	3.6	3
1404	Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine. Journal of Pharmaceutical Sciences, 2017, 106, 2535-2541.	3.3	40
1405	Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malaria Journal, 2017, 16, 161.	2.3	84
1411	The Effect of Uremic Solutes on the Organic Cation Transporter 2. Journal of Pharmaceutical Sciences, 2017, 106, 2551-2557.	3.3	23
1412	Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. Drug Metabolism and Disposition, 2017, 45, 779-789.	3.3	41
1413	Quantitative Analysis of Complex Drug–Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. Journal of Pharmaceutical Sciences, 2017, 106, 2715-2726.	3.3	18
1414	Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations. Journal of Pharmaceutical Sciences, 2017, 106, 2815-2825.	3.3	12
1415	Protonation–state–Coupled Conformational Dynamics in Reaction Mechanisms of Channel and Pump Rhodopsins. Photochemistry and Photobiology, 2017, 93, 1336-1344.	2.5	28
1416	Effect of Liver Disease on Hepatic Transporter Expression and Function. Journal of Pharmaceutical Sciences, 2017, 106, 2282-2294.	3.3	86
1417	Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 165-230.	0.6	0
1418	Involvement of Proton-Coupled Organic Cation Antiporter in Varenicline Transport at Blood-Brain Barrier of Rats and in Human Brain Capillary Endothelial Cells. Journal of Pharmaceutical Sciences, 2017, 106, 2576-2582.	3.3	20
1419	A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies. Journal of Pharmaceutical Sciences, 2017, 106, 2909-2913.	3.3	31
1420	Imaging Probes and Modalities for the Study of Solute Carrier O (SLCO)-Transport Function In Vivo. Journal of Pharmaceutical Sciences, 2017, 106, 2335-2344.	3.3	14
1421	In Vitro–In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug–Drug Interactions–Overview of Basic Prediction Methods. Journal of Pharmaceutical Sciences, 2017, 106, 2209-2213.	3.3	51
1422	In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1. Drug Metabolism and Disposition, 2017, 45, 137-144.	3.3	12
1423	β -adrenergic receptor-mediated in vitro regulation of human hepatic drug transporter expression by epinephrine. European Journal of Pharmaceutical Sciences, 2017, 106, 302-312.	4.0	8

#	ARTICLE	IF	CITATIONS
1424	Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine. <i>Molecular Pharmaceutics</i> , 2017, 14, 2245-2253.	4.6	31
1425	<i>In vitro</i> evaluation of potential transporter-mediated drug interactions of evogliptin. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 398-403.	1.9	5
1426	Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP. <i>Journal of Computer-Aided Molecular Design</i> , 2017, 31, 507-521.	2.9	20
1427	Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. <i>Pharmaceutical Research</i> , 2017, 34, 1741-1750.	3.5	16
1428	Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice. <i>Food and Chemical Toxicology</i> , 2017, 107, 68-73.	3.6	9
1429	The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 436-449.	4.7	74
1430	Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers. <i>Pharmaceutical Research</i> , 2017, 34, 1601-1614.	3.5	57
1431	Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2251-2256.	3.3	0
1432	Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2515-2523.	3.3	4
1433	Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 106, 122-132.	4.0	18
1434	Orally Absorbed Cyclic Peptides. <i>Chemical Reviews</i> , 2017, 117, 8094-8128.	47.7	307
1435	Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 132-143.	5.1	600
1436	In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties. <i>Toxicological Sciences</i> , 2017, 157, 487-499.	3.1	25
1437	Influence of OATP1B1 Function on the Disposition of Sorafenib- β -Glucuronide. <i>Clinical and Translational Science</i> , 2017, 10, 271-279.	3.1	31
1438	Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions. <i>Drugs</i> , 2017, 77, 859-883.	10.9	85
1439	Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures. <i>Journal of Cheminformatics</i> , 2017, 9, 18.	6.1	25
1440	Membrane protein reconstitution in nanodiscs for luminescence spectroscopy studies. <i>Nanotechnology Reviews</i> , 2017, 6, 33-46.	5.8	7
1441	Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites. <i>Drug Metabolism and Disposition</i> , 2017, 45, 646-656.	3.3	12

#	ARTICLE	IF	CITATIONS
1442	Nanoscale lipid membrane mimetics in spin-labeling and electron paramagnetic resonance spectroscopy studies of protein structure and function. <i>Nanotechnology Reviews</i> , 2017, 6, 75-92.	5.8	16
1443	CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5943-5954.	6.4	75
1445	Activity of Multidrug Resistance-Associated Proteins 1â€“5 (MRP1â€“5) in the RPMI 2650 Cell Line and Explants of Human Nasal Turbinate. <i>Molecular Pharmaceutics</i> , 2017, 14, 1577-1590.	4.6	15
1446	Environmental Electrophiles: Protein Adducts, Modulation of Redox Signaling, and Interaction with Persulfides/Polysulfides. <i>Chemical Research in Toxicology</i> , 2017, 30, 203-219.	3.3	49
1447	Extrapolation of Elementary Rate Constants of P-glycoproteinâ€“Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells. <i>Drug Metabolism and Disposition</i> , 2017, 45, 190-197.	3.3	9
1448	Interaction of 2,4-Diaminopyrimidineâ€“Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters. <i>Drug Metabolism and Disposition</i> , 2017, 45, 76-85.	3.3	30
1449	The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo. <i>Toxicology in Vitro</i> , 2017, 40, 26-33.	2.4	22
1450	Modulation of Molecular Flux Using a Graphene Nanopore Capacitor. <i>Journal of Physical Chemistry B</i> , 2017, 121, 3724-3733.	2.6	14
1451	Predicting transporterâ€“mediated drug interactions: Commentary on: â€œPharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatinâ€“and â€œValidation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3Aâ€“. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 447-449.	4.7	17
1452	Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure. <i>Toxicological Sciences</i> , 2017, 155, 270-282.	3.1	15
1453	Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein. <i>AAPS Journal</i> , 2017, 19, 409-420.	4.4	20
1454	Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 135-142.	2.4	6
1455	Warm ischemia time-dependent variation in liver damage, inflammation, and function in hepatic ischemia/reperfusion injury. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 375-385.	3.8	45
1456	Role of ABC transporters in transâ€“epithelial transport of vitamin K antagonists. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 20-32.	1.9	3
1457	Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 251-259.	1.9	20
1458	Inhibition of SLC drug transporter activities by environmental bisphenols. <i>Toxicology in Vitro</i> , 2017, 40, 34-44.	2.4	15
1459	Effects of frequently used pharmaceutical excipients on the organic cation transporters 1â€“3 and peptide transporters 1/2 stably expressed in MDCKII cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 112, 187-195.	4.3	23
1460	Potent inhibition of human organic cation transporter 2 (hOCT2) by Î²-carboline alkaloids. <i>Xenobiotica</i> , 2017, 47, 1112-1120.	1.1	4

#	ARTICLE	IF	CITATIONS
1461	Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 519-530.	4.7	103
1462	Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats. <i>Journal of Nutritional Biochemistry</i> , 2017, 40, 178-186.	4.2	13
1463	The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion. <i>Scientific Reports</i> , 2017, 7, 13767.	3.3	62
1464	Alternative Splicing: Expanding Diversity in Major ABC and SLC Drug Transporters. <i>AAPS Journal</i> , 2017, 19, 1643-1655.	4.4	6
1465	Progress in the formulation and delivery of somatostatin analogs for acromegaly. <i>Therapeutic Delivery</i> , 2017, 8, 867-878.	2.2	14
1466	Reversible core-crosslinked nanocarriers with pH-modulated targeting and redox-controlled drug release for overcoming drug resistance. <i>Journal of Materials Chemistry B</i> , 2017, 5, 8399-8407.	5.8	8
1467	Mechanistic inÂvitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (<scp>MATE</scp>) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00357.	2.4	37
1468	Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases. <i>Scientific Reports</i> , 2017, 7, 13925.	3.3	19
1469	Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. <i>Drug Resistance Updates</i> , 2017, 32, 23-46.	14.4	109
1470	An easy and fast adenosine 5â€²-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5â€²-triphosphatase activity of the human breast cancer resistance protein ABCG2. <i>Journal of Chromatography A</i> , 2017, 1521, 123-130.	3.7	6
1471	Concomitant solubility-permeability increase: Vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 121, 97-103.	4.3	44
1472	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	2.4	8
1473	Usefulness of kidney slices for functional analysis of apical reabsorptive transporters. <i>Scientific Reports</i> , 2017, 7, 12814.	3.3	11
1474	Substrate-induced conformational changes in the nucleotide-binding domains of lipid bilayerâ€™associated P-glycoprotein during ATP hydrolysis. <i>Journal of Biological Chemistry</i> , 2017, 292, 20412-20424.	3.4	59
1475	Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 334-346.	4.0	9
1476	Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine. <i>Pharmaceutical Research</i> , 2017, 34, 2336-2348.	3.5	10
1477	Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport. <i>Molecular Pharmaceutics</i> , 2017, 14, 3299-3311.	4.6	7
1478	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-<i>O</i>-Methyltransferase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1282-1291.	3.3	19

#	ARTICLE	IF	CITATIONS
1479	Influence of B-Complex Vitamins on the Pharmacokinetics of Ginsenosides Rg ₁ , Rb ₁ , and Ro After Oral Administration. <i>Journal of Medicinal Food</i> , 2017, 20, 1127-1132.	1.5	5
1480	pH-mediated gating and formate transport mechanism in the <i>Escherichia coli</i> formate channel. <i>Molecular Simulation</i> , 2017, 43, 1300-1306.	2.0	3
1481	Continuous Intestinal Absorption Model Based on the Convection–Diffusion Equation. <i>Molecular Pharmaceutics</i> , 2017, 14, 3069-3086.	4.6	12
1482	Scaffold-Free Liver-On-A-Chip with Multiscale Organotypic Cultures. <i>Advanced Materials</i> , 2017, 29, 1701545.	21.0	57
1483	Regulation of PDZ domain-containing 1 (PDZK1) expression by hepatocyte nuclear factor-1 \pm (HNF1 \pm) in human kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F973-F983.	2.7	16
1484	Prediction of Transporter-Mediated Drug–Drug Interactions for Baricitinib. <i>Clinical and Translational Science</i> , 2017, 10, 509-519.	3.1	50
1485	Evaluation of transporters in drug development: Current status and contemporary issues. <i>Advanced Drug Delivery Reviews</i> , 2017, 116, 100-118.	13.7	62
1486	Deciphering the origins of molecular toxicity of combretastatin A4 and its glycoconjugates: interactions with major drug transporters and their safety profiles in vitro and in vivo. <i>MedChemComm</i> , 2017, 8, 1542-1552.	3.4	2
1487	Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity. <i>Clinical and Translational Science</i> , 2017, 10, 412-420.	3.1	39
1488	Development of a rapid and sensitive multiple reaction monitoring proteomic approach for quantification of transporters in human liver tissue. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 356-363.	2.3	13
1489	Impact of the <i>OATP1B1</i> c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 547-553.	1.5	8
1490	The conditional stimulation of rat organic cation transporter 2, but not its human ortholog, by mesoridazine: the possibility of the involvement of the high-affinity binding site of the transporter in the stimulation. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1513-1523.	2.4	3
1491	Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug–drug interactions mediated by organic anion transporter 3. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 501-508.	1.9	31
1492	Time-sequenced drug delivery approaches towards effective chemotherapeutic treatment of glioma. <i>Materials Horizons</i> , 2017, 4, 977-996.	12.2	14
1493	Synergistic effect of Chitosan-Zinc Oxide Hybrid Nanoparticles on antibiofouling and water disinfection of mixed matrix polyethersulfone nanocomposite membranes. <i>Carbohydrate Polymers</i> , 2017, 175, 661-670.	10.2	73
1494	Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. <i>Scientific Reports</i> , 2017, 7, 17379.	3.3	5
1496	Organic Ion Transporters and Statin Drug Interactions. <i>Current Atherosclerosis Reports</i> , 2017, 19, 65.	4.8	11
1497	Proton movement and coupling in the POT family of peptide transporters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13182-13187.	7.1	81

#	ARTICLE	IF	CITATIONS
1498	Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1237-1250.	3.3	15
1499	PharmGKB summary. Pharmacogenetics and Genomics, 2017, 27, 420-427.	1.5	25
1500	On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent. Metallomics, 2017, 9, 1786-1795.	2.4	20
1501	The Ussing Chamber Assay to Study Drug Metabolism and Transport in the Human Intestine. Current Protocols in Pharmacology, 2017, 77, 7.17.1-7.17.19.	4.0	25
1502	Predicting drug-induced liver injury: The importance of data curation. Toxicology, 2017, 389, 139-145.	4.2	78
1503	MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	23
1504	Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2. Molecular Pharmaceutics, 2017, 14, 2726-2739.	4.6	9
1505	Eribulin shows high concentration and long retention in xenograft tumor tissues. Cancer Chemotherapy and Pharmacology, 2017, 80, 377-384.	2.3	8
1506	Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicology in Vitro, 2017, 44, 27-35.	2.4	8
1507	A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 269-279.	1.6	5
1508	Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. Clinical Pharmacokinetics, 2017, 56, 139-152.	3.5	65
1509	In Silico and In Vitro Screening for P-Glycoprotein Interaction with Tenofovir, Darunavir, and Dapivirine: An Antiretroviral Drug Combination for Topical Prevention of Colorectal HIV Transmission. Molecular Pharmaceutics, 2017, 14, 2660-2669.	4.6	13
1510	In silico re-identification of properties of drug target proteins. BMC Bioinformatics, 2017, 18, 248.	2.6	26
1511	Autophagy and multidrug resistance in cancer. Chinese Journal of Cancer, 2017, 36, 52.	4.9	497
1512	Effects of phenylpropanoids on human organic anion transporters hOAT1 and hOAT3. Biochemical and Biophysical Research Communications, 2017, 489, 375-380.	2.1	5
1513	Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. Drug Discovery Today, 2017, 22, 1478-1488.	6.4	5
1514	Profiles and Gender-Specifics of UDP-Glucuronosyltransferases and Sulfotransferases Expressions in the Major Metabolic Organs of Wild-Type and Efflux Transporter Knockout FVB Mice. Molecular Pharmaceutics, 2017, 14, 2967-2976.	4.6	9
1515	Disposition and clinical implications of protein-bound uremic toxins. Clinical Science, 2017, 131, 1631-1647.	4.3	39

#	ARTICLE	IF	CITATIONS
1516	Three-dimensional in vitro gut model on a villi-shaped collagen scaffold. <i>Biochip Journal</i> , 2017, 11, 219-231.	4.9	35
1517	Role of Passive Diffusion, Transporters, and Membrane Trafficking-Mediated Processes in Cellular Drug Transport. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 121-129.	4.7	28
1518	In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. <i>Biochemical Pharmacology</i> , 2017, 123, 85-96.	4.4	28
1519	Safety, Tolerability, and Pharmacokinetics of ARC520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 350-362.	1.6	69
1520	Assessment of the Blood-Brain Barrier Permeability of Potential Neuroprotective Aurones in Parallel Artificial Membrane Permeability Assay and Porcine Brain Endothelial Cell Models. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 502-510.	3.3	16
1521	P-gp activity and inhibition in the different regions of human intestine <i>ex vivo</i> . <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 127-138.	1.9	18
1523	Caco-2 cells " expression, regulation and function of drug transporters compared with human jejunal tissue. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 115-126.	1.9	50
1524	Effect of OATP-binding on the prediction of biliary excretion. <i>Xenobiotica</i> , 2017, 47, 614-631.	1.1	1
1525	Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms. <i>Medicinal Research Reviews</i> , 2017, 37, 52-97.	10.5	80
1526	Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis. <i>European Radiology</i> , 2017, 27, 1804-1811.	4.5	24
1527	Roles of organic anion transporters (OATs) in renal proximal tubules and their localization. <i>Anatomical Science International</i> , 2017, 92, 200-206.	1.0	43
1528	The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers " An in vitro and in vivo comparison. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 108, 13-22.	4.0	18
1529	Clinical disposition, metabolism and <i>in vitro</i> drug-drug interaction properties of omadacycline. <i>Xenobiotica</i> , 2017, 47, 682-696.	1.1	36
1530	Influence of testosterone on phase II metabolism and availability of soy isoflavones in male Wistar rats. <i>Archives of Toxicology</i> , 2017, 91, 1649-1661.	4.2	6
1531	Drug Metabolism in the Liver. <i>Clinics in Liver Disease</i> , 2017, 21, 1-20.	2.1	413
1532	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 259-277.	3.3	13
1533	Transporter effects on cell permeability in drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 385-401.	5.0	19
1534	Microvilli Morphology Can Affect Efflux Active P-Glycoprotein in Confluent MDCKII -hMDR1-NKI and Caco-2 Cell Monolayers. <i>Drug Metabolism and Disposition</i> , 2017, 45, 145-151.	3.3	11

#	ARTICLE	IF	CITATIONS
1535	Expression, regulation and function of intestinal drug transporters: an update. <i>Biological Chemistry</i> , 2017, 398, 175-192.	2.5	85
1536	The effects of dietary and herbal phytochemicals on drug transporters. <i>Advanced Drug Delivery Reviews</i> , 2017, 116, 45-62.	13.7	42
1537	Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. <i>Molecular Psychiatry</i> , 2017, 22, 1502-1508.	7.9	75
1538	Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions. <i>Xenobiotica</i> , 2017, 47, 825-832.	1.1	10
1539	Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. <i>Molecular Pharmaceutics</i> , 2017, 14, 4685-4693.	4.6	20
1540	The development of ruthenium(II) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications. <i>Chemical Society Reviews</i> , 2017, 46, 7706-7756.	38.1	326
1541	Transparent cell-capturing chip laminated by film photoresist with suction holes and channels and its application to transepithelial electric resistance measurement. , 2017, , .		0
1543	Introduction to Clinical Pharmacology. , 2017, , 365-388.		15
1544	Daikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawal. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00361.	2.4	5
1545	Liver uptake of cefditoren is mediated by OATP1B1 and OATP2B1 in humans and Oatp1a1, Oatp1a4, and Oatp1b2 in rats. <i>RSC Advances</i> , 2017, 7, 30038-30048.	3.6	5
1546	Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. <i>Frontiers in Pharmacology</i> , 2017, 8, 155.	3.5	18
1547	Genetically Humanized Animal Models. , 2017, , 130-149.		0
1548	Organic Anion Transport in the Developing Kidney. , 2017, , 1040-1045.e2.		0
1549	How Open Data Shapes In Silico Transporter Modeling. <i>Molecules</i> , 2017, 22, 422.	3.8	2
1550	Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity. <i>Pharmaceutics</i> , 2017, 9, 8.	4.5	9
1551	Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 764.	4.1	37
1552	Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays. <i>BioMed Research International</i> , 2017, 2017, 1-23.	1.9	39
1553	Salvia miltiorrhiza Roots against Cardiovascular Disease: Consideration of Herb-Drug Interactions. <i>BioMed Research International</i> , 2017, 2017, 1-12.	1.9	26

#	ARTICLE	IF	CITATIONS
1554	Drug-Induced Liver Injury: Mechanism-Informed Prediction in Drug Development. , 2017, , 217-238.		3
1555	Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS ONE, 2017, 12, e0169480.	2.5	33
1556	Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies. PLoS ONE, 2017, 12, e0173530.	2.5	18
1557	Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates. Malaria Journal, 2017, 16, 422.	2.3	17
1558	Revisiting atenolol as a low passive permeability marker. Fluids and Barriers of the CNS, 2017, 14, 30.	5.0	24
1559	Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy. Journal of Veterinary Medical Science, 2017, 79, 1245-1252.	0.9	4
1560	Geographic Differences in Persistent Organic Pollutant Levels of Yellowfin Tuna. Environmental Health Perspectives, 2017, 125, 067014.	6.0	33
1561	Cytotoxicity Assays. Comprehensive Analytical Chemistry, 2017, 78, 231-275.	1.3	3
1562	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0
1563	Perioperative oral supplementation with fish oil promotes liver regeneration following partial hepatectomy in mice via AMPK activation. Molecular Medicine Reports, 2018, 17, 3905-3911.	2.4	6
1564	Mechanisms of Drug Interactions II: Transport Proteins. , 2018, , 49-85.		3
1565	Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. Journal of Clinical Pharmacology, 2018, 58, 704-716.	2.0	10
1566	Caco-2 Cell Conditions Enabling Studies of Drug Absorption from Digestible Lipid-Based Formulations. Pharmaceutical Research, 2018, 35, 74.	3.5	55
1568	Generation of Highâ€Specificity Antibodies against Membrane Proteins Using DNAâ€Gold Micronanoplexes for Gene Gun Immunization. Current Protocols in Protein Science, 2018, 91, 29.20.1-29.20.22.	2.8	6
1569	Biomarkers for In Vivo Assessment of Transporter Function. Pharmacological Reviews, 2018, 70, 246-277.	16.0	59
1570	Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	79
1571	Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 147-154.	2.5	17
1572	Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System. Drug Metabolism and Disposition, 2018, 46, 729-739.	3.3	37

#	ARTICLE	IF	CITATIONS
1573	Antiparasitic, structural, pharmacokinetic, and toxicological properties of riparin derivatives. <i>Toxicology in Vitro</i> , 2018, 50, 1-10.	2.4	41
1574	Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1713-1723.	3.3	9
1575	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. <i>Biochemical Pharmacology</i> , 2018, 154, 10-17.	4.4	41
1576	P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats. <i>Toxicological Sciences</i> , 2018, 164, 353-362.	3.1	22
1577	Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels. <i>Journal of Neurochemistry</i> , 2018, 146, 670-685.	3.9	59
1578	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 803-817.	4.7	99
1579	Imaging techniques to study drug transporter function in vivo. , 2018, 189, 104-122.		57
1580	In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 688-699.	2.5	20
1581	Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1941-1949.	2.4	35
1582	Generation of Intestinal Organoids Suitable for Pharmacokinetic Studies from Human Induced Pluripotent Stem Cells. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1572-1580.	3.3	69
1583	Lack of association between <i>SLCO</i> 1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 647-655.	1.5	4
1584	Drug Transporters in Xenobiotic Disposition and Pharmacokinetic Prediction. <i>Drug Metabolism and Disposition</i> , 2018, 46, 561-566.	3.3	30
1585	An update on the clinical pharmacokinetics of fexofenadine enantiomers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 429-434.	3.3	14
1586	MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study. <i>Drug Metabolism and Disposition</i> , 2018, 46, 697-703.	3.3	14
1587	Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4020-4029.	6.4	1
1588	GeneGini: Assessment via the Gini Coefficient of Reference Housekeeping Genes and Diverse Human Transporter Expression Profiles. <i>Cell Systems</i> , 2018, 6, 230-244.e1.	6.2	61
1589	Repeated five-day administration of L-BMAA, microcystin-LR, or as mixture, in adult C57BL/6 mice - lack of adverse cognitive effects. <i>Scientific Reports</i> , 2018, 8, 2308.	3.3	16
1591	2D Ultrathin MXene-Based Drug-Delivery Nanoplatfor for Synergistic Photothermal Ablation and Chemotherapy of Cancer. <i>Advanced Healthcare Materials</i> , 2018, 7, e1701394.	7.6	316

#	ARTICLE	IF	CITATIONS
1592	Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 212-222.	4.0	4
1593	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1704-1718.	6.4	84
1594	Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 262-271.	2.5	46
1596	Role of efflux transporters in the absorption, distribution and elimination in rodents of a novel PDE4 inhibitor, CHF6001. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 100-108.	4.0	3
1597	The Drug-Drug Interaction Profile of Presatovir. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 771-780.	2.0	5
1598	Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1. <i>Scientific Reports</i> , 2018, 8, 2630.	3.3	42
1599	Simultaneous Assessment In Vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a Media Loss Approach. <i>Drug Metabolism and Disposition</i> , 2018, 46, 405-414.	3.3	13
1600	Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells. <i>Chinese Journal of Natural Medicines</i> , 2018, 16, 20-28.	1.3	16
1601	Mrp3 Transports Clopidogrel Acyl Glucuronide from the Hepatocytes into Blood. <i>Drug Metabolism and Disposition</i> , 2018, 46, 151-154.	3.3	8
1602	LST-3TM12 is a member of the OATP1B family and a functional transporter. <i>Biochemical Pharmacology</i> , 2018, 148, 75-87.	4.4	23
1603	A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability. <i>NeuroImage</i> , 2018, 172, 808-816.	4.2	25
1604	Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway. <i>Phytomedicine</i> , 2018, 44, 87-97.	5.3	24
1605	pH-responsive gold nanoclusters-based nanoprobe for lung cancer targeted near-infrared fluorescence imaging and chemo-photodynamic therapy. <i>Acta Biomaterialia</i> , 2018, 68, 308-319.	8.3	78
1606	Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5108-5121.	6.4	260
1607	Piperine-mediated drug interactions and formulation strategy for piperine: recent advances and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 43-57.	3.3	47
1608	Impact of Breast Cancer Resistance Protein Expression on the In Vitro Efficacy of Anticancer Drugs in Pancreatic Cancer Cell Lines. <i>Drug Metabolism and Disposition</i> , 2018, 46, 214-222.	3.3	6
1609	Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	26
1610	Transporter expression in non-cancerous and cancerous liver tissue from subjects with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, S18-S19.	2.2	0

#	ARTICLE	IF	CITATIONS
1611	Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals. <i>Respiratory Research</i> , 2018, 19, 68.	3.6	27
1612	Investigational drugs for hyperuricemia, an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 437-444.	4.1	52
1613	Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance. <i>Drug Metabolism and Disposition</i> , 2018, 46, 989-1000.	3.3	45
1614	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. <i>Molecular Pharmacology</i> , 2018, 94, 689-699.	2.3	40
1615	Contribution of multidrug and toxin extrusion protein 1 (MATE1) to renal secretion of trimethylamine-N-oxide (TMAO). <i>Scientific Reports</i> , 2018, 8, 6659.	3.3	20
1616	Hepatobiliary Disposition of Atovaquone: A Case of Mechanistically Unusual Biliary Clearance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 37-45.	2.5	1
1617	Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems. <i>Drug Discovery Today</i> , 2018, 23, 1357-1372.	6.4	52
1619	Molecular insight into drug exporters within the cellular membrane. <i>Pharmacological Research</i> , 2018, 133, 328.	7.1	0
1620	Structural patterns of the human ABCC4/MRP4 exporter in lipid bilayers rationalize clinically observed polymorphisms. <i>Pharmacological Research</i> , 2018, 133, 318-327.	7.1	19
1621	Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. <i>Pharmacogenomics</i> , 2018, 19, 475-393.	1.3	11
1622	Microdosing Cocktail Assay Development for Drug–Drug Interaction Studies. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1973-1986.	3.3	6
1623	The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. <i>Life Sciences</i> , 2018, 200, 63-68.	4.3	8
1624	Amino Acid Transporters as Disease Modifiers and Drug Targets. <i>SLAS Discovery</i> , 2018, 23, 303-320.	2.7	41
1625	Identification and evaluation of clinical substrates of organic anion transporting polypeptides 1B1 and 1B3. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, S19.	2.2	0
1626	Noninvasive Preclinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 627-651.	0.2	5
1627	Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance. <i>International Journal of Pharmaceutics</i> , 2018, 542, 266-279.	5.2	45
1628	Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP). <i>Xenobiotica</i> , 2018, 48, 467-477.	1.1	7
1629	Vectorization of agrochemicals: amino acid carriers are more efficient than sugar carriers to translocate phenylpyrrole conjugates in the Ricinus system. <i>Environmental Science and Pollution Research</i> , 2018, 25, 14336-14349.	5.3	21

#	ARTICLE	IF	CITATIONS
1630	Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 69-80.	1.6	25
1631	Intestinal absorption of pallidifloside D are limited by P-glycoprotein in mice. <i>Xenobiotica</i> , 2018, 48, 739-744.	1.1	1
1632	<i>In vitro</i> drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes. <i>Xenobiotica</i> , 2018, 48, 637-646.	1.1	13
1633	The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. <i>Pharmacogenomics Journal</i> , 2018, 18, 422-430.	2.0	47
1634	The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 271-291.	9.4	43
1635	Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. <i>Drug Metabolism and Disposition</i> , 2018, 46, 11-19.	3.3	30
1636	Active intestinal drug absorption and the solubility-permeability interplay. <i>International Journal of Pharmaceutics</i> , 2018, 537, 84-93.	5.2	51
1637	High hepatic exposure of furanocoumarins in <i>Radix Angelica dahuricae</i> is associated with transporter mediated active uptake. <i>Journal of Ethnopharmacology</i> , 2018, 212, 74-85.	4.1	17
1638	PDZ domain containing protein 1 (PDZK1), a modulator of membrane proteins, is regulated by the nuclear receptor THR12. <i>Molecular and Cellular Endocrinology</i> , 2018, 461, 215-225.	3.2	9
1639	Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 233-242.	4.7	25
1640	BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. <i>Biochemical Pharmacology</i> , 2018, 147, 201-210.	4.4	61
1641	Deuterium- und tritiummarkierte Verbindungen: Anwendungen in den modernen Biowissenschaften. <i>Angewandte Chemie</i> , 2018, 130, 1774-1802.	2.0	104
1642	Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 139-147.	4.7	43
1643	Improving oral bioavailability of cyclic peptides by N-methylation. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2766-2773.	3.0	150
1644	Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 957-969.	3.0	4
1645	In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 183-191.	1.6	42
1646	Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 202-211.	2.0	13
1647	Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles. <i>Xenobiotica</i> , 2018, 48, 1173-1183.	1.1	8

#	ARTICLE	IF	CITATIONS
1648	Organ-on-a-chip Systems. , 2018, , 55-78.		0
1649	A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance. Cancer Research, 2018, 78, 265-277.	0.9	91
1650	Quantitative Expression of Hepatobiliary Transporters and Functional Uptake of Substrates in Hepatic Two-Dimensional Sandwich Cultures: A Comparative Evaluation of Upcyte and Primary Human Hepatocytes. Drug Metabolism and Disposition, 2018, 46, 166-177.	3.3	15
1651	Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology and Therapeutics, 2018, 104, 564-574.	4.7	56
1652	Expression, activity and pharmacokinetic impact of ocular transporters. Advanced Drug Delivery Reviews, 2018, 126, 3-22.	13.7	42
1653	Efflux transport of estrogen glucuronides by human MRP2, MRP3, MRP4 and BCRP. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 99-107.	2.5	25
1654	Experimental Study on the Influence of Excipients on the Heterogeneous Crystallization and Dissolution Properties of an Active Pharmaceutical Ingredient. Crystal Growth and Design, 2018, 18, 338-350.	3.0	18
1655	Autophagy and doxorubicin resistance in cancer. Anti-Cancer Drugs, 2018, 29, 1-9.	1.4	136
1656	Renal organic anion transporters in drug-drug interactions and diseases. European Journal of Pharmaceutical Sciences, 2018, 112, 8-19.	4.0	48
1657	Simultaneous determination of tilianin and its metabolites in mice using ultra-high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. Biomedical Chromatography, 2018, 32, e4139.	1.7	10
1658	Deuterium- and Tritium-Labelled Compounds: Applications in the Life Sciences. Angewandte Chemie - International Edition, 2018, 57, 1758-1784.	13.8	488
1659	Machine Learning for Classification of Inhibitors of Hepatic Drug Transporters. , 2018, , .		3
1660	Drug Transport at the Brain and Endothelial Dysfunction in Preeclampsia: Implications and Perspectives. Frontiers in Physiology, 2018, 9, 1502.	2.8	9
1661	Molecular Biology of ABC Transporters. , 2018, , 180-220.		0
1662	Enantioselective Drug Recognition by Drug Transporters. Molecules, 2018, 23, 3062.	3.8	13
1663	Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1315-1330.	3.3	11
1664	Efficient Generation of Small Intestinal Epithelial-like Cells from Human iPSCs for Drug Absorption and Metabolism Studies. Stem Cell Reports, 2018, 11, 1539-1550.	4.8	45
1665	ABCG2: does resolving its structure elucidate the mechanism?. Biochemical Society Transactions, 2018, 46, 1485-1494.	3.4	15

#	ARTICLE	IF	CITATIONS
1666	Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2. <i>Frontiers in Pharmacology</i> , 2018, 9, 1115.	3.5	22
1668	Establishment and Validation of Competitive Counterflow as a Method To Detect Substrates of the Organic Anion Transporting Polypeptide 2B1. <i>Molecular Pharmaceutics</i> , 2018, 15, 5501-5513.	4.6	25
1669	Modeling <i>Pseudomonas aeruginosa</i> inner plasma membrane in planktonic and biofilm modes. <i>Journal of Chemical Physics</i> , 2018, 149, 215102.	3.0	7
1670	Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. <i>Current Pharmaceutical Biotechnology</i> , 2018, 18, 1151-1158.	1.6	8
1671	Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. <i>Cancers</i> , 2018, 10, 503.	3.7	44
1672	ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC. <i>Frontiers in Pharmacology</i> , 2018, 9, 1312.	3.5	32
1674	Bioavailability of Flavonoids: The Role of Cell Membrane Transporters. , 2018, , 295-320.		11
1675	Evaluating the Utility of Canine Mdr1 Knockout Madin-Darby Canine Kidney I Cells in Permeability Screening and Efflux Substrate Determination. <i>Molecular Pharmaceutics</i> , 2018, 15, 5103-5113.	4.6	27
1676	Cell culture models of oral mucosal barriers: A review with a focus on applications, culture conditions and barrier properties. <i>Tissue Barriers</i> , 2018, 6, 1479568.	3.2	46
1677	Assessing Herbâ€“Drug Interactions of Herbal Products With Therapeutic Agents for Metabolic Diseases: Analytical and Regulatory Perspectives. <i>Studies in Natural Products Chemistry</i> , 2018, 59, 283-322.	1.8	12
1678	Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging. <i>Journal of Biological Chemistry</i> , 2018, 293, 17829-17837.	3.4	28
1679	Transporters in Drug Development: Scientific and Regulatory Considerations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 793-796.	4.7	15
1681	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drugâ€“Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 836-864.	4.7	141
1682	How do oral insecticidal compounds cross the insect midgut epithelium?. <i>Insect Biochemistry and Molecular Biology</i> , 2018, 103, 22-35.	2.7	54
1683	Humanization of the bloodâ€“brain barrier transporter ABCB1 in mice disrupts genomic locus â€“ lessons from three unsuccessful approaches. <i>European Journal of Microbiology and Immunology</i> , 2018, 8, 78-86.	2.8	2
1684	Anion Exchange Drives Reversible Phase Transfer of Coordination Cages and Their Cargoes. <i>Journal of the American Chemical Society</i> , 2018, 140, 14770-14776.	13.7	41
1685	A Monolayer of Primary Colonic Epithelium Generated on a Scaffold with a Gradient of Stiffness for Drug Transport Studies. <i>Analytical Chemistry</i> , 2018, 90, 13331-13340.	6.5	20
1686	Correlation Analysis of Potential Breast Cancer Resistance Protein Probes in Different Monolayer Systems. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2742-2747.	3.3	2

#	ARTICLE	IF	CITATIONS
1687	Overview of Transporters in Pharmacokinetics and Drug Discovery. Current Protocols in Pharmacology, 2018, 82, e46.	4.0	8
1688	Effect of Rifampicin on the Distribution of [¹¹ C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 2018, 15, 4589-4598.	4.6	17
1689	Relevance of Transporters in Clinical Studies. , 2018, , 1-15.		0
1690	When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions. Drug Metabolism and Disposition, 2018, 46, 1487-1496.	3.3	11
1691	Solute carrier transporters: potential targets for digestive system neoplasms. Cancer Management and Research, 2018, Volume 10, 153-166.	1.9	30
1692	Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure. Frontiers in Immunology, 2018, 9, 1983.	4.8	14
1693	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 322-334.	2.5	44
1694	Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. EJNMMI Research, 2018, 8, 81.	2.5	8
1695	Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. British Journal of Clinical Pharmacology, 2018, 84, 2106-2119.	2.4	24
1696	Neue Methoden und Designprinzipien für zellgängige Peptide. Angewandte Chemie, 2018, 130, 12042-12057.	2.0	18
1697	An update on efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 613-624.	3.3	22
1698	P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of [¹¹ C]-Metoclopramide Across the Blood-Brain Barrier: A PET Study on Nonhuman Primates. Journal of Nuclear Medicine, 2018, 59, 1609-1615.	5.0	39
1699	Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Current Opinion in Virology, 2018, 30, 68-79.	5.4	58
1700	The scaffold protein PDZK1 modulates expression and function of the organic anion transporting polypeptide 2B1. European Journal of Pharmaceutical Sciences, 2018, 120, 181-190.	4.0	26
1701	Modeling Gadoxetate Liver Uptake and Efflux Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Enables Preclinical Quantification of Transporter Drug-Drug Interactions. Investigative Radiology, 2018, 53, 563-570.	6.2	5
1702	Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects. Journal of Clinical Pharmacology, 2018, 58, 1427-1435.	2.0	26
1703	Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. Cancer Chemotherapy and Pharmacology, 2018, 82, 199-210.	2.3	33
1704	Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. Advances in Pharmacology, 2018, 83, 65-91.	2.0	34

#	ARTICLE	IF	CITATIONS
1705	Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats. <i>Reproductive Toxicology</i> , 2018, 79, 57-65.	2.9	16
1706	Detection of Chemical Engagement of Solute Carrier Proteins by a Cellular Thermal Shift Assay. <i>ACS Chemical Biology</i> , 2018, 13, 1480-1486.	3.4	37
1707	LC-MS/MS assay for N ¹ -methylnicotinamide in humans, an endogenous probe for renal transporters. <i>Bioanalysis</i> , 2018, 10, 673-689.	1.5	11
1708	Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120. <i>European Journal of Medicinal Chemistry</i> , 2018, 154, 367-391.	5.5	35
1709	The activity of organic anion transporter-3: Role of dexamethasone. <i>Journal of Pharmacological Sciences</i> , 2018, 136, 79-85.	2.5	7
1710	Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite. <i>Molecular Pharmaceutics</i> , 2018, 15, 2384-2390.	4.6	27
1711	Efficient Generation of Cynomolgus Monkey Induced Pluripotent Stem Cell-Derived Intestinal Organoids with Pharmacokinetic Functions. <i>Stem Cells and Development</i> , 2018, 27, 1033-1045.	2.1	8
1712	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 900-915.	4.7	91
1713	Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers. <i>Clinical and Translational Science</i> , 2018, 11, 590-596.	3.1	31
1714	Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-8.	0.8	12
1715	Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. <i>Life Sciences</i> , 2018, 207, 428-435.	4.3	18
1716	Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6779-6800.	6.4	27
1717	Challenges with the precise prediction of ABC-transporter interactions for improved drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 697-707.	5.0	3
1718	Antiepileptic Drugs and Chemotherapy: Potential Interactions and Impact on Treatment of Patients With Cancer. , 2018, , 45-58.		0
1719	Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 269-294.	5.5	25
1720	iPSC-Derived Enterocyte-like Cells for Drug Absorption and Metabolism Studies. <i>Trends in Molecular Medicine</i> , 2018, 24, 696-708.	6.7	19
1721	Assessment of Liver Function Using Pharmacokinetic Parameters of Gd-EOB-DTPA: Experimental Study in Rat Hepatectomy Model. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-7.	0.8	3
1722	Synergized Multimodal Therapy for Safe and Effective Reversal of Cancer Multidrug Resistance Based on Low-Level Photothermal and Photodynamic Effects. <i>Small</i> , 2018, 14, e1800785.	10.0	27

#	ARTICLE	IF	CITATIONS
1723	An imidazole based H-Phe-Phe-NH ₂ peptidomimetic with anti-allodynic effect in spared nerve injury mice. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2446-2450.	2.2	4
1724	In Silico and in Vitro Assessment of OATP1B1 Inhibition in Drug Discovery. <i>Molecular Pharmaceutics</i> , 2018, 15, 3060-3068.	4.6	12
1725	New Human Organotypic Corneal Tissue Model for Ophthalmic Drug Delivery Studies. , 2018, 59, 2880.		38
1726	Emerging Kidney Models to Investigate Metabolism, Transport, and Toxicity of Drugs and Xenobiotics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1692-1702.	3.3	64
1727	A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng. <i>Clinical Therapeutics</i> , 2018, 40, 1322-1337.	2.5	24
1728	An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 502-514.	4.0	63
1729	Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types. <i>Frontiers in Pharmacology</i> , 2018, 9, 27.	3.5	184
1730	Anticoagulants. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 503-515.	1.7	16
1731	Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters <i>In Vitro</i>. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	19
1732	Hybrid Molecular Container Based on Glycoluril and Triptycene: Synthesis, Binding Properties, and Triggered Release. <i>Chemistry - A European Journal</i> , 2018, 24, 14101-14110.	3.3	13
1733	Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 277-294.	4.0	10
1734	Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease. <i>Molecular Pharmaceutics</i> , 2018, 15, 4073-4083.	4.6	23
1735	Physiologic Factors Related to Drug Absorption. , 2018, , 117-147.		1
1736	A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies. <i>PLoS ONE</i> , 2018, 13, e0197101.	2.5	90
1737	Molecular Modeling of Drug-Transporter Interactions—An International Transporter Consortium Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 818-835.	4.7	43
1738	Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition. <i>Molecular Pharmaceutics</i> , 2018, 15, 3425-3433.	4.6	23
1739	Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. <i>Journal of Personalized Medicine</i> , 2018, 8, 14.	2.5	31
1740	Thiodipeptides targeting the intestinal oligopeptide transporter as a general approach to improving oral drug delivery. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 180-189.	5.5	15

#	ARTICLE	IF	CITATIONS
1741	Simultaneous Determination of Five Cytochrome P450 Probe Substrates and Their Metabolites and Organic Anion Transporting Polypeptide Probe Substrate in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Pharmaceutics</i> , 2018, 10, 79.	4.5	4
1742	Assessment of Transporter-Mediated and Passive Hepatic Uptake Clearance Using Rifamycin-SV as a Pan-Inhibitor of Active Uptake. <i>Molecular Pharmaceutics</i> , 2018, 15, 4677-4688.	4.6	8
1743	Capturing the applicability of in vitro-in silico membrane transporter data in chemical risk assessment and biomedical research. <i>Science of the Total Environment</i> , 2018, 645, 97-108.	8.0	13
1744	Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors. , 2018, , 297-356.		1
1745	Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 162-179.	5.5	28
1746	Emerging Methods and Design Principles for Cellâ€Penetrant Peptides. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 11868-11881.	13.8	116
1747	Developmental regulation of kidney and liver solute carrier and ATP-binding cassette drug transporters and drug metabolizing enzymes: the role of remote organ communication. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 561-570.	3.3	22
1748	Minimizing Context Dependency of Gene Networks Using Artificial Cells. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 30137-30146.	8.0	61
1749	Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules. <i>AAPS Journal</i> , 2018, 20, 90.	4.4	86
1750	Cigarette smoke condensate alters <i>Saccharomyces cerevisiae</i> efflux transporter mRNA and activity and increases caffeine toxicity. <i>Toxicology</i> , 2018, 409, 129-136.	4.2	8
1751	Pheophorbide A: Fluorescent Bcrp Substrate to Measure Oral Drug-Drug Interactions in Real-Time In Vivo. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1725-1733.	3.3	11
1752	Excretory Processes in Toxicology: Drug Transporters in Drug Development. , 2018, , 143-164.		0
1753	Oral aktive Peptide: Gibt es ein Patentrezept?. <i>Angewandte Chemie</i> , 2018, 130, 14614-14640.	2.0	15
1754	Orally Active Peptides: Is There a Magic Bullet?. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 14414-14438.	13.8	118
1755	Perspective on the Application of Microphysiological Systems to Drug Transporter Studies. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1647-1657.	3.3	15
1756	Targeted efflux transporter inhibitors â€“ A solution to improve poor cellular accumulation of anti-cancer agents. <i>International Journal of Pharmaceutics</i> , 2018, 550, 278-289.	5.2	19
1757	In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 795-802.	2.3	33
1758	Measuring Ligand Binding Kinetics to Membrane Proteins Using Virion Nano-oscillators. <i>Journal of the American Chemical Society</i> , 2018, 140, 11495-11501.	13.7	17

#	ARTICLE	IF	CITATIONS
1759	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 890-899.	4.7	185
1760	Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse. <i>Archives of Toxicology</i> , 2018, 92, 2875-2884.	4.2	11
1761	CRISPR-Cas9: A New Addition to the Drug Metabolism and Disposition Tool Box. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1776-1786.	3.3	28
1762	Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	1.7	4
1763	Intestinal permeability determinants of norfloxacin in Ussing chamber model. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 121, 236-242.	4.0	19
1764	Quantification of Hepatic Organic Anion Transport Proteins OAT2 and OAT7 in Human Liver Tissue and Primary Hepatocytes. <i>Molecular Pharmaceutics</i> , 2018, 15, 3227-3235.	4.6	21
1765	Reconstitution and functional studies of hamster P-glycoprotein in giant liposomes. <i>PLoS ONE</i> , 2018, 13, e0199279.	2.5	9
1766	Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates. <i>Molecular Pharmacology</i> , 2018, 94, 1057-1068.	2.3	77
1767	Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1179-1189.	3.3	34
1768	Interactions of pesticides with membrane drug transporters: implications for toxicokinetics and toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 739-752.	3.3	23
1769	Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1756-1766.	3.3	21
1770	The fruit fly <i>Drosophila melanogaster</i> as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy. <i>Drug Discovery Today</i> , 2018, 23, 1746-1760.	6.4	10
1771	A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase. <i>Scientific Reports</i> , 2018, 8, 9472.	3.3	65
1772	Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1381-1395.	2.0	14
1773	Impact of gastrointestinal disease states on oral drug absorption – implications for formulation design – a PEARRL review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 674-698.	2.4	53
1774	A Structural View on Medicinal Chemistry Strategies against Drug Resistance. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 3300-3345.	13.8	48
1775	Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. <i>Angewandte Chemie</i> , 2019, 131, 3336-3383.	2.0	5
1776	Modulation of transporter activity of OATP1B1 and OATP1B3 by the major active components of <i>Radix Ophiopogonis</i> . <i>Xenobiotica</i> , 2019, 49, 1221-1228.	1.1	10

#	ARTICLE	IF	CITATIONS
1777	Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 135-137.	1.6	8
1778	Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans. <i>Xenobiotica</i> , 2019, 49, 852-862.	1.1	17
1779	Influence of Orally Administered Borneol on the Expression of Hepatic Transporters in Rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 103-109.	1.6	5
1780	Efflux transport of nicotine, cotinine and trans-3-hydroxycotinine glucuronides by human hepatic transporters. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 125, 490-498.	2.5	5
1781	Role of OCT1 in hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6013-6022.	2.0	6
1782	Protein-protein interactions of drug uptake transporters that are important for liver and kidney. <i>Biochemical Pharmacology</i> , 2019, 168, 384-391.	4.4	17
1783	Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 360-368.	2.5	19
1784	Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F805-F814.	2.7	10
1785	Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples. <i>AAPS Journal</i> , 2019, 21, 88.	4.4	33
1786	Quantitative Kinetic Models from Intravital Microscopy: A Case Study Using Hepatic Transport. <i>Journal of Physical Chemistry B</i> , 2019, 123, 7302-7312.	2.6	8
1787	Self-Healing Hyper-Cross-Linked Metal-Organic Polyhedra (HCMOPs) Membranes with Antimicrobial Activity and Highly Selective Separation Properties. <i>Journal of the American Chemical Society</i> , 2019, 141, 12064-12070.	13.7	124
1788	Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2351-2359.	2.4	3
1789	P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability. <i>Molecular Pharmaceutics</i> , 2019, 16, 3842-3852.	4.6	30
1790	Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins. <i>Molecular Pharmaceutics</i> , 2019, 16, 4065-4076.	4.6	10
1791	Transepithelial transport mechanisms of 7,8-dihydroxyflavone, a small molecular TrkB receptor agonist, in human intestinal Caco-2 cells. <i>Food and Function</i> , 2019, 10, 5215-5227.	4.6	18
1792	Neonicotinoid pesticides poorly interact with human drug transporters. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22379.	3.0	8
1793	Mechanisms of Polymyxin-Induced Nephrotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 305-319.	1.6	26
1794	Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine. <i>Molecular Pharmaceutics</i> , 2019, 16, 3823-3830.	4.6	24

#	ARTICLE	IF	CITATIONS
1795	Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 781-790.	3.1	16
1796	Exploiting Cysteine Residues of SLC Membrane Transporters as Targets for Drugs. <i>SLAS Discovery</i> , 2019, 24, 867-881.	2.7	10
1797	Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2019, 47, 954-960.	3.3	13
1798	Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3434-3442.	3.3	4
1799	Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro. <i>Molecular Pharmaceutics</i> , 2019, 16, 921-930.	4.6	57
1800	Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1040-1049.	3.3	8
1801	STS-NLSP: A Network-Based Label Space Partition Method for Predicting the Specificity of Membrane Transporter Substrates Using a Hybrid Feature of Structural and Semantic Similarity. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 306.	4.1	17
1802	Proposal of a Parameter for OATP1B1 Inhibition Screening at the Early Drug Discovery Stage. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3898-3902.	3.3	1
1803	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9890-9905.	6.4	24
1804	Simultaneous Quantitative Analysis of Clarithromycin and Ranitidine, Probe Inhibitors of P-Glycoprotein and OCT1, to Evaluate Potential Pharmacokinetic Influence of Potential Transporter Substrates. <i>Chromatographia</i> , 2019, 82, 1749-1758.	1.3	2
1805	Kidney-based in vitro models for drug-induced toxicity testing. <i>Archives of Toxicology</i> , 2019, 93, 3397-3418.	4.2	79
1806	Beyond drugs: the evolution of genes involved in human response to medications. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2019, 286, 20191716.	2.6	15
1807	Direct Measurement of Kinetic Parameters of ABCG2-Dependent Transport of Natural Flavonoids Using a Fluorogenic Substrate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 309-319.	2.5	5
1808	Mapping the perturbome network of cellular perturbations. <i>Nature Communications</i> , 2019, 10, 5140.	12.8	40
1809	Estrogen receptor α (ER α) indirectly induces transcription of human renal organic anion transporter 1 (OAT1). <i>Physiological Reports</i> , 2019, 7, e14229.	1.7	11
1810	Molecular and cellular physiology of organic cation transporter 2. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F1669-F1679.	2.7	19
1811	OATP1B3-1B7 (LST-3TM12) Is a Drug Transporter That Affects Endoplasmic Reticulum Access and the Metabolism of Ezetimibe. <i>Molecular Pharmacology</i> , 2019, 96, 128-137.	2.3	7
1812	Role of L-Type Amino Acid Transporter 1 (LAT1) for the Selective Cytotoxicity of Sesamol in Human Melanoma Cells. <i>Molecules</i> , 2019, 24, 3869.	3.8	7

#	ARTICLE	IF	CITATIONS
1813	Physiologically-Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 759-768.	2.5	12
1814	Reversible inhibition of efflux transporters by hydrogel microdevices. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 145, 76-84.	4.3	12
1815	Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1433-1442.	3.3	19
1816	Kinetic basis of metformin-MPP interactions with organic cation transporter OCT2. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F720-F734.	2.7	9
1817	Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1635420.	12.2	104
1818	Different drug metabolism behavior between species in drug-induced hepatotoxicity: limitations and novel resolutions. <i>Toxin Reviews</i> , 2021, 40, 420-431.	3.4	1
1819	Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. <i>Biochemical Pharmacology</i> , 2019, 169, 113612.	4.4	8
1820	The potentially protective role of ATP-binding cassette transporters in preeclampsia via Nrf2. <i>Pregnancy Hypertension</i> , 2019, 18, 21-28.	1.4	13
1821	Risk of Developing Hepatocellular Carcinoma following Depressive Disorder Based on the Expression Level of Oatp2a1 and Oatp2b1. <i>BioMed Research International</i> , 2019, 2019, 1-11.	1.9	3
1822	Advances and Challenges in Rational Drug Design for SLCs. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 790-800.	8.7	40
1823	Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance. <i>Biomaterials</i> , 2019, 223, 119475.	11.4	90
1824	Interaction of cigarette smoke condensate and some of its components with chlorpromazine toxicity on <i>Saccharomyces cerevisiae</i> . <i>Drug and Chemical Toxicology</i> , 2022, 45, 77-87.	2.3	5
1825	The human organic cation transporter OCT1 and its role as a target for drug responses. <i>Drug Metabolism Reviews</i> , 2019, 51, 389-407.	3.6	18
1826	Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. <i>PLoS Genetics</i> , 2019, 15, e1008208.	3.5	23
1827	An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. <i>Chinese Journal of Natural Medicines</i> , 2019, 17, 490-497.	1.3	5
1828	Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1. <i>Scientific Reports</i> , 2019, 9, 13802.	3.3	16
1829	The Permeation of Acamprosate Is Predominantly Caused by Paracellular Diffusion across Caco-2 Cell Monolayers: A Paracellular Modeling Approach. <i>Molecular Pharmaceutics</i> , 2019, 16, 4636-4650.	4.6	9
1830	Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail. <i>Journal of Personalized Medicine</i> , 2019, 9, 45.	2.5	6

#	ARTICLE	IF	CITATIONS
1831	Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 387-395.	2.2	8
1832	Diosgenyl Saponin Inducing Endoplasmic Reticulum Stress and Mitochondria-Mediated Apoptotic Pathways in Liver Cancer Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 11428-11435.	5.2	18
1833	Identification and Characterization of Efflux Transporters That Modulate the Subtoxic Disposition of Diclofenac and Its Metabolites. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1080-1092.	3.3	12
1834	Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	21
1835	Principles of Pharmacogenomics. , 2019, , 1-53.		3
1836	Interaction Between Direct Factor Xa Inhibitors and Digoxin. <i>American Journal of Therapeutics</i> , 2019, 26, e649-e652.	0.9	1
1837	The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 358-363.	3.3	44
1838	Andrographolide is neither a human organic anion transporter 1 (hOAT1) substrate nor inhibitor. <i>Journal of Asian Natural Products Research</i> , 2019, 21, 754-771.	1.4	1
1839	The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective. <i>Pharmacological Research</i> , 2019, 146, 104283.	7.1	63
1840	Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption. <i>International Journal of Pharmaceutics</i> , 2019, 566, 410-433.	5.2	40
1841	UHPLC-HRMS study of anti-Alzheimerâ€™s drug candidates: metabolism of 7-MEOTA-tryptophan hybrids hampers their passage into brain. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 134-144.	2.8	2
1842	Endogenous, cholesterol-activated ATP-dependent transport in membrane vesicles from <i>Spodoptera frugiperda</i> cells. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 137, 104963.	4.0	4
1843	The effects of <i>Mannheimia haemolytica</i> and albendazole on marbofloxacin pharmacokinetics in lambs. <i>Tropical Animal Health and Production</i> , 2019, 51, 2603-2610.	1.4	2
1844	Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort. <i>PLoS Computational Biology</i> , 2019, 15, e1007157.	3.2	6
1845	Mechanistic Basis of Cabotegravirâ€™Glucuronide Disposition in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 269-277.	2.5	4
1846	Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity. <i>AAPS Journal</i> , 2019, 21, 67.	4.4	9
1847	A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1083-1092.	4.7	69
1848	The Efflux Mechanism of Fraxetin-O-Glucuronides in UGT1A9-Transfected HeLa Cells: Identification of Multidrug Resistance-Associated Proteins 3 and 4 (MRP3/4) as the Important Contributors. <i>Frontiers in Pharmacology</i> , 2019, 10, 496.	3.5	12

#	ARTICLE	IF	CITATIONS
1849	Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019, 98, 106590.	0.7	31
1850	Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review. <i>Drug Discovery Today</i> , 2019, 24, 1899-1910.	6.4	52
1851	Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 278-287.	2.5	14
1852	Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. <i>Drug Metabolism and Disposition</i> , 2019, 47, 890-898.	3.3	21
1853	Generation and Characterization of an <i>Abcc1</i> Humanized Mouse Model (<i>hABCC1</i> ^{flx/flx}) with Knockout Capability. <i>Molecular Pharmacology</i> , 2019, 96, 138-147.	2.3	4
1854	Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q ⁺ -TRAP. <i>Biomedical Chromatography</i> , 2019, 33, e4573.	1.7	31
1855	Introduction: Biomembrane Structure, Dynamics, and Reactions. <i>Chemical Reviews</i> , 2019, 119, 5535-5536.	47.7	9
1856	Apical Shear Stress Enhanced Organic Cation Transport in Human OCT2/MATE1-Transfected Madin-Darby Canine Kidney Cells Involves Ciliary Sensing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 523-530.	2.5	17
1857	Positron Emission Tomography Imaging of [¹¹ C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1056-1066.	4.7	51
1858	An updated patent review on P-glycoprotein inhibitors (2011-2018). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 455-461.	5.0	49
1859	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. <i>Drug Metabolism and Disposition</i> , 2019, 47, 699-709.	3.3	15
1860	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983386.	3.2	39
1861	The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis. <i>Drug Metabolism and Disposition</i> , 2019, 47, 854-864.	3.3	34
1862	Effects of naringenin on renal expression of organic cation transporter 1 and 2 proteins and metformin disposition in diabetic rats. <i>Journal of Functional Foods</i> , 2019, 59, 1-7.	3.4	4
1863	Enhanced Intestinal Permeability and Plasma Concentration of Metformin in Rats by the Repeated Administration of Red Ginseng Extract. <i>Pharmaceutics</i> , 2019, 11, 189.	4.5	20
1864	Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin—an Intracerebral Microdialysis Study in Sprague-Dawley Rats. <i>Drug Metabolism and Disposition</i> , 2019, 47, 710-714.	3.3	3
1865	Current Advances in Studying Clinically Relevant Transporters of the Solute Carrier (SLC) Family by Connecting Computational Modeling and Data Science. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 390-405.	4.1	24
1866	Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2019, 47, 690-698.	3.3	8

#	ARTICLE	IF	CITATIONS
1867	Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort. <i>Cells</i> , 2019, 8, 363.	4.1	46
1868	Come Dance With Me: Transformative Changes in the Science and Practice of Drug-Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1272-1278.	4.7	8
1869	Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2756-2764.	3.3	13
1870	In-vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 1133-1141.	2.4	9
1871	Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. <i>AAPS Journal</i> , 2019, 21, 61.	4.4	14
1872	Xenobiotic transporter activity in zebrafish embryo ionocytes. <i>Aquatic Toxicology</i> , 2019, 212, 88-97.	4.0	17
1873	Peppermint (<i>Mentha piperita</i> L.) extract effectively inhibits cytochrome P450 3A4 (CYP3A4) mRNA induction in rifampicin-treated HepG2 cells. <i>Bioscience, Biotechnology and Biochemistry</i> , 2019, 83, 1181-1192.	1.3	4
1874	Effects of the Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trosipium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1319-1330.	2.0	5
1875	Relationship of MATE1 Inhibition and Cytotoxicity in Nephrotoxicity: Application for Safety Evaluation in Early Drug Discovery. <i>Toxicological Sciences</i> , 2019, 170, 223-233.	3.1	4
1876	Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications. <i>Frontiers in Pharmacology</i> , 2019, 10, 208.	3.5	99
1877	Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2019, 8, 393.	2.4	20
1878	Modeling Exposure to Understand and Predict Kidney Injury. <i>Seminars in Nephrology</i> , 2019, 39, 176-189.	1.6	5
1879	Novel in situ visualisation of rat intestinal absorption of polyphenols via matrix-assisted laser desorption/ionisation mass spectrometry imaging. <i>Scientific Reports</i> , 2019, 9, 3166.	3.3	20
1880	Recovery of OATP1B Activity after Living Kidney Transplantation in Patients with End-Stage Renal Disease. <i>Pharmaceutical Research</i> , 2019, 36, 59.	3.5	12
1881	Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 570-580.	2.5	94
1882	Constructing Supported Cell Membranes with Controllable Orientation. <i>Scientific Reports</i> , 2019, 9, 2747.	3.3	2
1883	Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1345-1361.	4.7	107
1884	Induction of multidrug resistance-associated protein 3 expression by diesel exhaust particle extract in human bronchial epithelial BEAS-2B cells. <i>Toxicology in Vitro</i> , 2019, 58, 60-68.	2.4	6

#	ARTICLE	IF	CITATIONS
1885	Interaction of Anticancer Drugs with Human Organic Anion Transporter hOAT4. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	1.3	5
1886	Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives. <i>Environment International</i> , 2019, 126, 659-671.	10.0	18
1887	Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools. <i>SLAS Discovery</i> , 2019, 24, 523-536.	2.7	16
1888	Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen. <i>Archives of Toxicology</i> , 2019, 93, 953-964.	4.2	20
1889	Role of ABCG2 in Secretion into Milk of the Anti-Inflammatory Flunixin and Its Main Metabolite: In Vitro-In Vivo Correlation in Mice and Cows. <i>Drug Metabolism and Disposition</i> , 2019, 47, 516-524.	3.3	11
1890	Pharmacological characterization of the 3D MucilAir [®] nasal model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 139, 186-196.	4.3	39
1891	Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1281-1294.	3.5	98
1892	Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2484-2489.	3.3	13
1893	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: <i>SLC-Phenotyping</i> Using Primary Human Hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 72-83.	2.5	58
1894	Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1049-1060.	2.0	10
1895	Organic anion transporter 3 (OAT3)-mediated transport of dicaffeoylquinic acids and prediction of potential drug-drug interaction. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 133, 95-103.	4.0	11
1896	Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy. <i>Drug Metabolism and Disposition</i> , 2019, 47, 648-656.	3.3	7
1897	Regulation of P-glycoprotein by Bajijiasu <i>in vitro</i> and <i>in vivo</i> by activating the Nrf2-mediated signalling pathway. <i>Pharmaceutical Biology</i> , 2019, 57, 184-192.	2.9	12
1898	Genotoxicity and pharmacokinetic characterization of <i>Cereus jamacaru</i> ethanolic extract in rats. <i>Bioscience Reports</i> , 2019, 39, .	2.4	9
1899	Proteomic Quantification of Human Bloodâ€‘Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients. <i>Molecular Pharmaceutics</i> , 2019, 16, 1220-1233.	4.6	85
1900	Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. <i>Pharmacogenomics</i> , 2019, 20, 279-290.	1.3	41
1901	The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta. <i>Toxicology and Applied Pharmacology</i> , 2019, 368, 18-25.	2.8	10
1902	A teaching laboratory on the activation of xenobiotic transporters at fertilization of sea urchins. <i>Methods in Cell Biology</i> , 2019, 150, 429-447.	1.1	1

#	ARTICLE	IF	CITATIONS
1903	Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology. <i>Molecular Pharmacology</i> , 2019, 95, 490-506.	2.3	55
1904	Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications. <i>Experimental Neurology</i> , 2019, 317, 10-21.	4.1	5
1905	Inhibition of the amino acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2711-2718.	3.6	34
1906	Multi-omics comparisons of <i>p</i> -aminosalicylic acid (PAS) resistance in <i>folC</i> mutated and un-mutated <i>Mycobacterium tuberculosis</i> strains. <i>Emerging Microbes and Infections</i> , 2019, 8, 248-261.	6.5	14
1907	Current Noninvasive MR-Based Imaging Methods in Assessing NAFLD Patients. , 0, .		0
1908	Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver. <i>World Journal of Clinical Cases</i> , 2019, 7, 3915-3933.	0.8	32
1909	Analysing the antidepressant and drug efflux competence of <i>Clitoria ternatea</i> L. as P-glycoprotein inhibitor to facilitate blood brain barrier. <i>Acta Scientiarum - Biological Sciences</i> , 0, 41, e46629.	0.3	0
1910	Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin. <i>Clinical Infectious Diseases</i> , 2019, 69, S552-S558.	5.8	62
1911	The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid. <i>Nature Communications</i> , 2019, 10, 5433.	12.8	44
1912	Quantitative Protein Expression in the Human Retinal Pigment Epithelium: Comparison Between Apical and Basolateral Plasma Membranes With Emphasis on Transporters. , 2019, 60, 5022.		18
1913	Evaluation of Drug Biliary Excretion Using Sandwich-Cultured Human Hepatocytes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 13-30.	1.6	10
1914	A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4. <i>Clinical Pharmacokinetics</i> , 2019, 58, 503-523.	3.5	10
1915	Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. <i>Toxicology in Vitro</i> , 2019, 54, 10-22.	2.4	10
1916	Multiple binding sites in organic cation transporters require sophisticated procedures to identify interactions of novel drugs. <i>Biological Chemistry</i> , 2019, 400, 195-207.	2.5	41
1917	A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes. <i>Archives of Toxicology</i> , 2019, 93, 819-829.	4.2	22
1918	Pharmacokinetic mechanisms underlying the detoxification effect of <i>Glycyrrhizae Radix et Rhizoma</i> (<i>Gancao</i>): drug metabolizing enzymes, transporters, and beyond. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 167-177.	3.3	27
1919	Hepatic microcirculation and mechanisms of portal hypertension. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 221-234.	17.8	148
1920	OCTN: A Small Transporter Subfamily with Great Relevance to Human Pathophysiology, Drug Discovery, and Diagnostics. <i>SLAS Discovery</i> , 2019, 24, 89-110.	2.7	56

#	ARTICLE	IF	CITATIONS
1921	Structural biology and structure–function relationships of membrane proteins. <i>Biochemical Society Transactions</i> , 2019, 47, 47-61.	3.4	24
1922	The Use of Molecular Descriptors To Model Pharmaceutical Uptake by a Fish Primary Gill Cell Culture Epithelium. <i>Environmental Science & Technology</i> , 2019, 53, 1576-1584.	10.0	14
1923	Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2019, 58, 593-613.	3.5	37
1924	Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1204-1212.	4.7	92
1925	Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study. <i>Acta Oncologica</i> , 2019, 58, 168-174.	1.8	4
1926	Clinical Aspects of Transporter-Mediated Drug–Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1386-1394.	4.7	88
1927	ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. <i>Reproductive Toxicology</i> , 2019, 85, 1-5.	2.9	8
1928	Structural basis for prodrug recognition by the SLC15 family of proton-coupled peptide transporters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 804-809.	7.1	43
1929	No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 818-826.	1.6	5
1930	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between <i>SLC38A7</i> and <i>ALPPL2</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 219-227.	4.7	10
1931	The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1085-1089.	3.3	3
1932	The impact of lipophilicity on environmental processes, drug delivery and bioavailability of food components. <i>Microchemical Journal</i> , 2019, 146, 393-406.	4.5	67
1933	Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine. , 2019, 195, 39-53.		39
1934	Identification of competitive inhibitors of the human taurine transporter TauT in a human kidney cell line. <i>Pharmacological Reports</i> , 2019, 71, 121-129.	3.3	7
1935	Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters. <i>Investigational New Drugs</i> , 2019, 37, 1075-1085.	2.6	14
1936	Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior. <i>Biomaterials</i> , 2019, 190-191, 24-37.	11.4	141
1937	Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 125-135.	2.5	36
1938	Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[¹¹ C]Methylpurine in Mice. <i>Molecular Imaging and Biology</i> , 2019, 21, 306-316.	2.6	15

#	ARTICLE	IF	CITATIONS
1939	Lipidic prodrug approach for improved oral drug delivery and therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 579-607.	10.5	54
1940	A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 7-19.	2.0	17
1941	Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. <i>Xenobiotica</i> , 2019, 49, 912-921.	1.1	6
1943	Vectorizing agrochemicals: enhancing bioavailability via carrier-mediated transport. <i>Pest Management Science</i> , 2019, 75, 1507-1516.	3.4	37
1944	Rat Organic Cation Transporter 1 Contains Three Binding Sites for Substrate 1-Methyl-4-phenylpyridinium per Monomer. <i>Molecular Pharmacology</i> , 2019, 95, 169-182.	2.3	28
1945	A three-dimensional microfluidized liver system to assess hepatic drug metabolism and hepatotoxicity. <i>Biotechnology and Bioengineering</i> , 2019, 116, 1152-1163.	3.3	25
1946	Folate and choline absorption and uptake: Their role in fetal development. <i>Biochimie</i> , 2019, 158, 10-19.	2.6	32
1947	Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 21-25.	3.3	228
1948	Simultaneous absolute quantitation of ATP-binding cassette transporters in normal dog tissues by signature peptide analysis using a LC/MS/MS method. <i>Research in Veterinary Science</i> , 2019, 122, 93-101.	1.9	6
1949	Segmental-Dependent Intestinal Drug Permeability: Development and Model Validation of In Silico Predictions Guided by In Vivo Permeability Values. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 316-325.	3.3	16
1950	Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 87-94.	2.2	8
1951	Synergy of clavine alkaloid <i>chanoclavine</i> ™ with tetracycline against multi-drug-resistant <i>E. coli</i> . <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 1307-1325.	3.5	42
1952	Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. <i>Xenobiotica</i> , 2019, 49, 363-374.	1.1	25
1953	Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 247-265.	6.4	44
1954	A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery. <i>Drug Metabolism Letters</i> , 2020, 13, 78-94.	0.8	7
1955	Microsystem for the single molecule analysis of membrane transport proteins. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129330.	2.4	5
1956	Effect of Bisoprolol on the Level of Dabigatran. <i>American Journal of Therapeutics</i> , 2020, 27, e159-e164.	0.9	7
1957	A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats. <i>Xenobiotica</i> , 2020, 50, 536-544.	1.1	5

#	ARTICLE	IF	CITATIONS
1959	Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1082-1115.	4.7	88
1960	LPS-induced inflammation delays the transportation of ASP ⁺ due to down-regulation of OCTN1/2 in alveolar epithelial cells. <i>Journal of Drug Targeting</i> , 2020, 28, 437-447.	4.4	12
1961	Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2292-2307.	6.4	21
1962	Involvement of organic anion-transporting polypeptides and organic cation transporter in the hepatic uptake of jatrorrhizine. <i>Xenobiotica</i> , 2020, 50, 479-487.	1.1	6
1963	Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 107-116.	2.0	5
1964	Implication of human drug transporters to toxicokinetics and toxicity of pesticides. <i>Pest Management Science</i> , 2020, 76, 18-25.	3.4	16
1965	Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of <sc>DDI</sc>. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 269-277.	4.7	48
1966	<i>In vitro</i> metabolism and <i>in vivo</i> pharmacokinetics of bentysrepinine (Y101), an investigational new drug for anti-HBV-infected hepatitis: focus on interspecies comparison. <i>Xenobiotica</i> , 2020, 50, 468-478.	1.1	4
1967	In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 109-119.	1.9	18
1968	Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 178-190.	2.9	16
1969	VARIDT1.0: variability of drug transporter database. <i>Nucleic Acids Research</i> , 2020, 48, D1042-D1050.	14.5	126
1970	Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein. , 2020, , 67-96.		1
1971	Changes in Organic Anion Transporting Polypeptide Uptake in HEK293 Overexpressing Cells in the Presence and Absence of Human Plasma. <i>Drug Metabolism and Disposition</i> , 2020, 48, 18-24.	3.3	16
1972	Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188319.	7.4	51
1973	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. <i>Drug Resistance Updates</i> , 2020, 48, 100663.	14.4	180
1974	Human efflux transport of testosterone, epitestosterone and other androgen glucuronides. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 197, 105518.	2.5	14
1975	Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8. <i>Clinical Pharmacokinetics</i> , 2020, 59, 757-770.	3.5	5
1976	Preliminary <i>in Vitro</i> Assessment of the Potential of EST64454, a Sigma-1 Receptor Antagonist, for Pharmacokinetic Drug-Drug Interactions. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 68-76.	1.4	4

#	ARTICLE	IF	CITATIONS
1977	Recent progress in inÂvivo phenotyping technologies for better prediction of transporter-mediated drugâ€drug interactions. Drug Metabolism and Pharmacokinetics, 2020, 35, 76-88.	2.2	6
1978	OCTN2-targeted nanoparticles for oral delivery of paclitaxel: differential impact of the polyethylene glycol linker size on drug delivery <i>inÂvitro</i>, <i>in situ</i>, and <i>inÂvivo</i>. Drug Delivery, 2020, 27, 170-179.	5.7	19
1979	Recent advances in preclinical inÂvitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters. Drug Metabolism and Pharmacokinetics, 2020, 35, 56-70.	2.2	18
1980	Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions. Drug Metabolism and Pharmacokinetics, 2020, 35, 18-29.	2.2	6
1981	Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space. Molecular Pharmaceutics, 2020, 17, 488-498.	4.6	9
1982	Organic Cation Transporters in Health and Disease. Pharmacological Reviews, 2020, 72, 253-319.	16.0	180
1983	Mechanical Deformation Mediated Transmembrane Transport. Macromolecular Rapid Communications, 2020, 41, 1900518.	3.9	5
1984	Targeting uptake transporters for cancer imaging and treatment. Acta Pharmaceutica Sinica B, 2020, 10, 79-90.	12.0	46
1985	Synthesis, spectroscopic characterization and molecular docking study of ethyl 2-(4-(5,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 427 Td (9 chemotherapeutic treatment of breast cancer cells. Chemical Physics, 2020, 530, 110596.	1.9	4
1986	Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicology Letters, 2020, 321, 114-121.	0.8	2
1987	Placental transporterâ€mediated drug interactions and offspring congenital anomalies. British Journal of Clinical Pharmacology, 2020, 86, 868-879.	2.4	9
1988	The Brain Exposure Efficiency (BEE) Score. ACS Chemical Neuroscience, 2020, 11, 205-224.	3.5	12
1989	Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease. Acta Pharmaceutica Sinica B, 2020, 10, 850-860.	12.0	23
1990	5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2020, 206, 107447.		449
1991	A novel fluorescenceâ€based functional assay for human OATP1A2 and OATP1C1 identifies interaction between thirdâ€generation Pâ€gp inhibitors and OATP1A2. FEBS Journal, 2020, 287, 2468-2485.	4.7	18
1992	Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats. Biological and Pharmaceutical Bulletin, 2020, 43, 384-392.	1.4	3
1993	Cadmium exposure enhances organic cation transporter 2 trafficking to the kidney membrane and exacerbates cisplatin nephrotoxicity. Kidney International, 2020, 97, 765-777.	5.2	13
1994	Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations. Journal of Clinical Pharmacology, 2020, 60, 477-488.	2.0	8

#	ARTICLE	IF	CITATIONS
1995	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). <i>International Journal of Pharmaceutics</i> , 2020, 573, 118842.	5.2	10
1996	A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug–Drug Interactions with Orally Administered Medications. <i>Clinical Pharmacokinetics</i> , 2020, 59, 447-462.	3.5	50
1997	The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109657.	5.6	7
1998	Interaction of Organic Anion Transporter 3-Mediated Uptake of Steviol Acyl Glucuronide, a Major Metabolite of Rebaudioside A, with Selected Drugs. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 1579-1587.	5.2	6
1999	Drug–nutrient interactions: discovering prescription drug inhibitors of the thiamine transporter ThTR-2 (SLC19A3). <i>American Journal of Clinical Nutrition</i> , 2020, 111, 110-121.	4.7	24
2000	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 96-101.	4.7	6
2001	Absorption difference between hepatotoxic pyrrolizidine alkaloids and their N-oxides – Mechanism and its potential toxic impact. <i>Journal of Ethnopharmacology</i> , 2020, 249, 112421.	4.1	22
2002	ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. <i>Pharmaceutics</i> , 2020, 12, 20.	4.5	80
2003	Completing the Enalaprilat Excretion Pathway—Renal Handling by the Proximal Tubule. <i>Pharmaceutics</i> , 2020, 12, 935.	4.5	4
2004	The Development and Validation of a Novel –Dual Cocktail–Probe for Cytochrome P450s and Transporter Functions to Evaluate Pharmacokinetic Drug-Drug and Herb-Drug Interactions. <i>Pharmaceutics</i> , 2020, 12, 938.	4.5	9
2005	Toward a Systematic Structural and Functional Annotation of Solute Carriers Transporters—Example of the SLC6 and SLC7 Families. <i>Frontiers in Pharmacology</i> , 2020, 11, 1229.	3.5	8
2006	Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11831-11844.	6.4	14
2007	Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion–transporting polypeptides. <i>Journal of Biological Chemistry</i> , 2020, 295, 17349-17364.	3.4	28
2008	Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery. <i>Cancers</i> , 2020, 12, 2837.	3.7	20
2009	Tumor-targeted Strategies. , 2020, , 27-55.		0
2010	Apigenin by targeting hnRNP A2 sensitizes triple-negative breast cancer spheroids to doxorubicin-induced apoptosis and regulates expression of ABCC4 and ABCG2 drug efflux transporters. <i>Biochemical Pharmacology</i> , 2020, 182, 114259.	4.4	32
2011	Unassisted N-acetyl-phenylalanine-amide transport across membrane with varying lipid size and composition: kinetic measurements and atomistic molecular dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-16.	3.5	1
2012	The ABCG2/BCRP transporter and its variants – from structure to pathology. <i>FEBS Letters</i> , 2020, 594, 4012-4034.	2.8	36

#	ARTICLE	IF	CITATIONS
2013	Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. Journal of Controlled Release, 2020, 327, 500-511.	9.9	12
2014	Development of a novel molecular probe for the detection of liver mitochondrial redox metabolism. Scientific Reports, 2020, 10, 16489.	3.3	0
2015	Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26245-26253.	7.1	137
2016	Application of genetically modified rodent models in drug discovery and development for translation of clinical ADME properties. , 2020, , 555-594.		0
2017	Protective effect of cilastatin against diclofenac-induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters. British Journal of Pharmacology, 2020, 177, 1933-1948.	5.4	21
2018	Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters. European Journal of Clinical Pharmacology, 2020, 76, 1659-1665.	1.9	2
2019	Discovery of Novel Resorcinol Dibenzy Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2020, 63, 8338-8358.	6.4	50
2020	Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. Biomedicine and Pharmacotherapy, 2020, 129, 110506.	5.6	6
2021	Role of transporters in drug disposition and drug-drug interactions. , 2020, , 311-337.		3
2022	Predictive and translational models for renal drug safety evaluation. , 2020, , 507-534.		0
2023	Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs). FEBS Letters, 2020, 594, 4158-4185.	2.8	12
2024	Applying Biopharmaceutical Classification System criteria to predict the potential effect of Cremophor [®] RH 40 on fexofenadine bioavailability at higher doses. Therapeutic Delivery, 2020, 11, 447-464.	2.2	1
2025	Drug-Exosome Interactions: The Next Frontier in Precision Medicine. Trends in Pharmacological Sciences, 2020, 41, 994-1005.	8.7	34
2026	In silico investigation of phytoconstituents from Indian medicinal herb <i>Tinospora cordifolia</i> (giloy) against SARS-CoV-2 (COVID-19) by molecular dynamics approach. Journal of Biomolecular Structure and Dynamics, 2021, 39, 6792-6809.	3.5	109
2027	Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract. International Journal of Molecular Sciences, 2020, 21, 5737.	4.1	11
2028	Neurobiology of glycine transporters: From molecules to behavior. Neuroscience and Biobehavioral Reviews, 2020, 118, 97-110.	6.1	27
2029	Rifampicin Transport by OATP1B1 Variants. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
2030	Membrane Chemistry Tunes the Structure of a Peptide Transporter. Angewandte Chemie - International Edition, 2020, 59, 19121-19128.	13.8	21

#	ARTICLE	IF	CITATIONS
2031	Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration. <i>Pharmaceutical Research</i> , 2020, 37, 158.	3.5	4
2032	Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans. <i>Drug Metabolism and Disposition</i> , 2020, 48, 841-848.	3.3	21
2033	Mathematical modeling analysis of hepatic uric acid disposition using human sandwich-cultured hepatocytes. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 432-440.	2.2	6
2034	Comparison of In Vitro to In Vivo Extrapolation Approaches for Predicting Transporter-Mediated Hepatic Uptake Clearance Using Suspended Rat Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2020, 48, 861-872.	3.3	14
2035	Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, , 177-215.	1.6	6
2036	Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models. <i>Blood Advances</i> , 2020, 4, 5062-5077.	5.2	6
2037	Hepatic impacts of gold nanoparticles with different surface coatings as revealed by assessing the hepatic drug-metabolizing enzyme and lipid homeostasis in mice. <i>NanoImpact</i> , 2020, 20, 100259.	4.5	12
2038	Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. <i>FEBS Letters</i> , 2020, 594, 4134-4150.	2.8	21
2039	Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. <i>FASEB Journal</i> , 2020, 34, 15734-15752.	0.5	21
2041	Enhancing Chemotherapy by RNA Interference. <i>BIO Integration</i> , 2020, 1, .	1.3	11
2042	Functional and Pharmacological Comparison of Human, Mouse, and Rat Organic Cation Transporter 1 toward Drug and Pesticide Interaction. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6871.	4.1	13
2043	Impact of In Vitro Passive Permeability in a P-gp-transfected LLC-PK1 Model on the Prediction of the Rat and Human Unbound Brain-to-Plasma Concentration Ratio. <i>Pharmaceutical Research</i> , 2020, 37, 175.	3.5	7
2044	Membrane Chemistry Tunes the Structure of a Peptide Transporter. <i>Angewandte Chemie</i> , 2020, 132, 19283-19290.	2.0	3
2045	Monodisperse Liposomes with Femtoliter Volume Enable Quantitative Digital Bioassays of Membrane Transporters and Cell-Free Gene Expression. <i>ACS Nano</i> , 2020, 14, 11700-11711.	14.6	17
2046	Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 761-770.	1.6	8
2047	Using Ex Vivo Porcine Jejunum to Identify Membrane Transporter Substrates: A Screening Tool for Early-Stage Drug Development. <i>Biomedicines</i> , 2020, 8, 340.	3.2	8
2048	In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. <i>Archives of Toxicology</i> , 2020, 94, 3799-3817.	4.2	14
2049	The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype. <i>PLoS ONE</i> , 2020, 15, e0226450.	2.5	15

#	ARTICLE	IF	CITATIONS
2050	High throughput profiling drug response and apoptosis of single polar cells. Journal of Materials Chemistry B, 2020, 8, 8614-8622.	5.8	3
2051	Computational Insights into Allosteric Conformational Modulation of P-Glycoprotein by Substrate and Inhibitor Binding. Molecules, 2020, 25, 6006.	3.8	9
2053	Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts. International Journal of Molecular Sciences, 2020, 21, 9168.	4.1	18
2054	Pharmacogenetics of Statin-Induced Myotoxicity. Frontiers in Genetics, 2020, 11, 575678.	2.3	33
2055	Pharmacokinetic drug–drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. Bioanalysis, 2020, 12, 1647-1664.	1.5	7
2056	The first intracellular loop is essential for the catalytic cycle of the human ABCG2 multidrug resistance transporter. FEBS Letters, 2020, 594, 4059-4075.	2.8	4
2057	Improved In Vitro-In Vivo Correlation by Using the Unbound-Fraction-Adjusted IC50 for Breast Cancer Resistance Protein Inhibition. Pharmaceutical Research, 2020, 37, 230.	3.5	3
2058	Differential interactions of carbamate pesticides with drug transporters. Xenobiotica, 2020, 50, 1380-1392.	1.1	10
2059	Interindividual Diversity in Expression of Organic Anion Uptake Transporters in Normal and Cirrhotic Human Liver. Hepatology Communications, 2020, 4, 739-752.	4.3	16
2060	Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2. Drug Metabolism and Disposition, 2020, 48, 603-612.	3.3	15
2061	Super-resolution Surface-Enhanced Raman Scattering Imaging of Single Particles in Cells. Analytical Chemistry, 2020, 92, 9389-9398.	6.5	29
2062	Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats. Pharmaceutics, 2020, 12, 486.	4.5	7
2063	Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. Pharmaceutics, 2020, 12, 440.	4.5	66
2064	Microphysiological Systems: Design, Fabrication, and Applications. ACS Biomaterials Science and Engineering, 2020, 6, 3231-3257.	5.2	32
2065	Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells. Drug Metabolism and Pharmacokinetics, 2020, 35, 374-382.	2.2	33
2066	Dually directional glycosylated phthalocyanines as extracellular red-emitting fluorescent probes. Dalton Transactions, 2020, 49, 9605-9617.	3.3	3
2067	Active transport of rhodamine 123 by the human multidrug transporter P-glycoprotein involves two independent outer gates. Pharmacology Research and Perspectives, 2020, 8, e00572.	2.4	4
2068	Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients. Antibiotics, 2020, 9, 307.	3.7	14

#	ARTICLE	IF	CITATIONS
2069	A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutaryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker. <i>Analytical Chemistry</i> , 2020, 92, 9745-9754.	6.5	24
2070	Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16009-16018.	7.1	39
2071	Abcg2 transporter affects plasma, milk and tissue levels of meloxicam. <i>Biochemical Pharmacology</i> , 2020, 175, 113924.	4.4	10
2072	Characterization of <i>Meta</i> -Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy. <i>Molecular Pharmacology</i> , 2020, 98, 109-119.	2.3	18
2073	Development of Artificial Cell Models Using Microfluidic Technology and Synthetic Biology. <i>Micromachines</i> , 2020, 11, 559.	2.9	27
2074	Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity. <i>Molecular Pharmaceutics</i> , 2020, 17, 2398-2410.	4.6	12
2075	Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4002.	4.1	160
2076	Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. <i>Pharmacological Reviews</i> , 2020, 72, 606-638.	16.0	360
2077	Physicochemical and biopharmaceutical characterization of novel Matrix-Liposomes. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 153, 158-167.	4.3	2
2078	Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1627-1639.	3.5	28
2079	Fluorescent probes for the dual investigation of MRP2 and OATP1B1 function and drug interactions. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 151, 105395.	4.0	16
2080	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. <i>Cancers</i> , 2020, 12, 1596.	3.7	13
2081	Environmental contaminants modulate transport activity of zebrafish organic anion transporters Oat1 and Oat3. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2020, 231, 108742.	2.6	1
2082	Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. <i>Drug Metabolism and Disposition</i> , 2020, 48, 387-394.	3.3	23
2083	Backbone Hydrogen Bond Energies in Membrane Proteins Are Insensitive to Large Changes in Local Water Concentration. <i>Journal of the American Chemical Society</i> , 2020, 142, 6227-6235.	13.7	9
2084	Differential interactions of the β -lactam cloxacillin with human renal organic anion transporters (OATs). <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 476-483.	1.9	1
2085	Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. <i>Biochemical Pharmacology</i> , 2020, 175, 113865.	4.4	13
2086	Glutamine transporters as pharmacological targets: From function to drug design. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 207-219.	9.1	26

#	ARTICLE	IF	CITATIONS
2087	Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. <i>Pharmaceutics</i> , 2020, 12, 295.	4.5	15
2088	Side-Chain Modification of Peptides Using a Phosphoranylidene Amino Acid. <i>Organic Letters</i> , 2020, 22, 2976-2980.	4.6	8
2089	Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1076-1086.	2.0	8
2090	Effects of Multiple Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 995-1002.	1.6	8
2091	The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1843-1849.	1.9	12
2092	Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats. <i>Pharmaceutics</i> , 2020, 12, 600.	4.5	14
2093	L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cells. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119585.	5.2	7
2094	Correlating single-molecule characteristics of the yeast aquaglyceroporin Fps1 with environmental perturbations directly in living cells. <i>Methods</i> , 2021, 193, 46-53.	3.8	10
2095	Regulation of Organic Anion Transporting Polypeptide 2B1 Expression by MicroRNA in the Human Liver. <i>Molecular Pharmaceutics</i> , 2020, 17, 2821-2830.	4.6	9
2096	Functional analysis of OCTN2 and ATB0,+ in normal human airway epithelial cells. <i>PLoS ONE</i> , 2020, 15, e0228568.	2.5	9
2097	A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits. <i>Molecules</i> , 2020, 25, 663.	3.8	4
2098	Synergistic Mechanisms of Constituents in Herbal Extracts during Intestinal Absorption: Focus on Natural Occurring Nanoparticles. <i>Pharmaceutics</i> , 2020, 12, 128.	4.5	77
2099	Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. <i>Pharmacotherapy</i> , 2020, 40, 274-290.	2.6	6
2100	Synthesis, cytotoxicity evaluation, and molecular modeling studies of 2,N10-substituted acridones as DNA-intercalating agents. <i>Journal of Chemical Research</i> , 2020, 44, 410-425.	1.3	1
2102	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. <i>British Journal of Pharmacology</i> , 2020, 177, 3060-3074.	5.4	14
2103	Mass Spectrometry of Human Transporters. <i>Annual Review of Analytical Chemistry</i> , 2020, 13, 223-247.	5.4	7
2104	Replacing the eleven native tryptophans by directed evolution produces an active P-glycoprotein with site-specific, non-conservative substitutions. <i>Scientific Reports</i> , 2020, 10, 3224.	3.3	9
2105	Adult Zebrafish Model for Screening Drug-Induced Kidney Injury. <i>Toxicological Sciences</i> , 2020, 174, 241-253.	3.1	14

#	ARTICLE	IF	CITATIONS
2106	Establishment of MDR1-knockout human induced pluripotent stem cell line. Drug Metabolism and Pharmacokinetics, 2020, 35, 288-296.	2.2	7
2107	Tumor microenvironment-activated self-recognizing nanodrug through directly tailored assembly of small-molecules for targeted synergistic chemotherapy. Journal of Controlled Release, 2020, 321, 222-235.	9.9	72
2108	Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 148, 27-37.	4.3	6
2109	<i>In Silico</i> Prediction of Human Renal Clearance of Compounds Using Quantitative Structure-Pharmacokinetic Relationship Models. Chemical Research in Toxicology, 2020, 33, 640-650.	3.3	16
2110	PPAR α -Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice. Molecules, 2020, 25, 392.	3.8	12
2111	Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-Glycoprotein. Molecules, 2020, 25, 247.	3.8	27
2112	Use of imaging to assess the activity of hepatic transporters. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 149-164.	3.3	17
2114	Effects of vitamin D on drugs: Response and disposal. Nutrition, 2020, 74, 110734.	2.4	6
2115	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	5.2	11
2116	Role of <i>SLC</i> transporters in toxicity induced by anticancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 493-506.	3.3	15
2117	Identification and experimental confirmation of novel cGMP efflux inhibitors by virtual ligand screening of vardenafil-analogues. Biomedicine and Pharmacotherapy, 2020, 126, 110109.	5.6	12
2118	Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. Journal of Controlled Release, 2020, 322, 486-508.	9.9	106
2119	Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	1
2120	Role of Genetic Variations in the Hepatic Handling of Drugs. International Journal of Molecular Sciences, 2020, 21, 2884.	4.1	15
2121	GM1 Oligosaccharide Crosses the Human Bloodâ€”Brain Barrier In Vitro by a Paracellular Route. International Journal of Molecular Sciences, 2020, 21, 2858.	4.1	29
2122	Advanced oxidation protein products upregulate efflux transporter expression and activity through activation of the Nrf-2-mediated signaling pathway in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2020, 149, 105342.	4.0	6
2123	Is aspirin a substrate of MDR1/P-glycoprotein?. Xenobiotica, 2020, 50, 1258-1264.	1.1	2
2124	Transporterâ€”enzyme interplay and the hepatic drug clearance: what have we learned so far?. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 387-401.	3.3	14

#	ARTICLE	IF	CITATIONS
2125	Ligand- and structural-based discovery of potential small molecules that target the colchicine site of tubulin for cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2020, 196, 112328.	5.5	21
2126	P-glycoprotein deficiency enhances metabolic activation of and platelet response to clopidogrel through marked up-regulation of Cyp3a11 in mice: Direct evidence for the interplay between P-glycoprotein and Cyp3a. <i>Biochemical Pharmacology</i> , 2021, 183, 114313.	4.4	8
2127	Recent advances and future directions in anti-tumor activity of cryptotanshinone: A mechanistic review. <i>Phytotherapy Research</i> , 2021, 35, 155-179.	5.8	21
2128	Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination. , 2021, 217, 107647.		44
2129	Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	12
2130	The Past, Present and Future of Intestinal In Vitro Cell Systems for Drug Absorption Studies. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 50-65.	3.3	51
2131	Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF- κ B pathway and regulating transporter mediated drug efflux. <i>Journal of Ethnopharmacology</i> , 2021, 264, 113388.	4.1	20
2132	Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 388-396.	3.3	9
2133	Human small intestinal organotypic culture model for drug permeation, inflammation, and toxicity assays. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2021, 57, 160-173.	1.5	24
2134	Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?. <i>Future Medicinal Chemistry</i> , 2021, 13, 157-171.	2.3	13
2135	Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. <i>Vox Sanguinis</i> , 2021, 116, 141-154.	1.5	3
2136	Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. <i>Drug Metabolism and Disposition</i> , 2021, 49, 159-168.	3.3	24
2137	Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 259-271.	3.3	16
2138	Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling. <i>Molecular Pharmacology</i> , 2021, 99, 147-162.	2.3	15
2139	Tissue-based biosensor for monitoring the antioxidant effect of orally administered drugs in the intestine. <i>Bioelectrochemistry</i> , 2021, 138, 107720.	4.6	13
2140	Drug concentration estimation using contrast-enhanced MRI in intra-arterial chemotherapy for head and neck cancers. <i>Auris Nasus Larynx</i> , 2021, 48, 496-501.	1.2	1
2141	Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 173-183.	1.6	6
2142	Inhibition of ABCG2/BCRP-mediated transport – correlation analysis of various expression systems and probe substrates. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 156, 105593.	4.0	3

#	ARTICLE	IF	CITATIONS
2143	Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study. <i>Clinical and Translational Science</i> , 2021, 14, 373-381.	3.1	13
2144	Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 347-353.	3.3	14
2145	A guide to plasma membrane solute carrier proteins. <i>FEBS Journal</i> , 2021, 288, 2784-2835.	4.7	168
2146	Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 762-771.	4.7	15
2147	Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters. , 2021, , .		1
2148	Circadian regulation of transporter expression and implications for drug disposition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 425-439.	3.3	10
2149	Principles and Experimental Considerations for In Vitro Transporter Interaction Assays. <i>Methods in Molecular Biology</i> , 2021, 2342, 339-365.	0.9	2
2150	Case Study 7: Transporters In Vitro Solutions for Translatable Outcomes. <i>Methods in Molecular Biology</i> , 2021, 2342, 709-735.	0.9	0
2151	Drug Transporters: Efflux. , 2021, , .		0
2152	Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide. <i>Pediatric Research</i> , 2021, 90, 832-839.	2.3	1
2153	Insights into Mechanisms and Models for Studying Neurological Adverse Events Mediated by Pharmacokinetic Interactions between Clinical Drugs and Illicit Substances of Herbal and Fungal Origin. , 2021, , 137-158.		1
2154	A multi-domain shear-stress dependent diffusive model of cell transport-aided dialysis: analysis and simulation. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 8188-8200.	1.9	1
2155	The Structure and Mechanism of Drug Transporters. <i>Methods in Molecular Biology</i> , 2021, 2342, 193-234.	0.9	14
2156	RNA editing enzyme ADAR1 governs the circadian expression of P-glycoprotein in human renal cells by regulating alternative splicing of the ABCB1 gene. <i>Journal of Biological Chemistry</i> , 2021, 296, 100601.	3.4	6
2157	Evaluation of Pharmacokinetic Drug-Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches. <i>Metabolites</i> , 2021, 11, 75.	2.9	27
2158	Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. <i>Pharmaceutics</i> , 2021, 13, 83.	4.5	12
2159	Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [11C]Metoclopramide in Mice. <i>Pharmaceutical Research</i> , 2021, 38, 127-140.	3.5	1
2160	Drug Permeability and Transporter Assessment: Polarized Cell Lines. , 2021, , 1-13.		1

#	ARTICLE	IF	CITATIONS
2161	A key role for the transporter OAT1 in systemic lipid metabolism. Journal of Biological Chemistry, 2021, 296, 100603.	3.4	19
2162	Oral Drug Delivery. , 2021, , 1-8.		0
2163	Highlighting membrane protein structure and function: A celebration of the Protein Data Bank. Journal of Biological Chemistry, 2021, 296, 100557.	3.4	42
2164	Transporter proteins and its implication in human diseases. Advances in Protein Chemistry and Structural Biology, 2021, 124, 1-21.	2.3	4
2165	Cynaroside inhibits <i>Leishmania donovani</i> UDP-galactopyranose mutase and induces reactive oxygen species to exert antileishmanial response. Bioscience Reports, 2021, 41, .	2.4	11
2166	Quantitative Analysis of Intracellular Drug Concentrations in Hepatocytes. Methods in Pharmacology and Toxicology, 2021, , 97-125.	0.2	0
2167	Drug Transport Assessment: Transfected Cells and Membrane Vesicles. , 2021, , 1-13.		1
2168	Advances in Oral Drug Delivery. Frontiers in Pharmacology, 2021, 12, 618411.	3.5	305
2169	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. British Journal of Pharmacology, 2021, 178, 1459-1474.	5.4	7
2170	Preliminary <i>in vitro</i> approach to evaluate the drug-drug interaction potential of EST73502, a dual μ -opioid receptor partial agonist and f1 receptor antagonist. Xenobiotica, 2021, 51, 501-512.	1.1	2
2171	Differential <i>in vitro</i> interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters. Xenobiotica, 2021, 51, 467-478.	1.1	3
2172	Intestinal membrane transporter-mediated approaches to improve oral drug delivery. Journal of Pharmaceutical Investigation, 2021, 51, 137-158.	5.3	25
2173	The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy. Chemical Biology and Drug Design, 2021, 97, 997-1015.	3.2	14
2174	Molecular Structure, Molecular Docking and Absorption, Distribution, Metabolism, Excretion and Toxicity study of cellulose II. Journal of the Chinese Chemical Society, 2021, 68, 1250-1262.	1.4	1
2175	ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells. Cancer Cell International, 2021, 21, 108.	4.1	10
2177	Drug-Drug Interactions at Organic Cation Transporter 1. Frontiers in Pharmacology, 2021, 12, 628705.	3.5	14
2178	Generation of Human-Induced Pluripotent Stem Cell-Derived Functional Enterocyte-Like Cells for Pharmacokinetic Studies. Stem Cell Reports, 2021, 16, 295-308.	4.8	18
2179	Identification of Specific Trafficking Defects of Naturally Occurring Variants of the Human ABCG2 Transporter. Frontiers in Cell and Developmental Biology, 2021, 9, 615729.	3.7	5

#	ARTICLE	IF	CITATIONS
2180	Impacts of Drug Interactions on Pharmacokinetics and the Brain Transporters: A Recent Review of Natural Compound-Drug Interactions in Brain Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1809.	4.1	6
2181	Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions. <i>Pharmaceutics</i> , 2021, 13, 314.	4.5	5
2182	Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarinâ€drug interactions. <i>Phytotherapy Research</i> , 2021, 35, 3286-3297.	5.8	4
2183	Optimization of dose and route of administration of the Pâ€glycoprotein inhibitor, valspodar (PSCâ€833) and the Pâ€glycoprotein and breast cancer resistance protein dualâ€inhibitor, elacridar (GF120918) as dual infusion in rats. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00740.	2.4	6
2184	Repurposing 99mTc-Mebrofenin as a Probe for Molecular Imaging of Hepatocyte Transporters. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1043-1047.	5.0	4
2185	Medically Important Alterations in Transport Function and Trafficking of ABCG2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2786.	4.1	17
2186	Study of Pharmaceutical Excipient PEG400 Alteration of Pharmacokinetics and Tissue Distribution of Main Flavonoids Metabolites of Baicalin. <i>Current Pharmaceutical Analysis</i> , 2021, 17, 609-623.	0.6	3
2187	UPLCâ€MS/MS method for the simultaneous quantification of pravastatin, fexofenadine, rosuvastatin, and methotrexate in a hepatic uptake model and its application to the possible drugâ€drug interaction study of triptolide. <i>Biomedical Chromatography</i> , 2021, 35, e5093.	1.7	0
2188	Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy. , 2021, 3, 47-59.		12
2189	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1173-1182.	4.1	6
2190	Hepatic transporterâ€mediated pharmacokinetic drugâ€drug interactions: Recent studies and regulatory recommendations. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 45-77.	1.9	3
2191	Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. <i>Pharmaceutics</i> , 2021, 13, 369.	4.5	14
2192	Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies. <i>Medicine in Drug Discovery</i> , 2021, 9, 100079.	4.5	23
2193	<i>In vitro</i> evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. <i>Xenobiotica</i> , 2021, 51, 522-535.	1.1	8
2194	Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction?. <i>Frontiers in Pharmacology</i> , 2021, 12, 648388.	3.5	9
2195	The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105740.	4.0	5
2196	Early patterning of ABCB, ABCC, and ABCG transporters establishes unique territories of small molecule transport in embryonic mesoderm and endoderm. <i>Developmental Biology</i> , 2021, 472, 115-124.	2.0	6
2197	The Alteration of L-Carnitine Transport and Pretreatment Effect under Glutamate Cytotoxicity on Motor Neuron-Like NSC-34 Lines. <i>Pharmaceutics</i> , 2021, 13, 551.	4.5	6

#	ARTICLE	IF	CITATIONS
2198	Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 662535.	3.5	11
2199	Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics. <i>AAPS Journal</i> , 2021, 23, 59.	4.4	12
2200	Multidrug Resistance in Mammals and Fungi—From MDR to PDR: A Rocky Road from Atomic Structures to Transport Mechanisms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4806.	4.1	28
2203	CRISPR/Cas9 mutagenesis reveals a role for ABCB1 in gut immune responses to <i>Vibrio diazotrophicus</i> in sea urchin larvae. <i>Journal of Experimental Biology</i> , 2021, 224, .	1.7	15
2204	Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS). <i>Chemical Reviews</i> , 2021, 121, 5289-5335.	47.7	199
2205	Stabilization of supramolecular membrane protein—lipid bilayer assemblies through immobilization in a crystalline exoskeleton. <i>Nature Communications</i> , 2021, 12, 2202.	12.8	35
2206	Divergent Regulation of OCT and MATE Drug Transporters by Cadmium Exposure. <i>Pharmaceutics</i> , 2021, 13, 537.	4.5	4
2207	From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation. <i>Frontiers in Chemistry</i> , 2021, 9, 672267.	3.6	77
2208	Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 118-127.	1.9	11
2209	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111223.	5.6	12
2210	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1513-1526.	3.3	8
2211	Drug interaction (50. Drug interaction mediated transporters). <i>Okayama Igakkai Zasshi</i> , 2021, 133, 68-72.	0.0	0
2212	Treatment and protective effects of metalloproteinase inhibitors alone and in combination with N-Acetyl cysteine plus vitamin E in rats exposed to aflatoxin B1. <i>Toxicol</i> , 2021, 194, 79-85.	1.6	4
2213	Evaluation of the drug—drug interaction potential for trazpiroben (TAK-906), a D ₂ /D ₃ receptor antagonist for gastroparesis, towards cytochrome P450s and transporters. <i>Xenobiotica</i> , 2021, 51, 1-12.	1.1	7
2214	Characterization of Transport Activity of SLC11 Transporters in <i>Xenopus laevis</i> Oocytes by Fluorophore Quenching. <i>SLAS Discovery</i> , 2021, 26, 798-810.	2.7	1
2215	Drug—drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H ₃ receptor antagonist. <i>Xenobiotica</i> , 2021, 51, 786-795.	1.1	2
2216	Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity. <i>Toxicological Sciences</i> , 2021, 182, 183-194.	3.1	3
2217	A nanosensor for precise discrimination of nephrotoxic drug mechanisms via dynamic fluorescence fingerprint strategy. <i>Analytica Chimica Acta</i> , 2021, 1160, 338447.	5.4	3

#	ARTICLE	IF	CITATIONS
2218	Integrated Isogenic Human Induced Pluripotent Stem Cellâ€Based Liver and Heart Microphysiological Systems Predict Unsafe Drugâ€Drug Interaction. <i>Frontiers in Pharmacology</i> , 2021, 12, 667010.	3.5	29
2219	Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys. <i>Clinical and Translational Science</i> , 2021, 14, 1924-1934.	3.1	5
2220	Choroid Plexus and Drug Removal Mechanisms. <i>AAPS Journal</i> , 2021, 23, 61.	4.4	14
2221	Improving the Translation of Organic Anion Transporting Polypeptide Substrates using HEK293 Cell Data in the Presence and Absence of Human Plasma via PBPK Modeling. <i>Drug Metabolism and Disposition</i> , 2021, 49, DMD-AR-2020-000315.	3.3	5
2222	Associations among total p-cresylsulfate, indoxyl sulfate and hippuric acid levels with hemodialysis quality indicators in maintenance hemodialysis patients. <i>Clinica Chimica Acta</i> , 2021, 516, 83-91.	1.1	3
2223	[11C]K-2 image with positron emission tomography represents cell surface AMPA receptors. <i>Neuroscience Research</i> , 2021, 173, 106-113.	1.9	7
2224	Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 467-477.	2.5	9
2225	Drug Metabolism in Drug Discovery and Preclinical Development. , 0, , .		0
2226	Drugs in COVIDâ€19 Clinical Trials: Predicting Transporterâ€Mediated Drugâ€Drug Interactions Using In Vitro Assays and Realâ€World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 108-122.	4.7	16
2227	A systematic literature review (SLR): evaluation pharmacokinetic profile of drug combined p-glycoprotein (p-gp) alkaloid inhibitor in white rats (<i>rattus norvegicus</i>). <i>Journal of Physics: Conference Series</i> , 2021, 1912, 012047.	0.4	0
2228	Mechanisms of Drug Resistance in the Pathogenesis of Epilepsy: Role of Neuroinflammation. A Literature Review. <i>Brain Sciences</i> , 2021, 11, 663.	2.3	30
2229	Considerations to Be Taken When Carrying Out Medicinal Plant Researchâ€What We Learn from an Insight into the IC50 Values, Bioavailability and Clinical Efficacy of Exemplary Anti-Inflammatory Herbal Components. <i>Pharmaceuticals</i> , 2021, 14, 437.	3.8	13
2230	Data-Driven Ensemble Docking to Map Molecular Interactions of Steroid Analogs with Hepatic Organic Anion Transporting Polypeptides. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3109-3127.	5.4	7
2231	Transporter-mediated drugâ€drug interactions: advancement in models, analytical tools, and regulatory perspective. <i>Drug Metabolism Reviews</i> , 2021, 53, 285-320.	3.6	5
2232	Pharmacokinetic Modeling of Morphineâ€™s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers. <i>Frontiers in Physiology</i> , 2021, 12, 663170.	2.8	5
2233	Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 869-886.	3.3	9
2234	mPEG2k-PCLx Polymeric Micelles Influence Pharmacokinetics and Hypoglycemic Efficacy of Metformin through Inhibition of Organic Cation Transporters in Rats. <i>Molecular Pharmaceutics</i> , 2021, 18, 2586-2599.	4.6	1
2235	Luminogenic Dâ€Luciferin Derivatives as OATP1B1 and 1B3 Substrates in Noâ€wash Assays â€. <i>Photochemistry and Photobiology</i> , 2021, , .	2.5	1

#	ARTICLE	IF	CITATIONS
2236	Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1526-1540.	12.0	13
2237	Intra-Herb Interactions: Primary Metabolites in <i>Coptidis Rhizoma</i> Extract Improved the Pharmacokinetics of Oral Berberine Hydrochloride in Mice. <i>Frontiers in Pharmacology</i> , 2021, 12, 675368.	3.5	5
2238	Generation of tetracycline-controllable CYP3A4-expressing Caco-2 cells by the piggyBac transposon system. <i>Scientific Reports</i> , 2021, 11, 11670.	3.3	5
2239	Recent developments in ligands and chemical probes targeting solute carrier transporters. <i>Current Opinion in Chemical Biology</i> , 2021, 62, 53-63.	6.1	12
2240	Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices. <i>Frontiers in Pharmacology</i> , 2021, 12, 684156.	3.5	8
2241	Comparative Hepatic and Intestinal Efflux Transport of Statins. <i>Drug Metabolism and Disposition</i> , 2021, 49, 750-759.	3.3	31
2242	Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2. <i>Journal of Molecular Biology</i> , 2021, 433, 166980.	4.2	52
2243	Global Analysis of Models for Predicting Human Absorption: QSAR, <i>In Vitro</i> , and Preclinical Models. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9389-9403.	6.4	13
2244	ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C>A) May Lead to Increased Drug Exposure. <i>Frontiers in Pharmacology</i> , 2021, 12, 698966.	3.5	6
2245	Ursodeoxycholic acid markedly promotes the absorption of microemulsion-formulated cyclosporine A: A case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	1.5	1
2246	Highlights in targeted nanoparticles as a delivery strategy for glioma treatment. <i>International Journal of Pharmaceutics</i> , 2021, 604, 120758.	5.2	18
2248	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697927.	3.7	8
2249	Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss. <i>Molecular Pharmacology</i> , 2021, 100, MOLPHARM-AR-2021-000274.	2.3	4
2250	Identification of novel inhibitors of rat Mrp3. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105813.	4.0	1
2252	Regulation of drug transporters by microRNA and implications in disease treatment. <i>Journal of Pharmaceutical Investigation</i> , 0, , 1.	5.3	5
2254	Three dimensional modeling of biologically relevant fluid shear stress in human renal tubule cells mimics in vivo transcriptional profiles. <i>Scientific Reports</i> , 2021, 11, 14053.	3.3	22
2255	Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 96-107.	2.5	7
2256	Application of proteomics to understand maturation of drug metabolizing enzymes and transporters for the optimization of pediatric drug therapy. <i>Drug Discovery Today: Technologies</i> , 2021, 39, 31-48.	4.0	11

#	ARTICLE	IF	CITATIONS
2257	Generation of Budding-Like Intestinal Organoids from Human Induced Pluripotent Stem Cells. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 2637-2650.	3.3	8
2258	Classification of drugs for evaluating drug interaction in drug development and clinical management. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 41, 100414.	2.2	12
2259	Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2 <i>H</i> -benzo[<i>b</i>][1,4]oxazin-6-yl Moiety. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11014-11044.	6.4	18
2260	Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. <i>Scientific Reports</i> , 2021, 11, 14948.	3.3	32
2261	Brij-functionalized chitosan nanocarrier system enhances the intestinal permeability of P-glycoprotein substrate-like drugs. <i>Carbohydrate Polymers</i> , 2021, 266, 118112.	10.2	10
2262	Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice. <i>Pharmaceutics</i> , 2021, 13, 1286.	4.5	7
2263	Current Trends and Research Topics Regarding Intestinal Organoids: An Overview Based on Bibliometrics. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 609452.	3.7	3
2264	Drug Screening, Oral Bioavailability and Regulatory Aspects: A Need for Human Organoids. <i>Pharmaceutics</i> , 2021, 13, 1280.	4.5	12
2266	In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers. <i>Xenobiotica</i> , 2021, 51, 1122-1131.	1.1	7
2267	Comparative in silico prediction of P-glycoprotein-mediated transport for 2010-2020 US FDA-approved drugs using six Web-tools. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 393-398.	1.9	8
2268	Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1509-1535.	3.5	7
2269	Acetylation turns leucine into a drug by membrane transporter switching. <i>Scientific Reports</i> , 2021, 11, 15812.	3.3	16
2270	Liver Fibrosis Staging with Gadolinium Ethoxybenzyl Diethylenetriamine Penta-Acetic Acid-enhanced: A Systematic Review and Meta-analysis. <i>Current Medical Imaging</i> , 2021, 17, 854-863.	0.8	2
2271	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0239920.	3.2	10
2273	An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters. <i>Frontiers in Pharmacology</i> , 2021, 12, 722889.	3.5	31
2274	Nanoplatfrom-based natural products co-delivery system to surmount cancer multidrug-resistant. <i>Journal of Controlled Release</i> , 2021, 336, 396-409.	9.9	31
2276	Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1526-1536.	4.7	38
2277	Feature, Function, and Information of Drug Transporter-Related Databases. <i>Drug Metabolism and Disposition</i> , 2022, 50, 76-85.	3.3	3

#	ARTICLE	IF	CITATIONS
2278	X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13072-13095.	6.4	13
2279	8-acetoxy-6-sulfopyrene as the first activatable fluorogenic probe for <i>in situ</i> assessment of Organic anion-transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1. <i>FASEB Journal</i> , 2021, 35, e21863.	0.5	9
2280	Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1622-1632.	4.7	20
2281	Membrane Transporters Involved in the Antimicrobial Activities of Pyrithione in <i>Escherichia coli</i> . <i>Molecules</i> , 2021, 26, 5826.	3.8	6
2282	Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 505-516.	3.3	3
2283	Transporter-mediated drug-drug interactions – Study design, data analysis, and implications for <i>in vitro</i> evaluations. <i>Medicine in Drug Discovery</i> , 2021, 11, 100096.	4.5	5
2284	Importance of the Azole Moiety of Cimetidine Derivatives for the Inhibition of Human Multidrug and Toxin Extrusion Transporter 1 (hMATE1). <i>Chemical and Pharmaceutical Bulletin</i> , 2021, 69, 905-912.	1.3	4
2285	Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation. <i>Molecules</i> , 2021, 26, 5500.	3.8	14
2286	The Influence of OAT1 Density and Functionality on Indoxyl Sulfate Transport in the Human Proximal Tubule: An Integrated Computational and <i>In Vitro</i> Study. <i>Toxins</i> , 2021, 13, 674.	3.4	1
2287	Potential and Limits of Kidney Cells for Evaluation of Renal Excretion. <i>Pharmaceutics</i> , 2021, 14, 908.	3.8	6
2288	Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach. <i>Frontiers in Pharmacology</i> , 2021, 12, 726669.	3.5	12
2289	Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. <i>Scientific Reports</i> , 2021, 11, 17810.	3.3	28
2290	Pharmacogenomics of celiprolol – evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. <i>Clinical and Translational Science</i> , 2022, 15, 409-421.	3.1	4
2291	Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARP – a comparison of PARP imaging agents. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 834-846.	6.4	10
2292	Pulmonary surfactants affinity Pluronic-hybridized liposomes enhance the treatment of drug-resistant lung cancer. <i>International Journal of Pharmaceutics</i> , 2021, 607, 120973.	5.2	9
2293	Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. <i>AAPS Journal</i> , 2021, 23, 106.	4.4	7
2294	Pharmacogenetic approach to methotrexate-related toxicity prediction in psoriasis. <i>Russian Journal of Skin and Venereal Diseases</i> , 2021, 24, 119-132.	0.2	0
2295	Natural Nano-Drug Delivery System in <i>Coptidis Rhizoma</i> Extract with Modified Berberine Hydrochloride Pharmacokinetics. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 6297-6311.	6.7	18

#	ARTICLE	IF	CITATIONS
2296	Integration of Clinical and Scientific Principles in the Teaching of Drug-Drug Interactions. Medical Science Educator, 2021, 31, 2169-2176.	1.5	0
2297	Assessing donor-to-donor variability in human intestinal organoid cultures. Stem Cell Reports, 2021, 16, 2364-2378.	4.8	21
2298	Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics. Drug Metabolism and Disposition, 2021, 49, 1038-1046.	3.3	20
2299	Specifically Targeted Transport of Plasma Membrane Transporters: From Potential Mechanisms for Regulating Cell Health or Disease to Applications. Membranes, 2021, 11, 736.	3.0	6
2300	Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. Cancer Chemotherapy and Pharmacology, 2021, 88, 941-952.	2.3	10
2301	Regulation of solute carriers oct2 and OAT1/3 in the kidney: a phylogenetic, ontogenetic, and cell dynamic perspective. Physiological Reviews, 2022, 102, 993-1024.	28.8	11
2303	The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes. Molecules, 2021, 26, 5629.	3.8	14
2304	Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes. European Journal of Pharmaceutical Sciences, 2021, 165, 105951.	4.0	7
2305	ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacological Research, 2021, 172, 105850.	7.1	6
2306	Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms. Biomedicine and Pharmacotherapy, 2021, 142, 112080.	5.6	25
2307	Transporter-interfering chemicals inhibit P-glycoprotein of yellowfin tuna (Thunnus albacares). Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2021, 248, 109101.	2.6	6
2308	Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. European Journal of Pharmaceutical Sciences, 2021, 165, 105932.	4.0	8
2309	Advances in understanding the specificity function of transporters by machine learning. Computers in Biology and Medicine, 2021, 138, 104893.	7.0	7
2310	Impact of kidney dysfunction on hepatic and intestinal drug transporters. Biomedicine and Pharmacotherapy, 2021, 143, 112125.	5.6	7
2311	Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. Journal of Ethnopharmacology, 2021, 280, 114469.	4.1	15
2312	Core-shell nanomaterials engineered to reverse cancer multidrug resistance by immunotherapy and promote photo-responsive chemotherapy. Chemical Engineering Journal, 2022, 429, 132329.	12.7	5
2313	Genetic and Epigenetic Regulation of Organic Cation Transporters. Handbook of Experimental Pharmacology, 2021, 266, 81-100.	1.8	8
2314	Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 2021, 23, 180-185.	2.6	0

#	ARTICLE	IF	CITATIONS
2315	OATs and OCTs: The SLC22 Family of Organic Anion and Cation Transporters. RSC Drug Discovery Series, 2021, , 128-142.	0.3	0
2316	OATPs: The SLCO Family of Organic Anion Transporting Polypeptide Transporters. RSC Drug Discovery Series, 2021, , 143-159.	0.3	0
2317	In silico investigation of phytoconstituents of medicinal herb "Piper Longum"™ against SARS-CoV-2 by molecular docking and molecular dynamics analysis. Results in Chemistry, 2021, 3, 100199.	2.0	32
2318	Drug Efflux Transporters: P-gp and BCRP. RSC Drug Discovery Series, 2021, , 109-127.	0.3	0
2319	Transporter Gene Regulation in Sandwich Cultured Human Hepatocytes Through the Activation of Constitutive Androstane Receptor (CAR) or Aryl Hydrocarbon Receptor (AhR). Frontiers in Pharmacology, 2020, 11, 620197.	3.5	7
2320	Phytotherapeutics: The Rising Role of Drug Transporters in Herb-Drug Interactions with Botanical Supplements. , 2021, , 469-494.		2
2322	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	3
2325	The Role of Transporters in Drug Development: Regulatory Science Perspectives from the FDA. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 257-283.	0.6	2
2326	In Vitro Characterization of Interactions with Drug Transporting Proteins. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 37-65.	0.6	1
2327	Applications of Targeted Proteomics in ADME for IVIVE. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 99-119.	0.6	1
2328	Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the Old to the New Paradigm and Assessment of Drug"Transporter Interactions. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 339-374.	0.6	4
2329	Recent Progress in Blood"Brain Barrier and Blood"CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the Brain. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 23-62.	0.6	11
2330	Text Mining for Drug"Drug Interaction. Methods in Molecular Biology, 2014, 1159, 47-75.	0.9	19
2331	Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. Methods in Molecular Biology, 2014, 1175, 91-120.	0.9	20
2332	Diagnosing Biopharmaceutical Limitations. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 141-175.	0.6	1
2333	Analysis of Sinusoidal Drug Uptake Transporter Activities in Primary Human Hepatocytes. Methods in Molecular Biology, 2015, 1250, 287-302.	0.9	6
2334	Drug-Cytokine Interactions. , 2011, , 167-201.		3
2335	A Structural Model for the Mass Action Kinetic Analysis of P-gp Mediated Transport Through Confluent Cell Monolayers. Methods in Molecular Biology, 2014, 1113, 289-316.	0.9	4

#	ARTICLE	IF	CITATIONS
2336	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. , 2018, , 15-47.		1
2337	Drug-Cytokine Interactions. , 2018, , 163-204.		5
2338	Indocyanine Green-Related Transporters in Hepatocellular Carcinoma. , 2016, , 351-362.		3
2339	Mass Transport via Cellular Barriers and Endocytosis. Fundamental Biomedical Technologies, 2011, , 3-55.	0.2	4
2340	Pharmacogenomics in Drug Development. Translational Bioinformatics, 2014, , 225-241.	0.0	2
2341	Intestinal Transporter-Associated Drug Absorption and Toxicity. Advances in Experimental Medicine and Biology, 2019, 1141, 361-405.	1.6	11
2342	Membrane interactions in drug delivery: Model cell membranes and orthogonal techniques. Advances in Colloid and Interface Science, 2020, 281, 102177.	14.7	21
2343	The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. , 2020, 212, 107574.		19
2344	Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban. Journal of Pharmaceutical Sciences, 2017, 106, 2524-2534.	3.3	8
2345	The biology of ergothioneine, an antioxidant nutraceutical. Nutrition Research Reviews, 2020, 33, 190-217.	4.1	122
2346	How Physicochemical Properties of Drugs Affect Their Metabolism and Clearance. RSC Drug Discovery Series, 2015, , 1-26.	0.3	9
2347	Prodrugs in the Treatment of Viral Diseases. RSC Drug Discovery Series, 2013, , 421-450.	0.3	1
2348	Recent advances in understanding prodrug transport through the SLC15 family of proton-coupled transporters. Biochemical Society Transactions, 2020, 48, 337-346.	3.4	26
2349	Honey flavonoids inhibit hOATP2B1 and hOATP1A2 transporters and hOATP-mediated rosuvastatin cell uptake <i>in vitro</i> . Xenobiotica, 2018, 48, 745-755.	1.1	11
2350	Facilitating the mechanical properties of a high-performance pH-sensitive membrane by cross-linking graphene oxide and polyacrylic acid. Nanotechnology, 2013, 24, 335704.	2.6	14
2351	Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals. Pharmacogenetics and Genomics, 2012, 22, 344-354.	1.5	15
2356	In Vivo Gene Expression Profile of Human Intestinal Epithelial Cells: From the Viewpoint of Drug Metabolism and Pharmacokinetics. Drug Metabolism and Disposition, 2021, 49, 221-232.	3.3	14
2357	Recent advances in understanding hepatic drug transport. F1000Research, 2016, 5, 2465.	1.6	13

#	ARTICLE	IF	CITATIONS
2358	Uremic Toxins Inhibit Transport by Breast Cancer Resistance Protein and Multidrug Resistance Protein 4 at Clinically Relevant Concentrations. PLoS ONE, 2011, 6, e18438.	2.5	113
2359	Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers. PLoS ONE, 2012, 7, e43236.	2.5	13
2360	A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp. PLoS ONE, 2013, 8, e64854.	2.5	25
2361	Transport Inhibition of Digoxin Using Several Common P-gp Expressing Cell Lines Is Not Necessarily Reporting Only on Inhibitor Binding to P-gp. PLoS ONE, 2013, 8, e69394.	2.5	28
2362	Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE, 2013, 8, e70896.	2.5	46
2363	Characterization of SLC05A1/OATP5A1, a Solute Carrier Transport Protein with Non-Classical Function. PLoS ONE, 2013, 8, e83257.	2.5	34
2364	Human Transporter Database: Comprehensive Knowledge and Discovery Tools in the Human Transporter Genes. PLoS ONE, 2014, 9, e88883.	2.5	24
2365	A Permeability Study of O2 and the Trace Amine p-Tyramine through Model Phosphatidylcholine Bilayers. PLoS ONE, 2015, 10, e0122468.	2.5	12
2366	Human Brain Microvascular Endothelial Cells Derived from the BC1 iPS Cell Line Exhibit a Blood-Brain Barrier Phenotype. PLoS ONE, 2016, 11, e0152105.	2.5	110
2367	Multispecific Organic Cation Transporter 1 (OCT1) from Bos taurus Has High Affinity and Slow Binding Kinetics towards Prostaglandin E2. PLoS ONE, 2016, 11, e0152969.	2.5	2
2368	Regulation of the Axillary Osmidrosis-Associated ABCC11 Protein Stability by N-Linked Glycosylation: Effect of Glucose Condition. PLoS ONE, 2016, 11, e0157172.	2.5	15
2369	Atomistic modeling of alternating access of a mitochondrial ADP/ATP membrane transporter with molecular simulations. PLoS ONE, 2017, 12, e0181489.	2.5	17
2370	Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS ONE, 2017, 12, e0189521.	2.5	32
2371	Effect of Curcumin on SMCT-1 Expression and Dichloroacetate Toxicity in HCT116 Colon Cancer Cells. Pharmaceutical Sciences, 2017, 23, 112-120.	0.2	2
2372	Effects of Trichostatin A on drug uptake transporters in primary rat hepatocyte cultures. EXCLI Journal, 2015, 14, 567-76.	0.7	5
2373	Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. Oncotarget, 2017, 8, 90185-90196.	1.8	6
2374	P-glycoprotein and its role in drug-drug interactions. Australian Prescriber, 2014, 37, 137-139.	1.0	114
2375	SLCO1B1 GENE IN THE ASPECT OF PHARMACOGENETICS. Siberian Medical Review, 2015, , 5-15.	0.2	4

#	ARTICLE	IF	CITATIONS
2376	Flavonoids as P-gp Inhibitors: A Systematic Review of SARs. Current Medicinal Chemistry, 2019, 26, 4799-4831.	2.4	22
2377	ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. Current Pharmaceutical Design, 2014, 20, 793-807.	1.9	441
2378	Strategies for Skeletal Muscle Targeting in Drug Discovery. Current Pharmaceutical Design, 2015, 21, 1327-1336.	1.9	19
2379	Absorption, Disposition, and Pharmacokinetics of Saponins from Chinese Medicinal Herbs: What Do We Know and What Do We Need to Know More?. Current Drug Metabolism, 2012, 13, 577-598.	1.2	132
2380	2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists. Current Drug Metabolism, 2020, 21, 403-426.	1.2	73
2381	Planar Bioadhesive Microdevices: A New Technology for Oral Drug Delivery. Current Pharmaceutical Biotechnology, 2014, 15, 673-683.	1.6	16
2382	Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters. Current Topics in Medicinal Chemistry, 2013, 13, 843-856.	2.1	85
2383	Characterization of Liver- and Cancer-type-Organic Anion Transporting Polypeptide (OATP) 1B3 Messenger RNA Expression in Normal and Cancerous Human Tissues. Drug Metabolism Letters, 2018, 12, 24-32.	0.8	15
2384	Assessing the Activity of Multidrug Resistance-Associated Protein 1 at the Lung Epithelial Barrier. Journal of Nuclear Medicine, 2020, 61, 1650-1657.	5.0	16
2385	Receptor Recognition and Lysosomal Targeting to Enhance Cytotoxicity of Novel Anti-Cancer Agents that Bind Iron and Copper. Vitamins & Minerals, 2014, 03, .	0.2	1
2386	In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol. Journal of Bioequivalence & Bioavailability, 2011, 01, .	0.1	18
2387	Membrane Protein Quantification by Peptide-Based Mass Spectrometry Approaches: Studies on the Organic Anion-Transporting Polypeptide Family. Journal of Proteomics and Bioinformatics, 2013, 06, .	0.4	16
2388	A study of the interaction of drugs with liposomes with isothermal titration calorimetry. Journal of Biophysical Chemistry, 2013, 04, 11-21.	0.5	13
2389	Anti-Aging Efficacy of a New Alendronate-Pravastatin Cosmetic Combination: A Randomized Double Blind Comparative Study. Journal of Cosmetics Dermatological Sciences and Applications, 2013, 03, 163-171.	0.2	2
2390	In silico Study on the Interaction between P-glycoprotein and Its Inhibitors at the Drug Binding Pocket. Bulletin of the Korean Chemical Society, 2014, 35, 2317-2325.	1.9	10
2391	Pharmacogenetics in older people: what we know and what we need to know. Journal of Nephrology, 2012, 25, 38-47.	2.0	10
2392	Differential Cytotoxic Effects of Jaspine B in Various Cancer Cells. Journal of Life Science, 2016, 26, 1392-1399.	0.2	2
2393	Drug-transporter interaction testing in drug discovery and development. World Journal of Pharmacology, 2013, 2, 35.	2.3	10

#	ARTICLE	IF	CITATIONS
2394	Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers. Advanced Pharmaceutical Bulletin, 2014, 4, 219-24.	1.4	36
2395	Topics on Drug Metabolism. , 2012, , .		9
2396	VARIDT 2.0: structural variability of drug transporter. Nucleic Acids Research, 2022, 50, D1417-D1431.	14.5	65
2397	Experimental Cell Line Models for Nephrotoxicity Screening. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2021, 11, 160-166.	0.2	3
2398	Clinical and Molecular Perspectives on Inflammation-Mediated Regulation of Drug Metabolism and Transport. Clinical Pharmacology and Therapeutics, 2022, 112, 277-290.	4.7	28
2399	Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam. Drug Metabolism and Disposition, 2022, 50, 65-75.	3.3	7
2400	Heptamethine Cyanine Dye MHI-148-Mediated Drug Delivery System to Enhance the Anticancer Efficiency of Paclitaxel. International Journal of Nanomedicine, 2021, Volume 16, 7169-7180.	6.7	3
2401	Polysorbate-Based Drug Formulations for Brain-Targeted Drug Delivery and Anticancer Therapy. Applied Sciences (Switzerland), 2021, 11, 9336.	2.5	22
2402	Protein kinase C regulates organic anion transporter 1 through phosphorylating ubiquitin ligase Nedd4. BMC Molecular and Cell Biology, 2021, 22, 53.	2.0	7
2403	Î1-Carrageenan nanocomposites for enhanced stability and oral bioavailability of curcumin. Biomaterials Research, 2021, 25, 32.	6.9	7
2404	Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions. Clinical Pharmacology and Therapeutics, 2022, 111, 404-415.	4.7	21
2405	Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ, 2021, 9, e12338.	2.0	7
2407	The Role of Drug Transporters on Psychotropic Penetration of the Blood–Brain Barrier. Clinical Neuropsychopharmacology and Therapeutics, 2012, 3, 8-14.	0.3	1
2408	Biological Membranes. , 2012, , 182-197.		0
2409	S13-1. Clinical Examples of Transporter-Mediated Drug-Drug Interactions and Their Evaluation Methods. Japanese Journal of Clinical Pharmacology and Therapeutics, 2012, 43, 253-254.	0.1	0
2410	Lack of Pharmacokinetic Interaction between Pilsicainide and Rifampicin in Healthy Volunteers. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 301-305.	0.1	0
2411	Application of Molecular Imaging Technology for Innovative Drug Development Targeting to Brain. Drug Delivery System, 2013, 28, 328-334.	0.0	0
2412	In Vitro Kinetic Characterization of Transporter-Mediated Permeability. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 23-35.	0.6	0

#	ARTICLE	IF	CITATIONS
2414	Pharmaco-epigenomics. , 2013, , 63-75.		0
2415	Industrial Evaluation of Drug Transporters in ADME. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 285-307.	0.6	0
2416	Toxicokinetics and Drug Disposition. , 2013, , 55-76.		0
2418	In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP). Methods in Pharmacology and Toxicology, 2014, , 353-367.	0.2	0
2419	Case Study 6. Transporter Case Studies: In Vitro Solutions for Translatable Outcomes. Methods in Molecular Biology, 2014, 1113, 485-511.	0.9	0
2420	Membrane Transporters. , 2014, , 1-5.		0
2421	INFLUENCE OF POLYMORPHISM OF OATP1B1 TRANSPORTER TO THE PHARMACOKINETICS AND THERAPEUTIC EFFECTS OF STATINS. Siberian Medical Review, 2014, , 15-23.	0.2	0
2422	Consideration of Metabolism in In Vitro Cellular Systems. Methods in Pharmacology and Toxicology, 2014, , 501-519.	0.2	0
2423	Membrane Transporters. , 2014, , 2724-2727.		0
2424	Current Status and Implications of Transporters: QSAR Analysis Method to Evaluate Drug-Drug Interactions of Human Bile Salt Export Pump (ABCB11/BSEP) and Prediction of Intrahepatic Cholestasis Risk. RSC Drug Discovery Series, 2015, , 333-347.	0.3	0
2427	Drug Delivery: Oral Route. , 0, , 2782-2811.		3
2428	Molecular Modelling, Dynamics, and Docking of Membrane Proteins. Advances in Medical Technologies and Clinical Practice Book Series, 2016, , 186-208.	0.3	0
2429	General Discussion about Human CYP2D6. , 2016, , 483-494.		0
2430	Towards a personalized risk assessment for exposure of humans to toxic substances. Cadernos Saude Coletiva, 2016, 24, 262-273.	0.6	1
2431	Nanofabrication Techniques and Their Applications in Drug Delivery. , 2016, , 425-439.		0
2432	Molecular Modelling, Dynamics, and Docking of Membrane Proteins. , 2017, , 747-769.		0
2433	Nanotemplated Materials for Advanced Drug Delivery Systems. , 2017, , 289-308.		0
2435	Some Methodologic Considerations in the Assessment of Methods for Predicting Pharmacokinetic Drug-Drug Interactions. Clinical Pharmacology in Drug Development, 2017, 6, 529-533.	1.6	0

#	ARTICLE	IF	CITATIONS
2436	Inside of the Transport Processes in Biomedical Systems. , 2017, , 209-216.		0
2437	Novel 'Housekeeping' Genes and an Unusually Heterogeneous Distribution of Transporter Expression Profiles in Human Tissues and Cell Lines, Assessed Using the Gini Coefficient. SSRN Electronic Journal, 0, , .	0.4	0
2438	Genomics and Drug Transporters and Application in Drug Discovery, Delivery, and Development. , 2018, , 133-175.		0
2440	Intestinal cells differentiated from human induced pluripotent stem cells for use in drug development studies. Translational and Regulatory Sciences, 2019, 1, 24-30.	0.2	0
2441	Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. , 2019, , 57-89.		3
2442	Current Research Method in Transporter Study. Advances in Experimental Medicine and Biology, 2019, 1141, 203-240.	1.6	7
2443	Generation of a Small Library of Natural Products Designed to Cover Chemical Space Inexpensively. , 2019, 1, e190005.		6
2444	Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers. , 2019, 2, 428-446.		3
2445	Assessment of drugs belonging to inhibitors and inducers of p-glycoprotein in vitro. Reviews on Clinical Pharmacology and Drug Therapy, 2019, 17, 71-78.	0.6	4
2447	Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition. Current Drug Metabolism, 2019, 20, 633-645.	1.2	1
2448	Development of a Liver-Gut device for the Evaluation of Drug Bioavailability. Drug Delivery System, 2019, 34, 249-260.	0.0	0
2449	THE ROLE OF GENE POLYMORPHISMS IN INDIVIDUALLY CHANGING OF THE LIPID PROFILE AMONG PATIENTS WITH CORONARY ARTERY DISEASE UNDER THE INFLUENCE OF THE STATIN THERAPY. Modern Medical Technologies, 2019, 42, 72-77.	0.2	0
2450	A Non-Nutritive Feeding Intervention Alters the Expression of Efflux Transporters in the Gastrointestinal Tract. Pharmaceutics, 2021, 13, 1789.	4.5	2
2451	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETENVIMO). Pharmaceutics, 2021, 14, 1087.	3.8	2
2452	Ontogeny of renal, hepatic, and placental expression of ATP-binding cassette and solute carrier transporters in the rat and the rabbit. Reproductive Toxicology, 2021, 107, 1-9.	2.9	1
2453	Towards next-generation personalization of tacrolimus treatment: a review on advanced diagnostic and therapeutic approaches. Pharmacogenomics, 2021, 22, 1151-1175.	1.3	2
2455	<i>In Situ&/i> Absorption Study of Acebutolol by Modulating P-glycoprotein with Verapamil in Rats. Turkish Journal of Pharmaceutical Sciences, 2020, 17, 673-678.	1.4	0
2456	Drug-drug interactions. , 2022, , 241-265.		3

#	ARTICLE	IF	CITATIONS
2457	Relevance of Transporters in Clinical Studies. , 2020, , 989-1003.		0
2458	Circadian Clock and Uptake Transporters. , 2020, , 131-158.		0
2459	Pharmacogenomics in Therapeutic Drug Monitoring. , 2020, , 155-179.		0
2460	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2020, , .		0
2463	Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals. Pharmaceutical Research, 2021, 38, 1777-1791.	3.5	4
2464	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Molecular Pharmaceutics, 2021, 18, 4371-4384.	4.6	6
2465	Mechanistic Computational Models of Epithelial Cell Transporters-the Adorned Heroes of Pharmacokinetics. Frontiers in Pharmacology, 2021, 12, 780620.	3.5	4
2466	Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. Cancer Reports, 2022, 5, e1575.	1.4	5
2467	How many skin barriers haveth we: Percutaneous egression of ions?. Skin Research and Technology, 2022, 28, 382-387.	1.6	4
2468	Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment. Journal of Clinical Pharmacology, 2021, , .	2.0	2
2469	Evaluation of ADMET Predictor in Early Discovery Drug Metabolism and Pharmacokinetics Project Work. Drug Metabolism and Disposition, 2022, 50, 95-104.	3.3	18
2470	Cloning and tissue expression of ATP-binding cassette transporters in cynomolgus macaques. Drug Metabolism and Pharmacokinetics, 2021, 42, 100431.	2.2	0
2471	Liver Fibrosis: Histopathologic and Biochemical Influences on Diagnostic Efficacy of Hepatobiliary Contrast-enhanced MR Imaging in Staging. Radiology, 2013, 269, 460-468.	7.3	27
2472	β ² -Lactam Antibiotics-drug-drug Interaction Mediated by Organic Anion Transporters OAT1 and OAT3. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2020, 10, 177-183.	0.2	1
2473	Applications of Pediatric PBPK Modeling: Current Status for Drug Development Processes and Use in Clinical Settings. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 267-276.	0.1	1
2478	UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter. American Journal of Cancer Research, 2014, 4, 148-60.	1.4	6
2481	Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4. International Journal of Biochemistry and Molecular Biology, 2016, 7, 11-8.	0.1	3
2482	Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing. American Journal of Translational Research (discontinued), 2016, 8, 3986-3994.	0.0	20

#	ARTICLE	IF	CITATIONS
2483	Potential herb-drug interaction of shexiang baoxin pill in vitro based on drug metabolism/transporter. American Journal of Translational Research (discontinued), 2016, 8, 5545-5556.	0.0	4
2484	A Cell-Based Assay to Assess Hemichannel Function. Yale Journal of Biology and Medicine, 2017, 90, 87-95.	0.2	3
2486	An Informatics-based Approach to Identify Key Pharmacological Components in Drug-Drug Interactions. AMIA Summits on Translational Science Proceedings, 2020, 2020, 142-151.	0.4	0
2487	Photothermal therapy technology of metastatic colorectal cancer. American Journal of Translational Research (discontinued), 2020, 12, 3089-3115.	0.0	7
2488	Effect of herbs for treating coronary heart disease on the CYP450 enzyme system and transporters. American Journal of Translational Research (discontinued), 2020, 12, 3182-3197.	0.0	0
2489	Drug Transportâ€™Uptake. , 2021, , .		0
2490	Advanced approaches for improving bioavailability and controlled release of anthocyanins. Journal of Controlled Release, 2022, 341, 285-299.	9.9	45
2491	Mechanisms and genetics of drug transport. , 2022, , 213-239.		1
2492	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicology and Applied Pharmacology, 2022, 434, 115797.	2.8	4
2493	Physiologically Based Modeling of the Effect of Physiological and Anthropometric Variability on Indocyanine Green Based Liver Function Tests. Frontiers in Physiology, 2021, 12, 757293.	2.8	2
2494	The role of DMPK science in improving pharmaceutical research and development efficiency. Drug Discovery Today, 2022, 27, 705-729.	6.4	7
2495	Foundations of gastrointestinal-based drug delivery and future developments. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 219-238.	17.8	66
2496	Substrate-Dependent Trans-Stimulation of Organic Cation Transporter 2 Activity. International Journal of Molecular Sciences, 2021, 22, 12926.	4.1	2
2497	Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 114-125.	2.5	13
2498	Intratumor hemodynamics using contrast-enhanced MRI in intra-arterial chemotherapy for head and neck cancers. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, , .	0.4	0
2499	ATP binding cassette transporters and cancer: revisiting their controversial role. Pharmacogenomics, 2021, 22, 1211-1235.	1.3	12
2500	All layers matter: Innovative three-dimensional epithelium-stroma-endothelium intestinal model for reliable permeability outcomes. Journal of Controlled Release, 2022, 341, 414-430.	9.9	16
2501	Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. Journal of Controlled Release, 2022, 341, 676-701.	9.9	16

#	ARTICLE	IF	CITATIONS
2502	Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 835-846.	2.0	5
2503	PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. <i>Journal of Controlled Release</i> , 2022, 342, 44-52.	9.9	11
2504	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 170, 106098.	4.0	29
2505	Emerging Roles of the Human Solute Carrier 22 Family. <i>Drug Metabolism and Disposition</i> , 2022, 50, 1193-1210.	3.3	26
2507	Transport Turnover Rates for Human OCT2 and MATE1 Expressed in Chinese Hamster Ovary Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1472.	4.1	5
2509	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. <i>Circulation</i> , 2022, 145, 279-294.	1.6	46
2510	Interactions of Environmental Chemicals and Natural Products With ABC and SLC Transporters in the Digestive System of Aquatic Organisms. <i>Frontiers in Physiology</i> , 2021, 12, 767766.	2.8	6
2511	The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates. <i>Frontiers in Pharmacology</i> , 2021, 12, 802539.	3.5	34
2513	Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy. <i>Pharmaceutics</i> , 2022, 14, 160.	4.5	0
2514	Mechanisms by Which Inducers of Drug Metabolizing Enzymes Alter Thyroid Hormones in Rats. <i>Drug Metabolism and Disposition</i> , 2022, 50, 508-517.	3.3	8
2515	High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3. <i>Pharmaceutical Research</i> , 2022, 39, 1599-1613.	3.5	13
2516	Research Progress and Prospects of Autophagy in the Mechanism of Multidrug Resistance in Tumors. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	1.3	9
2517	UV-DIB: label-free permeability determination using droplet interface bilayers. <i>Lab on A Chip</i> , 2022, 22, 972-985.	6.0	4
2518	Approaches to minimize the effects of P-glycoprotein in drug transport: A review. <i>Drug Development Research</i> , 2022, 83, 825-841.	2.9	16
2519	Systematic identification and characterization of cynomolgus macaque solute carrier transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 43, 100437.	2.2	0
2521	Why 90% of clinical drug development fails and how to improve it?. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3049-3062.	12.0	348
2522	Prediction of drug–drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 383-392.	2.3	5
2523	The MicroRNA-Based Strategies to Combat Cancer Chemoresistance via Regulating Autophagy. <i>Frontiers in Oncology</i> , 2022, 12, 841625.	2.8	10

#	ARTICLE	IF	CITATIONS
2524	Promoter haplotype structure of solute carrier 22 member 2 (SLC22A2) in the Xhosa population of South Africa and their differential effect on gene expression. <i>Gene</i> , 2022, 820, 146292.	2.2	0
2525	Small molecule splicing modifiers with systemic HTT-lowering activity. <i>Nature Communications</i> , 2021, 12, 7299.	12.8	45
2526	Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 798882.	4.1	23
2527	Drug Delivery Challenges in Brain Disorders across the Blood–Brain Barrier: Novel Methods and Future Considerations for Improved Therapy. <i>Biomedicines</i> , 2021, 9, 1834.	3.2	32
2528	Targets in nuclear medicine imaging: Past, present and future. , 2022, , .		0
2529	Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. <i>Pharmaceuticals</i> , 2022, 15, 242.	3.8	3
2530	Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy. <i>Global Medical Genetics</i> , 2022, 09, 090-096.	0.9	3
2531	Live Tissue Imaging Reveals Distinct Transcellular Pathways for Organic Cations and Anions at the Blood-Cerebrospinal Fluid Barrier. <i>Molecular Pharmacology</i> , 2022, 101, 334-342.	2.3	4
2532	Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of <i>meta</i> -Iodobenzylguanidine. <i>Drug Metabolism and Disposition</i> , 2022, 50, 1218-1227.	3.3	6
2533	Structure–tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2462-2478.	12.0	6
2534	Two Faces of Nrf2 in Cancer. , 0, , .		0
2535	Spatial proteomics finds CD155 and Endophilin-A1 as mediators of growth and invasion in medulloblastoma. <i>Life Science Alliance</i> , 2022, 5, e202201380.	2.8	5
2536	Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats. <i>Pharmaceuticals</i> , 2022, 15, 392.	3.8	2
2537	Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2751-2777.	12.0	27
2538	Transporter-mediated Natural Product-Drug Interactions. <i>Planta Medica</i> , 2023, 89, 119-133.	1.3	3
2539	Mitochondrial DNA Release Contributes to Intestinal Ischemia/Reperfusion Injury. <i>Frontiers in Pharmacology</i> , 2022, 13, 854994.	3.5	15
2540	The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 27-37.	3.3	2
2541	Tanshinone <i>IIA</i> prevents acetaminophen-induced nephrotoxicity through the activation of the <i>Nrf2</i> – <i>Mrp2</i> /4 pathway in mice. <i>Environmental Toxicology</i> , 2022, 37, 1618-1628.	4.0	5

#	ARTICLE	IF	CITATIONS
2542	Insights into the glycerol transport of <i>Yarrowia lipolytica</i> . <i>Yeast</i> , 2022, 39, 323-336.	1.7	13
2543	Evaluation of Platinum Anticancer Drug-Induced Kidney Injury in Primary Culture of Rat Kidney Tissue Slices by Using Gas-Permeable Plates. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 316-322.	1.4	2
2544	Characterization of Clofazimine as a Potential Substrate of Drug Transporter. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0215821.	3.2	2
2545	Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population. <i>Bioengineered</i> , 2022, 13, 7709-7745.	3.2	9
2546	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001056.	1.6	40
2547	Identifying Novel Inhibitors for Hepatic Organic Anion Transporting Polypeptides by Machine Learning-Based Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6323-6335.	5.4	11
2548	Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites. <i>Frontiers in Pharmacology</i> , 2022, 13, 855000.	3.5	2
2549	Gestational Age Variation in Human Placental Drug Transporters. <i>Frontiers in Pharmacology</i> , 2022, 13, 837694.	3.5	6
2553	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. <i>Pharmacological Research</i> , 2022, 178, 106137.	7.1	4
2554	Regulation of Drug Transport Proteins—From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 461-484.	4.7	26
2555	Protein phosphatase 2A regulates cytotoxicity and drug resistance by dephosphorylating AHR and MDR1. <i>Journal of Biological Chemistry</i> , 2022, 298, 101918.	3.4	4
2556	Recent trends in miRNA therapeutics and the application of plant miRNA for prevention and treatment of human diseases. <i>Future Journal of Pharmaceutical Sciences</i> , 2022, 8, 24.	2.8	25
2559	Toxicokinetics of Î²-Amanitin in Mice and In Vitro Drug–Drug Interaction Potential. <i>Pharmaceutics</i> , 2022, 14, 774.	4.5	8
2560	Current status and future directions for a neurotoxicity hazard assessment framework that integrates in silico approaches. <i>Computational Toxicology</i> , 2022, 22, 100223.	3.3	15
2561	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. <i>European Journal of Pharmacology</i> , 2022, 922, 174836.	3.5	3
2562	Organic Anion Transporting Polypeptide 2B1 in Human Fetal Membranes: A Novel Gatekeeper for Drug Transport During Pregnancy?. <i>Frontiers in Pharmacology</i> , 2021, 12, 771818.	3.5	12
2563	Computational binding affinity and molecular dynamic characterization of annonaceous acetogenins at nucleotide binding domain (NBD) of multi-drug resistance ATP-binding cassette sub-family B member 1 (ABCB1). <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 821-832.	3.5	5
2564	Evolutionary conservative analysis revealed novel functional sites in the efflux pump NorA of <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 675-681.	3.0	4

#	ARTICLE	IF	CITATIONS
2565	Absorption and Transport Characteristics and Mechanisms of Carnosic Acid. <i>Biology</i> , 2021, 10, 1278.	2.8	6
2566	<i>in vitro</i> drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymes. <i>Xenobiotica</i> , 2022, 52, 1-15.	1.1	4
2567	Isolation of MDCK cells with low expression of <i>mdr1</i> gene and their use in membrane permeability screening. <i>Acta Pharmaceutica</i> , 2022, 72, 275-288.	2.0	3
2568	Human Organic Anion Transporting Polypeptides 1B1, 1B3, and 2B1 Are Involved in the Hepatic Uptake of Phenolsulfonphthalein. <i>ACS Omega</i> , 2021, 6, 35844-35851.	3.5	3
2569	Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-to-In Vivo Translation. <i>Drug Metabolism and Disposition</i> , 2022, 50, 299-319.	3.3	14
2570	Novel treatment for refractory rheumatoid arthritis with total glucosides of paeony and nobiletin codelivered in a self-nanoemulsifying drug delivery system. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2094-2108.	6.1	7
2571	Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. <i>MedComm</i> , 2021, 2, 765-777.	7.2	15
2572	Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers. <i>Autophagy</i> , 2022, 18, 1822-1840.	9.1	10
2573	Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia. <i>Pharmaceutics</i> , 2022, 14, 878.	4.5	5
2574	Application of CRISPR-Cas9 System to Study Biological Barriers to Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 894.	4.5	2
2575	Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114282.	13.7	4
2576	Fraxinellone Induces Hepatotoxicity in Zebrafish through Oxidative Stress and the Transporters Pathway. <i>Molecules</i> , 2022, 27, 2647.	3.8	3
2577	Construction and Functional Evaluation of a Three-Dimensional Blood-Brain Barrier Model Equipped With Human Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells. <i>Pharmaceutical Research</i> , 2022, 39, 1535-1547.	3.5	16
2585	A Chemogenomic Toolkit to Evaluate the In and Out of Yeast Plasma Membrane Transporters. <i>MBio</i> , 2022, , e0095522.	4.1	0
2586	Interplay of metabolizing enzymes and transporter of xenobiotics. <i>Xenobiotica</i> , 2016, 46, 25-33.	1.1	2
2588	An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2022, 13, 886377.	3.5	14
2589	Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 527-539.	4.7	4
2590	Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 485-500.	4.7	27

#	ARTICLE	IF	CITATIONS
2591	A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption. AAPS Journal, 2022, 24, 60.	4.4	5
2592	Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 501-526.	4.7	21
2593	Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study. Molecules, 2022, 27, 3104.	3.8	12
2594	Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 8345-8379.	6.4	3
2595	Pharmacogenomics for the efficacy and side effects of antihistamines. Experimental Dermatology, 2022, 31, 993-1004.	2.9	24
2596	Synergistic treatment of doxorubicin-resistant breast cancer by the combination of chemotherapy and photodynamic therapy. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2022, 648, 129167.	4.7	5
2597	Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologicallyâ€Based Pharmacokinetic Modeling and Dose Adjustment. Clinical Pharmacology and Therapeutics, 2022, 112, 643-652.	4.7	12
2598	Characterization of a novel pesticide transporter and P-glycoprotein orthologues in <i>Drosophila melanogaster</i>. Proceedings of the Royal Society B: Biological Sciences, 2022, 289, 20220625.	2.6	3
2599	Selection of an optimal in vitro model to assess P-gp inhibition: comparison of vesicular and bi-directional transcellular transport inhibition assays. Drug Metabolism and Disposition, 2022, , DMD-AR-2021-000807.	3.3	2
2600	Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model. Drug Metabolism and Disposition, 2022, , DMD-AR-2022-000836.	3.3	2
2602	Associations of environmental phthalate exposure with male steroid hormone synthesis and metabolism: An integrated epidemiology and toxicology study. Journal of Hazardous Materials, 2022, 436, 129213.	12.4	18
2603	A Biological Basis for Pharmacokinetics: The Remote Sensing and Signaling Theory. Clinical Pharmacology and Therapeutics, 2022, 112, 456-460.	4.7	7
2605	In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions. Pharmacology Research and Perspectives, 2022, 10, .	2.4	9
2606	Membrane transporter identification and modulation via adaptive laboratory evolution. Metabolic Engineering, 2022, 72, 376-390.	7.0	16
2607	Transcriptional Regulation of Solute Carrier Drug Transporters. Drug Metabolism and Disposition, 2022, 50, 1238-1250.	3.3	10
2608	Multidrug resistance-associated protein 2 (MRP2) is an efflux transporter of EGCG and its metabolites in the human small intestine. Journal of Nutritional Biochemistry, 2022, , 109071.	4.2	9
2609	In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. Pharmacology Research and Perspectives, 2022, 10, .	2.4	8
2610	Proton coupling and the multiscale kinetic mechanism of a peptide transporter. Biophysical Journal, 2022, 121, 2266-2278.	0.5	9

#	ARTICLE	IF	CITATIONS
2611	Synthesis and preclinical evaluation of [11C]LR111 and [18F]EW-7197 as PET tracers of the activin-receptor like kinase-5. Nuclear Medicine and Biology, 2022, 112-113, 9-19.	0.6	1
2612	The importance of plasma protein and tissue binding in a drug discovery program to successfully deliver a preclinical candidate. Progress in Medicinal Chemistry, 2022, , 163-214.	10.4	5
2613	Drug Permeability and Transporter Assessment: Polarized Cell Lines. , 2022, , 401-412.		0
2614	Drug Transport Assessment: Transfected Cells and Membrane Vesicles. , 2022, , 436-447.		0
2615	Transporter Drug Interactions. , 2022, , 1156-1167.		0
2616	Oral Drug Delivery. , 2022, , 725-732.		1
2617	P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease. Heliyon, 2022, 8, e09777.	3.2	38
2618	Label-free detection of transport kinetics and inhibitor binding of membrane transport proteins with a two-mode plasmonic sensor. Biosensors and Bioelectronics: X, 2022, , 100183.	1.7	1
2619	Relevance of ABC Transporters in Drug Development. Current Drug Metabolism, 2022, 23, 434-446.	1.2	7
2620	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers, 2022, 14, 2928.	3.7	34
2621	Glucose-Sensitive Delivery of Vitamin K by Using Surface-Functionalized, Dextran-Capped Mesoporous Silica Nanoparticles To Alleviate Hyperglycemia. ACS Applied Materials & Interfaces, 2022, 14, 26489-26500.	8.0	3
2622	Enzyme-based digital bioassay technology “ key strategies and future perspectives. Lab on A Chip, 2022, 22, 3092-3109.	6.0	24
2623	Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades. Drug Metabolism and Disposition, 2022, 50, 1211-1217.	3.3	3
2624	Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy. Journal of the American Chemical Society, 2022, 144, 12367-12380.	13.7	6
2625	Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	3
2626	Slc2a6 regulates myoblast differentiation by targeting LDHB. Cell Communication and Signaling, 2022, 20, .	6.5	3
2627	Metabolic modeling-based drug repurposing in Glioblastoma. Scientific Reports, 2022, 12, .	3.3	4
2628	Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 621-637.	1.6	2

#	ARTICLE	IF	CITATIONS
2629	Trends in <scp>FDA Transporterâ€Based</scp> Postâ€Marketing Requirements and Commitments Over the Last Decade. Clinical Pharmacology and Therapeutics, 2022, 112, 635-642.	4.7	2
2631	ABCB1 restricts brain accumulation of the novel RORÎ³ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 177, 135-146.	4.3	1
2632	Novel Method for Kinetic Analysis Applied to Transport by the Uniporter, OCT2. American Journal of Physiology - Renal Physiology, 0, , .	2.7	0
2633	Gene Expression and Protein Abundance of Nuclear Receptors in Human Intestine and Liver: A New Application for Mass Spectrometry-Based Targeted Proteomics. Molecules, 2022, 27, 4629.	3.8	5
2634	Challenges and opportunities in achieving the full potential of droplet interface bilayers. Nature Chemistry, 2022, 14, 862-870.	13.6	6
2635	Suspension culture of human induced pluripotent stem cell-derived intestinal organoids using natural polysaccharides. Biomaterials, 2022, 288, 121696.	11.4	3
2636	Red-Absorbing Ru(II) Polypyridyl Complexes with Biotin Targeting Spontaneously Assemble into Nanoparticles in Biological Media. Inorganic Chemistry, 2022, 61, 13576-13585.	4.0	14
2637	Bromoacetic acid causes oxidative stress and uric acid metabolism dysfunction via disturbing mitochondrial function and Nrf2 pathway in chicken kidney. Environmental Toxicology, 2022, 37, 2910-2923.	4.0	7
2638	Synergistic prostaglandin E synthesis by myeloid and endothelial cells promotes fetal hematopoietic stem cell expansion in vertebrates. EMBO Journal, 2022, 41, .	7.8	5
2640	A proof of concept using the Ussing chamber methodology to study pediatric intestinal drug transport and ageâ€dependent differences in absorption. Clinical and Translational Science, 2022, 15, 2392-2402.	3.1	7
2641	Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics. Pharmaceutics, 2022, 14, 1755.	4.5	12
2642	The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 459-468.	3.3	6
2643	COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed. European Journal of Clinical Pharmacology, 2022, 78, 1697-1701.	1.9	6
2644	Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation. , 2022, 238, 108268.		8
2645	A structure and evolutionary-based classification of solute carriers. IScience, 2022, 25, 105096.	4.1	16
2646	Hepatic drug metabolism and gut microbiome. Progress in Molecular Biology and Translational Science, 2022, , 207-228.	1.7	1
2647	Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods in Molecular Biology, 2022, , 63-94.	0.9	1
2648	A biopharmaceutics perspective on oral peptide developability and drug delivery. , 2022, , 87-130.		0

#	ARTICLE	IF	CITATIONS
2649	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2022, , .		0
2650	Hydrogen-deuterium exchange coupled to mass spectrometry: A multifaceted tool to decipher the molecular mechanism of transporters. <i>Biochimie</i> , 2022, , .	2.6	1
2651	Treprostinil Supplementation Ameliorates Hepatic Ischemia Reperfusion Injury and Regulates Expression of Hepatic Drug Transporters: An Isolated Perfused Rat Liver (IPRL) Study. <i>Pharmaceutical Research</i> , 2022, 39, 2979-2990.	3.5	1
2652	An integrated computational study for screening medicinal plant phytochemicals for possible inhibitors of the human bile salt exporter pump. <i>International Journal of Research in Medical Sciences</i> , 2022, 10, 2072.	0.1	0
2653	A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drugâ€“Drug Interaction Liabilities. <i>Pharmaceutics</i> , 2022, 14, 1933.	4.5	1
2654	Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions. <i>Pharmaceutics</i> , 2022, 14, 1948.	4.5	0
2656	Quantifying the transport of biologics across intestinal barrier models in real-time by fluorescent imaging. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	4
2657	Establishment of MDR1-knockout human enteroids for pharmaceutical application. <i>Drug Metabolism and Pharmacokinetics</i> , 2023, 48, 100476.	2.2	5
2658	Findings on In Vitro Transporter-Mediated Drug Interactions and Their Follow-Up Actions for Labeling: Analysis of Drugs Approved by US FDA between 2017 and 2021. <i>Pharmaceutics</i> , 2022, 14, 2078.	4.5	1
2659	Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
2661	OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 637-660.	9.4	15
2662	Studying the right transporter at the right time: an <i>in vitro</i> strategy for assessing drug-drug interaction risk during drug discovery and development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 619-655.	3.3	2
2663	Mirogabalin, a novel μ ligand, is not a substrate of LAT1, but of PEPT1, PEPT2, OAT1, OAT3, OCT2, MATE1 and MATE2-K. <i>Xenobiotica</i> , 0, , 1-13.	1.1	2
2664	Do differences in cell lines and methods used for calculation of IC ₅₀ values influence categorisation of drugs as P-glycoprotein substrates and inhibitors?. <i>Xenobiotica</i> , 0, , 1-7.	1.1	0
2665	DrugMAP: molecular atlas and pharma-information of all drugs. <i>Nucleic Acids Research</i> , 2023, 51, D1288-D1299.	14.5	33
2666	Machine Learning Models Identify New Inhibitors for Human OATP1B1. <i>Molecular Pharmaceutics</i> , 2022, 19, 4320-4332.	4.6	7
2667	Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12763.	4.1	0
2668	Intracellular Metabolomics Identifies Efflux Transporter Inhibitors in a Routine Caco-2 Cell Permeability Assayâ€“Biological Implications. <i>Cells</i> , 2022, 11, 3286.	4.1	2

#	ARTICLE	IF	CITATIONS
2669	Pharmacokinetic herb-drug interactions: Altered systemic exposure and tissue distribution of ciprofloxacin, a substrate of multiple transporters, after combined treatment with Polygonum capitatum Buch.-Ham. ex D. Don extracts. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	0
2670	The development and function of the brain barriers – an overlooked consideration for chemical toxicity. <i>Frontiers in Toxicology</i> , 0, 4, .	3.1	3
2671	Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells. <i>Pharmaceutics</i> , 2022, 14, 2181.	4.5	3
2672	Drug-Food Interactions with a Focus on Mediterranean Diet. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 10207.	2.5	6
2673	<i>In Vivo</i> Simultaneous Imaging of Plasma Membrane and Lipid Droplets in Hepatic Steatosis using Red-Emissive Two-Photon Probes. <i>Analytical Chemistry</i> , 2022, 94, 15100-15107.	6.5	7
2674	Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2023, 48, 1-10.	1.6	3
2676	Sex-specific effects of excipients on oral drug bioavailability. <i>International Journal of Pharmaceutics</i> , 2022, 629, 122365.	5.2	2
2677	<i>ABCG2</i> and <i>SLCO1B1</i> gene polymorphisms in the Croatian population. <i>Annals of Human Biology</i> , 2022, 49, 323-331.	1.0	0
2679	First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
2680	Synthetic Monosaccharide Channels: Size-Selective Transmembrane Transport of Glucose and Fructose Mediated by Porphyrin Boxes. <i>Angewandte Chemie</i> , 0, , .	2.0	0
2682	Synthetic Monosaccharide Channels: Size-Selective Transmembrane Transport of Glucose and Fructose Mediated by Porphyrin Boxes. <i>Angewandte Chemie - International Edition</i> , 0, , .	13.8	3
2683	Nanoformulation mediated silencing of P-gp efflux protein for the efficient oral delivery of anti-leishmanial drugs. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 78, 103959.	3.0	2
2684	[¹¹ C]glyburide PET imaging for quantitative determination of the importance of Organic Anion-Transporting Polypeptide transporter function in the human liver and whole-body. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113994.	5.6	2
2686	DMPK Lead Optimization. , 2022, , 63-139.		0
2687	Loss of Function <i>ABCG2</i> c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study. <i>Advances in Therapy</i> , 2023, 40, 601-618.	2.9	3
2688	Oral Pharmacokinetics of Hydroxycinnamic Acids: An Updated Review. <i>Pharmaceutics</i> , 2022, 14, 2663.	4.5	6
2689	Analysis of Time-Dependent Pharmacokinetics Using <i>In Vitro</i> – <i>In Vivo</i> Extrapolation and Physiologically Based Pharmacokinetic Modeling. <i>Pharmaceutics</i> , 2022, 14, 2562.	4.5	0
2690	Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4

#	ARTICLE	IF	CITATIONS
2693	Predicting transporter mediated drug-drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward. <i>Biopharmaceutics and Drug Disposition</i> , 2023, 44, 195-220.	1.9	3
2694	Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption. <i>Drug Metabolism and Disposition</i> , 2023, 51, 318-328.	3.3	9
2695	Capturing and Quantifying Particle Transcytosis with Microphysiological Intestine-on-a-Chip Models. <i>Small Methods</i> , 2023, 7, .	8.6	3
2696	Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 181, 106362.	4.0	7
2697	Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing. <i>Pharmaceutics</i> , 2023, 15, 29.	4.5	4
2698	Clinical Drug-Drug Interaction Between Vatisiquone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate. <i>Clinical Pharmacology in Drug Development</i> , 0, , .	1.6	1
2699	Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 4301-4310.	4.3	1
2700	Chiral Transport in Nanochannel Based Artificial Drug Transporters. <i>Small</i> , 2023, 19, .	10.0	2
2701	Pathophysiology of drug hypersensitivity. <i>British Journal of Clinical Pharmacology</i> , 0, , .	2.4	3
2702	Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
2703	Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil. <i>Pharmaceutical Research</i> , 2023, 40, 2499-2511.	3.5	1
2704	¹-Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 1070-1079.	4.7	5
2705	Pancreatic Hormone Insulin Modulates Organic Anion Transporter 1 in the Kidney: Regulation via Remote Sensing and Signaling Network. <i>AAPS Journal</i> , 2023, 25, .	4.4	2
2706	Drug Metabolizing Enzymes and Transporters of the Mesentery. , 2023, , 165-178.		0
2707	Clinical assessment of gepotidacin (¹) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters. <i>Clinical and Translational Science</i> , 2023, 16, 647-661.	3.1	3
2708	Dye labeling for optical imaging biases drug carriers' biodistribution and tumor uptake. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 48, 102650.	3.3	3
2709	Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114210.	5.6	0
2710	Functionalized liposomes for targeted breast cancer drug delivery. <i>Bioactive Materials</i> , 2023, 24, 401-437.	15.6	33

#	ARTICLE	IF	CITATIONS
2711	Intense endoplasmic reticulum stress (ERS) / IRE1 α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells. BMC Cancer, 2022, 22, .	2.6	1
2713	Sodium-Dependent Neutral Amino Acid Transporter 2 Can Serve as a Tertiary Carrier for <sc>I</sc>-Type Amino Acid Transporter 1-Utilizing Prodrugs. Molecular Pharmaceutics, 2023, 20, 1331-1346.	4.6	2
2714	The kidney drug transporter OAT1 regulates gut microbiomeâ€‘dependent host metabolism. JCI Insight, 2023, 8, .	5.0	5
2715	The Role of Autophagy Regulation as a Novel Approach for Cancer Immunotherapy. , 2023, , 1-24.		0
2716	Translatability of in vitro Inhibition Potency to in vivo P-Glycoprotein Mediated Drug Interaction Risk. Journal of Pharmaceutical Sciences, 2023, 112, 1715-1723.	3.3	3
2717	Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates. Journal of Clinical Psychopharmacology, 0, Publish Ahead of Print, .	1.4	0
2718	Glycochenodeoxycholate and glycodeoxycholate 3â€‘Oâ€‘glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDCâ€‘0810 in humans. British Journal of Clinical Pharmacology, 2023, 89, 1903-1907.	2.4	3
2719	Evaluation of Drugâ€‘Drug Interactions of Ensitrelvir, a SARSâ€‘CoVâ€‘2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies. Journal of Clinical Pharmacology, 2023, 63, 918-927.	2.0	5
2720	Recent advances in the <i>in vitro</i> and <i>in vivo</i> methods to assess impact of Pâ€‘glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition. Biopharmaceutics and Drug Disposition, 2023, 44, 7-25.	1.9	4
2721	Involvement of CYP3A4 and MDR1 in altered metabolism and transport of indinavir in 1,25(OH)2D3-treated Caco-2 cells. European Journal of Pharmaceutical Sciences, 2023, 183, 106396.	4.0	4
2722	Prandial state and biological sex modulate clinically relevant efflux transporters to different extents in Wistar and Sprague Dawley rats. Biomedicine and Pharmacotherapy, 2023, 160, 114329.	5.6	0
2723	Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science. Journal of Medicinal Chemistry, 2023, 66, 2832-2850.	6.4	7
2724	Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale. Biomedicine and Pharmacotherapy, 2023, 160, 114342.	5.6	0
2725	On the interplay between lipids and asymmetric dynamics of an NBS degenerate ABC transporter. Communications Biology, 2023, 6, .	4.4	5
2726	Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254). Pharmaceutics, 2023, 15, 521.	4.5	3
2727	Interplay of Breast Cancer Resistance Protein (Bcrp/Abcg2), Sex, and Fed State in Oral Pharmacokinetic Variability of Furosemide in Rats. Pharmaceutics, 2023, 15, 542.	4.5	1
2728	Experimental and computational models to investigate intestinal drug permeability and metabolism. Xenobiotica, 2023, 53, 25-45.	1.1	2
2729	Positron Emission Tomography-Based Pharmacokinetic Analysis To Assess Renal Transporter-Mediated Drug-Drug Interactions of Antimicrobial Drugs. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	1

#	ARTICLE	IF	CITATIONS
2730	Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	11
2731	Assessment of the role of nucleoside transporters, P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in the placental transport of entecavir using in vitro, ex vivo, and in situ methods. <i>Toxicology and Applied Pharmacology</i> , 2023, 463, 116427.	2.8	0
2732	A method for quantification of human transporter proteins by liquid chromatography–tandem mass spectrometry. <i>Separation Science Plus</i> , 2023, 6, 2200120.	0.6	0
2733	An <i>in silico</i> quest for next-generation antimalarial drugs by targeting <i>Plasmodium falciparum</i> hexose transporter protein: a multi-pronged approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 14450-14459.	3.5	1
2734	Lipid environment determines the drug-stimulated ATPase activity of P-glycoprotein. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	2
2735	Effect of budesonide on pulmonary activity of multidrug resistance-associated protein 1 assessed with PET imaging in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 184, 106414.	4.0	0
2736	Preincubation Time-Dependent, Long-Lasting Inhibition of Drug Transporters and Impact on the Prediction of Drug–Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2023, 51, 1077-1088.	3.3	5
2737	Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an <i>in silico</i> drug discovery study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13977-13992.	3.5	4
2738	Solid-Supported Membrane (SSM)-Based Electrophysiology Assays Using Surface Electrogenic Event Reader Technology (SURFER) in Early Drug Discovery. <i>Current Protocols</i> , 2023, 3, .	2.9	1
2739	Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells. <i>Pharmaceutics</i> , 2023, 15, 987.	4.5	1
2740	Imaging the TGF β 2 type I receptor in pulmonary arterial hypertension. <i>EJNMMI Research</i> , 2023, 13, .	2.5	0
2741	Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine. <i>ACS Omega</i> , 2023, 8, 12532-12537.	3.5	0
2743	Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1911-1941.	3.3	0
2744	N1-Methylnicotinamide: The Mysterious Anti-aging Actor in Renal Transplantation. <i>Current Pharmaceutical Design</i> , 2023, 29, 723-731.	1.9	1
2745	Iruplinalkib (WX-0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. <i>Investigational New Drugs</i> , 2023, 41, 254-266.	2.6	6
2746	Computational and structural insights into the pre- and post-hydrolysis states of bovine multidrug resistance-associated protein 1. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2023, 133, 508-525.	2.5	2
2747	Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo. <i>Drug Metabolism and Disposition</i> , 2023, 51, 851-861.	3.3	1
2748	Genetic variation in organic cation transporters and considerations in drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2023, 19, 149-164.	3.3	2

#	ARTICLE	IF	CITATIONS
2749	Integrated Use of In Vitro and In Vivo Information for Comprehensive Prediction of Drug Interactions Due to Inhibition of Multiple CYP Isoenzymes. <i>Clinical Pharmacokinetics</i> , 0, , .	3.5	0
2750	Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 Inhibition in Cynomolgus Monkeys. <i>Drug Metabolism and Disposition</i> , 2023, 51, 844-850.	3.3	1
2751	The Inhibitor Preincubation Effect Is Universal to SLC Transporter Assays and Is Only Partially Eliminated in the Presence of Extracellular Protein. <i>Drug Metabolism and Disposition</i> , 2023, 51, 982-994.	3.3	2
2752	Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	1
2753	<i>Drug Metabolism</i> . , 2023, , 265-297.		0
2754	Drugs that modulate resistance to antitumor agents. , 2023, , 901-963.		0
2755	A Simple and Rapid Bioluminescence-Based Functional Assay of Organic Anion Transporter 1 as a D-Luciferin Transporter. <i>Methods in Molecular Biology</i> , 2022, , 119-126.	0.9	0
2756	Regional Transcriptomics and Proteomics of Pharmacokinetics-Related Genes in Human Intestine. <i>Molecular Pharmaceutics</i> , 2023, 20, 2876-2890.	4.6	2
2757	Recent Advances in Photothermal Therapies Against Cancer and the Role of Membrane Transporter Modulators on the Efficacy of This Approach. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311680.	1.9	1
2758	In vitro validation of an in vivo phenotyping drug cocktail for major drug transporters in humans. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 186, 106459.	4.0	0
2759	Amino acid transporters as drug targets in disease modification. , 2023, , 57-76.		2
2760	Clinical outcomes of chemotherapy in cancer patients with different ethnicities. <i>Cancer Reports</i> , 0, , .	1.4	1
2761	The Effect of Trimethoprim on Thiamine Absorption: A <scp>Transporterâ€Mediated Drugâ€Nutrient</scp> Interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 114, 381-392.	4.7	2
2762	State-of-the-art Application of Artificial Intelligence to Transporter-centered Functional and Pharmaceutical Research. <i>Current Drug Metabolism</i> , 2023, 24, .	1.2	1
2763	Unravelling the Hepatic Elimination Mechanisms of Colistin. <i>Pharmaceutical Research</i> , 0, , .	3.5	0
2764	Recent Advances in Synthetic Drugs and Natural Actives Interacting with OAT3. <i>Molecules</i> , 2023, 28, 4740.	3.8	0
2765	Chloroquine and Hydroxychloroquine, as Proteasome Inhibitors, Upregulate the Expression and Activity of Organic Anion Transporter 3. <i>Pharmaceutics</i> , 2023, 15, 1725.	4.5	1
2766	P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice. <i>Pharmaceutical Research</i> , 0, , .	3.5	0

#	ARTICLE	IF	CITATIONS
2767	Application of Pharmacokinetic Modeling to Characterize Hepatobiliary Disposition of Imaging Agents and Alterations due to Liver Injury in Isolated Perfused Rat Livers. <i>Pharmaceutical Research</i> , 0, , .	3.5	0
2768	Recent Advances in Novel Recombinant RNAs for Studying Post-transcriptional Gene Regulation in Drug Metabolism and Disposition. <i>Current Drug Metabolism</i> , 2023, 24, 175-189.	1.2	1
2769	Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides. <i>Molecular Pharmaceutics</i> , 2023, 20, 3020-3032.	4.6	2
2770	Transporter proteins knowledge graph construction and its application in drug development. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2973-2984.	4.1	3
2771	Incubation Time Influences Organic Anion Transporter 1 Kinetics and Renal Clearance Predictions. <i>Journal of Xenobiotics</i> , 2023, 13, 205-217.	6.7	0
2772	Characterization of P-glycoprotein orthologs from human, sheep, pig, dog, and cat. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 0, , .	1.3	1
2773	Interactions of human drug transporters with chemical additives present in plastics: Potential consequences for toxicokinetics and health. <i>Environmental Pollution</i> , 2023, 331, 121882.	7.5	2
2774	Potential Involvement of Organic Anion Transporters in Drug Interactions with Shuganning Injection, a Traditional Chinese Patent Medicine. <i>Planta Medica</i> , 0, , .	1.3	0
2775	Impact of Clinical Pharmacology on the Modernization of Drug Development and Regulation. <i>AAPS Introductions in the Pharmaceutical Sciences</i> , 2023, , 165-202.	0.1	0
2776	Case study of OATP1B DDI assessment and challenges in drug discovery and development—real-life examples. , 2023, , 189-199.		0
2777	Targeting SLC transporters: small molecules as modulators and therapeutic opportunities. <i>Trends in Biochemical Sciences</i> , 2023, 48, 801-814.	7.5	7
2778	Nanoparticle oral absorption and its clinical translational potential. <i>Journal of Controlled Release</i> , 2023, 360, 149-162.	9.9	2
2779	The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition—Progress from 2016 to 2023. <i>Drug Metabolism and Disposition</i> , 2023, 51, 950-961.	3.3	2
2780	A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept. <i>Drug Metabolism and Disposition</i> , 2023, 51, 1067-1076.	3.3	2
2781	Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 114, 780-794.	4.7	3
2782	Critical Assessment of Phenotyping Cocktails for Clinical Use in an African Context. <i>Journal of Personalized Medicine</i> , 2023, 13, 1098.	2.5	1
2786	Molecular basis for selective uptake and elimination of organic anions in the kidney by OAT1. <i>Nature Structural and Molecular Biology</i> , 2023, 30, 1786-1793.	8.2	5
2787	The rise of degrader drugs. <i>Cell Chemical Biology</i> , 2023, 30, 864-878.	5.2	12

#	ARTICLE	IF	CITATIONS
2788	SuperNatural inhibitors to reverse multidrug resistance emerged by ABCB1 transporter: Database mining, lipid-mediated molecular dynamics, and pharmacokinetics study. PLoS ONE, 2023, 18, e0288919.	2.5	0
2789	Selective drug delivery to the retinal cells: Biological barriers and avenues. Journal of Controlled Release, 2023, 361, 1-19.	9.9	2
2790	The application of organ-on-chip models for the prediction of human pharmacokinetic profiles during drug development. Pharmacological Research, 2023, 195, 106853.	7.1	3
2791	pH and drug resistance. , 2023, , 151-162.		0
2792	Influence of <i>Slco2b1</i> knockout and <i>SLCO2B1</i> humanization on coproporphyrin I and III levels in rats. British Journal of Pharmacology, 2024, 181, 36-53.	5.4	1
2793	A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions. Clinical Pharmacology and Therapeutics, 2023, 114, 1058-1072.	4.7	2
2794	Goldenseal-mediated inhibition of intestinal uptake transporters decreases metformin systemic exposure in mice. Drug Metabolism and Disposition, 0, , DMD-AR-2023-001360.	3.3	0
2795	Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity. Pharmaceutical Research, 2023, 40, 2639-2651.	3.5	1
2796	Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-glycoprotein and Breast Cancer Resistance Protein Substrates. Journal of Clinical Pharmacology, 2024, 64, 94-102.	2.0	0
2797	Interactions of organophosphate flame retardants with human drug transporters. Ecotoxicology and Environmental Safety, 2023, 263, 115348.	6.0	0
2799	Toxicokinetics and tissue distribution of phalloidin in mice. Food and Chemical Toxicology, 2023, 179, 113994.	3.6	0
2800	Fused Imidazopyrazine-Based Tubulin Polymerization Inhibitors Inhibit Neuroblastoma Cell Function. ACS Medicinal Chemistry Letters, 0, , .	2.8	0
2801	TRP Channels: The Neglected Culprits in Breast Cancer Chemotherapy Resistance?. Membranes, 2023, 13, 788.	3.0	0
2802	Quantification of drug metabolising enzymes and transporter proteins in the paediatric duodenum via LC-MS/MS proteomics using a QconCAT technique. European Journal of Pharmaceutics and Biopharmaceutics, 2023, 191, 68-77.	4.3	2
2803	Challenges in Permeability Assessment for Oral Drug Product Development. Pharmaceutics, 2023, 15, 2397.	4.5	1
2804	Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier. Pharmaceutical Research, 2023, 40, 2667-2675.	3.5	1
2805	Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology. Environmental Research, 2023, 239, 117263.	7.5	6
2806	Interaction of ALK Inhibitors with Polyspecific Organic Cation Transporters and the Impact of Substrate-Dependent Inhibition on the Prediction of Drug-Drug Interactions. Pharmaceutics, 2023, 15, 2312.	4.5	0

#	ARTICLE	IF	CITATIONS
2807	Nano-phototherapy: Favorable prospects for cancer treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2024, 16, .	6.1	2
2808	Extracellular Vesicles as Surrogates for Drug Metabolism and Clearance: Promise vs. Reality. Life, 2023, 13, 1745.	2.4	1
2809	Mitochondrial Artificial K ⁺ Channel Construction Using MPTPP@5F8 Nanoparticles for Overcoming Cancer Drug Resistance via Disrupting Cellular Ion Homeostasis. Advanced Healthcare Materials, 2024, 13, .	7.6	0
2810	Nanocarrier mediated co-delivery of phytochemicals and chemo-drugs: an emerging strategy to combat lung cancer in a systemic way. Phytochemistry Reviews, 0, , .	6.5	0
2811	Structural basis of promiscuous substrate transport by Organic Cation Transporter 1. Nature Communications, 2023, 14, .	12.8	5
2812	Plasma lipidomic analysis to investigate putative biomarkers of P-glycoprotein activity in healthy volunteers. Clinical and Translational Science, 2023, 16, 1935-1946.	3.1	0
2813	Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c. Biomedicine and Pharmacotherapy, 2023, 166, 115304.	5.6	1
2814	Renal Pharmacokinetic Adaptation to Cholestasis Causes Increased Nephrotoxic Drug Accumulation by Mrp6 Downregulation in Mice. Journal of Pharmaceutical Sciences, 2023, , .	3.3	0
2815	Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents. Clinical Pharmacokinetics, 2023, 62, 1365-1392.	3.5	0
2816	Factors Affecting Drug Absorption and Disposition. , 2024, , 499-516.		0
2817	Kinetic modelling of the P-glycoprotein mediated efflux with a large-scale matched molecular pair analysis. European Journal of Medicinal Chemistry, 2023, 261, 115830.	5.5	1
2818	Utilization of OATP1B Biomarker Coproporphyrin to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry. Clinical Pharmacology and Therapeutics, 2023, 114, 1170-1183.	4.7	2
2819	Novel drug transporter substrates identification: An innovative approach based on metabolomic profiling, in silico ligand screening and biological validation. Pharmacological Research, 2023, 196, 106941.	7.1	1
2820	Oral Anticoagulants Beyond Warfarin. Annual Review of Pharmacology and Toxicology, 2024, 64, 551-575.	9.4	2
2821	Automated Fragmentation Quantum Mechanical Calculation of ¹⁵ N and ¹³ C Chemical Shifts in a Membrane Protein. Journal of Chemical Theory and Computation, 2023, 19, 7405-7422.	5.3	0
2822	Tracing the substrate translocation mechanism in P-glycoprotein. ELife, 0, 12, .	6.0	2
2823	Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model. Drug Metabolism and Pharmacokinetics, 2024, 54, 100531.	2.2	0
2824	Unveiling the Anti-Cancer Potential of Onoceranoid Triterpenes from Lansium domesticum Corr. cv. kokosan: An In Silico Study against Estrogen Receptor Alpha. International Journal of Molecular Sciences, 2023, 24, 15033.	4.1	1

#	ARTICLE	IF	CITATIONS
2825	Uptake Transporters at the Blood–Brain Barrier and Their Role in Brain Drug Disposition. <i>Pharmaceutics</i> , 2023, 15, 2473.	4.5	4
2826	Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etxilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. <i>Clinical Drug Investigation</i> , 0, , .	2.2	0
2827	Advances in Computational Approaches for Estimating Passive Permeability in Drug Discovery. <i>Membranes</i> , 2023, 13, 851.	3.0	0
2828	Sweet Cherry Extract as Permeation Enhancer of Tyrosine Kinase Inhibitors: A Promising Prospective for Future Oral Anticancer Therapies. <i>Pharmaceutics</i> , 2023, 16, 1527.	3.8	0
2829	Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1. <i>Pharmaceutics</i> , 2023, 16, 1529.	3.8	0
2830	Study Models of Drug–Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels. <i>Molecules</i> , 2023, 28, 7532.	3.8	0
2831	<i>In Silico</i> and <i>In Vitro</i> Analyses to Repurpose Quercetin as a Human Pancreatic α -Amylase Inhibitor. <i>ACS Omega</i> , 2023, 8, 43617-43631.	3.5	1
2832	The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors. <i>Viruses</i> , 2023, 15, 2234.	3.3	3
2833	Pharmacokinetics and absorption mechanism of tandospirone citrate. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
2834	Quercetin Enhances the Availability of 5-Heptadecylresorcinol by Inhibiting the Expression of P-gp. <i>Journal of Agricultural and Food Chemistry</i> , 2023, 71, 18375-18384.	5.2	0
2835	The Effect of BI 730357 (Retinoic Acid–Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open–Label, Non–randomized, 2–Period Fixed–Sequence Trial in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2024, 13, 197-207.	1.6	0
2836	Association between genetic variants of transmembrane transporters and susceptibility to anthracycline–induced cardiotoxicity: Current understanding and existing evidence. <i>Clinical Genetics</i> , 2024, 105, 115-129.	2.0	0
2837	Combined in silico and in vitro approaches to identify P–glycoprotein–inhibiting pesticides. <i>Journal of Biochemical and Molecular Toxicology</i> , 2024, 38, .	3.0	1
2838	Trifloxystrobin induced developmental toxicity by disturbing the ABC transporters, carbohydrate and lipid metabolism in adult zebrafish. <i>Chemosphere</i> , 2024, 349, 140747.	8.2	0
2839	Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2023, 9, .	1.0	1
2840	Amino acid derivative of probenecid potentiates apoptosis-inducing effects of vinblastine by increasing oxidative stress in a cancer cell-specific manner. <i>Chemico-Biological Interactions</i> , 2024, 388, 110833.	4.0	1
2841	Semi–Automated, high–content imaging of drug transporter knockout sea urchin (<i>Lytechinus</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 0, , .	1.3	1
2843	Overcoming multi drug resistance mediated by ABC transporters by a novel acetogenin- annonacin from <i>Annona muricata</i> L.. <i>Journal of Ethnopharmacology</i> , 2024, 322, 117598.	4.1	1

#	ARTICLE	IF	CITATIONS
2844	Comparative evaluation of recommendations for preclinical studies of transporter-mediated drug-drug interactions. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2023, 13, 560-566.	0.2	0
2845	Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development. Expert Opinion on Drug Delivery, 2024, 21, 13-29.	5.0	1
2846	Blood-brain barrier disruption in dementia: Nano-solutions as new treatment options. European Journal of Neuroscience, 0, , .	2.6	1
2847	The Use of Carboxyfluorescein Reveals the Transport Function of MCT6/SLC16A5 Associated with CD147 as a Chloride-Sensitive Organic Anion Transporter in Mammalian Cells. Journal of Pharmaceutical Sciences, 2023, , .	3.3	0
2848	Construction and characterization of a humanized SLCO1B1 rat model with its application in evaluating the uptake of different statins. Acta Pharmaceutica Sinica B, 2024, 14, 1592-1604.	12.0	0
2851	Human intestinal organoid-derived PDGFR α -mesenchymal stroma enables proliferation and maintenance of LGR4 $^{+}$ epithelial stem cells. Stem Cell Research and Therapy, 2024, 15, .	5.5	0
2853	Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics. Expert Opinion on Drug Delivery, 2024, 21, 71-89.	5.0	0
2854	Facilitated Transport of EGFR Inhibitors Plays an Important Role in Their Cellular Uptake. Analytical Chemistry, 2024, 96, 1547-1555.	6.5	0
2855	Air-liquid interface culture and modified culture medium promote the differentiation of human induced pluripotent stem cells into intestinal epithelial cells. Drug Metabolism and Pharmacokinetics, 2024, 55, 100994.	2.2	0
2856	Sustained release polymer and surfactant based solid dispersion of andrographolide exhibited improved solubility, dissolution, pharmacokinetics, and pharmacological activity. International Journal of Pharmaceutics, 2024, 651, 123786.	5.2	0
2857	A previously unidentified sugar transporter for engineering of high-yield Streptomyces. Applied Microbiology and Biotechnology, 2024, 108, .	3.6	1
2858	Accurate prediction of K _{p,uu,brain} based on experimental measurement of K _{p,brain} and computed physicochemical properties of candidate compounds in CNS drug discovery. Heliyon, 2024, 10, e24304.	3.2	1
2859	The Effect of Original Russian Neurotropic Drugs on Organic Anion Transporting Polypeptides OATP1B1 and OATP1B3. Bulletin of Experimental Biology and Medicine, 2023, 176, 170-175.	0.8	0
2860	Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling. Frontiers in Pharmacology, 0, 14, .	3.5	1
2862	Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points. Journal of Medicinal Chemistry, 2024, 67, 1406-1420.	6.4	0
2863	Performance and Sensitivity of [^{99m} Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver. Molecular Pharmaceutics, 2024, 21, 932-943.	4.6	0
2864	Tracing the substrate translocation mechanism in P-glycoprotein. ELife, 0, 12, .	6.0	0
2865	Membrane transporters in drug development and as determinants of precision medicine. Nature Reviews Drug Discovery, 2024, 23, 255-280.	46.4	3

#	ARTICLE	IF	CITATIONS
2866	Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases. Israel Journal of Chemistry, 0, , .	2.3	0
2867	Exploring Amino Acid Transporters as Therapeutic Targets for Cancer: An Examination of Inhibitor Structures, Selectivity Issues, and Discovery Approaches. Pharmaceutics, 2024, 16, 197.	4.5	0
2868	Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Bloodâ€”Brain Barrier: The Discovery of AZD1390. Journal of Medicinal Chemistry, 2024, 67, 3090-3111.	6.4	0
2869	Interaction and Transport of Benzalkonium Chlorides by the Organic Cation and Multidrug and Toxin Extrusion Transporters. Drug Metabolism and Disposition, 2024, 52, 312-321.	3.3	0
2870	Cadmium transport by mammalian ATP-binding cassette transporters. BioMetals, 0, , .	4.1	1
2871	Exposure to haloacetic acid disinfection by-products and male steroid hormones: An epidemiological and in vitro study. Journal of Hazardous Materials, 2024, 468, 133796.	12.4	0
2872	Nonclinical Development of Oncology Drugs. , 2024, , 721-742.		0
2873	Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning. Nature Biomedical Engineering, 2024, 8, 278-290.	22.5	0
2874	Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD. Hepatology Communications, 2024, 8, .	4.3	0
2875	Identification and subtype analysis of biomarkers associated with the solute carrier family in acute myocardial infarction. Medicine (United States), 2023, 102, e36515.	1.0	0
2876	Development of a Mature B Lymphocyte Probe through Gating-Oriented Live-Cell Distinction (GOLD) and Selective Imaging of Topical Spleen. JACS Au, 2024, 4, 1450-1457.	7.9	0
2877	<scp>ABCG2</scp> polymorphisms and susceptibility to <scp>ARV</scp>â€”associated hepatotoxicity. Molecular Genetics & Genomic Medicine, 2024, 12, .	1.2	0
2878	Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules. Molecules, 2024, 29, 1264.	3.8	0
2879	Membrane-assisted transmembrane access and binding mechanisms of human ATP-binding cassette transporter P-glycoprotein. Frontiers in Molecular Biosciences, 0, 11, .	3.5	0
2880	The ABCG2 protein in vitro transports the xenobiotic thiabendazole and increases the appearance of its residues in milk. Environmental Toxicology and Pharmacology, 2024, 107, 104421.	4.0	0
2881	An Untargeted Metabolomics Strategy to Identify Substrates of Known and Orphan E. coli Transporters. Membranes, 2024, 14, 70.	3.0	0
2882	Excretory Processes in Toxicology: Drug Transporters in Drug Development. , 2024, , .		0
2883	Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery. Drug Metabolism and Pharmacokinetics, 2024, 56, 101008.	2.2	0

#	ARTICLE	IF	CITATIONS
2884	A Clinical Practice Perspective on the Evaluation of <scp>OATP1B1</scp>â€associated Drug Interactions. Clinical Pharmacology and Therapeutics, 0, , .	4.7	0
2885	Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers. Diseases (Basel, Switzerland), 2024, 12, 63.	2.5	0
2886	Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults. Genes, 2024, 15, 379.	2.4	0